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Abstract 
Malaria, caused by Plasmodium parasites, remains a leading cause for morbidity and mortality 
worldwide, resulting in more than 430 000 deaths annually. P. falciparum is responsible for the vast 
majority of severe malaria cases, accounting for more than 90% of malaria-related fatalities, 
predominantly in subsaharan Africa. The parasite has a complex life cycle, which involves 
transitioning between multiple distinct morphologies. The severity of the disease is brought about 
by the variable expression of parasite proteins on the surface of infected red blood cells. The 
substantial morphological changes, together with the variable expression of cell surface proteins, 
are governed by tightly controlled stage-specific changes in gene expression patterns. 
Understanding the regulatory mechanisms that govern these changes is crucial to fully 
understanding the parasites biology and pathology at the molecular level, a key step toward 
identifying targets for the development of much needed novel antimalarial drugs.  
  
Ultimately, all gene regulatory mechanisms converge to regulate the assembly and function of the 
RNA polymerase II (RNAP-II) transcription initiation complex composed of RNAP-II and the general 
transcription factors (GTFs). Bioinformatics analyses show that the RNAP-II GTFs in P. falciparum 
have greatly diverged from those studied in other eukaryotes, suggesting the existence of parasite-
specific gene regulatory mechanisms, which have so far not been studied. This research project 
concerns the structure and function of P. falciparum TBP, TLP and TFIIA, key proteins involved in 
core promoter recognition, the first step in RNAP-II transcription initiation complex assembly. The 
work provides strong evidence for the existence of two different PfTFIIA complexes containing 
different PfTFIIA-γ subunits. The data further demonstrate that PfTBP and PfTLP DNA-binding 
activities differ distinctly from the classical TBP-DNA interactions seen in other eukaryotes and 
demonstrate interaction with and stimulation of PfTBP and PfTLP DNA-binding activity by one of 
the two PfTFIIA complexes. The work represents a first step towards understanding the regulation 
of transcription initiation in P. falciparum, gives first insights into Plasmodium-specific features, and 
provides a solid foundation for further investigations into this crucial aspect of malaria biology. 
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Common Abbreviations 
6H- Hexa-histidine tag 
A,T,G,C - adenine, thymine, guanine, cytosine 
Ad2ML- Adenovirus type 2 major late 
Amp - Ampicillin 
ATP - Adenosine tri-phosphate 
BC-100- BC-buffer; 100mM Salt 
BLAST - Basic Local Alignment Search Tool  
BREu /d - upstream/ downstream TFIIB    
recognition element 
BSA - Bovine serum albumin 
BTAF1 - TATA-binding protein-associated 
factor 172 
C-, N- terminus - carboxyl-; amino- terminus  
Cam- Chloramphenicol 
cDNA- Complimentary DNA 
COBALT- Constraint-based multiple protein 
alignment tool 
CPE- Core promoter element 
cryo-EM - Cryo-electron microscopy 
CTD- C-terminal domain 
DCE - Downstream core element 
DNA- Deoxyribonucleic acid 
DPE - Downstream promoter element  
DTIE- Downstream transcription initiation 
element 
DTSS- Downstream transcription start site 
EMSA- Electrophoretic mobility shift assay 
EPD- Eukaryotic promoter database 
FISH- Fluorescent in situ hybridization  
GBP-130 - glycophorin binding protein 130 
GCR - Gene coding regions 
GTF - General transcription factor 
HCA - Hydrophobic cluster analysis 
HCS - High-content screening 
Inr - Initiator element 
IPTG - Isopropyl β-D-1-thiogalactopyranoside 
IRS - indoor residual spraying 
ITA - Immobilised template assay 
KAHRP - Knob associated histidine rich 
protein 
LacUV5 - E. coli lac operon promoter 
LB - Luria broth 
LLIN - Long-lasting insecticidal nets 
mRNA - Messenger RNA 
MSP1 - Merozoite surface protein-1 
MTE - Motif ten element 
MW - Molecular weight 
NC2 - Negative cofactor 2 
Ni-NTA - Nickel- nitrilotriacetic acid resin 
OD - Optical density 
ORF- Open reading frame 
PCR - Polymerase chain reaction 
PfEMP1 - P. falciparum erythrocyte membrane 
protein 1 
PfTBP - P. falciparum TATA-binding protein 
PfTFIIA-αβ - P. falciparum transcription factor 
IIA αβ subunit 
PfTFIIA-γ1s - P. falciparum transcription factor 
IIA γ1s subunit 
PfTFIIA-γ2s -  P. falciparum transcription factor 
IIA γ2s subunit 
PfTLP - P. falciparum TBP-like protein 
PIC - Pre-initiation complex 
PlasmoDB- Plasmodium genome database 
poly(dG-dC) - poly(deoxyguanylic-
deoxycytidylic) acid 
Q-sepharose - quaternary-ammonium- 
sepharose  
SP-sepharose - sulphopropyl-sepharose 
RBC - Red blood cell 
RNA - Ribonucleic acid 
RNAP-II - RNA polymerase II 
RPB 1-12 - RNA polymerase II subunits 
RTS,S/AS01 - Mosquirix® , GSK malaria 
vaccine 
SELEX - Systematic evolution of ligands by 
exponential enrichment 
SDS-PAGE - Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis 
STF - Specific transcription factors 
TAF - TBP-associated factor 
TBP - TATA-binding protein 
TBST - Tris-buffered saline and Polysorbate 20 
TdT - Terminal deoxynucleotidyl transferase 
TFIIA - Trancription factor IIA 
TFIID - Transcription factor IID 
TLP - TBP-like protein 
TRF - TBP-related factor  
tRNA - Transport RNA 
TSS - Transcription start site 
UTR - Untranslated region  
WHO - World Health Organisation 
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1.1 Overview: Plasmodium spp Biology and Disease 
The malaria disease poses one of the greatest health challenges in the developing world. 
Each year there are in excess of 200 million reported cases of malaria resulting in at least 
500,000 deaths. The disease is caused by a parasitic infection of erythrocyte cells by one 
of several Plasmodium species: Plasmodium falciparum, Plasmodium vivax, Plasmodium 
ovale, Plasmodium malariae, and Plasmodium knowlesi (Kantele & Jokiranta, 2011). The 
degree of virulence is largely determined by the parasite species responsible as well as 
the relative vulnerability of the human host, with P. falciparum and P. vivax accounting for 
almost all severe cases of the disease. The 2016 World Health Organisation (WHO) 
malaria report estimates that 70% of the total malaria deaths in 2015 occurred in children 
under the age of 5 years, with >90% of these fatal malaria infections being attributed to 
P. falciparum, the malaria parasite prevalent in Africa (WHO, 2016). 
1.1.1  P. falciparum life cycle 
P. falciparum is a unicellular eukaryotic organism that forms part of a diverse group of 
parasites within the phylum Apicomplexa. Typically, Apicomplexans are obligate 




stages, some of which rely on multiple host organisms for propagation (Fig. 1) (reviewed in 
Plattner & Soldati-Favre, 2008). P. falciparum is not found in any known ecological niches  
outside its two host systems: the female Anopheles gambiae mosquito and humans. 
Infection of the human host begins when P. falciparum sporozoites enter the dermis 
through the salivary glands of an infected mosquito. The mosquito injects saliva into the 
dermis through repeated bites while probing for a blood vessel. The injected sporozoites 
rely on active transport known as gliding motility to migrate from the dermis into the human 
circulatory system, usually crossing within 1-3 hours post exposure (Keely & Soldati, 2004; 
Baum et al., 2006). Movement from the bloodstream into the hepatocytes occurs as the 
sporozoite traverses the epithelial and Kupffer cells lining the liver sinusoid to contact and 
subsequently enter the hepatocytes through the formation of a parasitophorous vacuoles 
at the cell surface (Plattner & Soldati-Favre, 2008; Tavares et al., 2013). Hepatocyte 
invasion from the bloodstream is a rapid process with entry of sporozoites shown to occur 
in mice within 2 minutes of intravenous injection (Shin et al., 1982). Once established in 
the hepatocyte, the sporozoite matures over 7-10 days to an exo-erythrocytic form called 
the merozoite. The parasite then multiplies to generate up to 40 000 new merozoites per 
infected hepatocyte (reviewed in Prodêncio et al., 2006; Cowman et al., 2016). Merozoites 
are released as membrane-bound merosomes into the lumen of the liver sinusoid (Sturm 
et al., 2006). Following this, the merosomes rupture, resulting in the re-entry of the 
parasite into the host circulatory system where they are free to enter the next stage of the 
life cycle by invading the host erythrocyte cells. Merozoite adherence to the erythrocyte 
surface is thought to be mediated by merozoite surface protein 1 (MSP1), the most 
abundant and functionally conserved coat protein. MSP1 has been shown to serve as a 
platform for other surface peptides, thus forming multiple distinct protein assemblies which 
may be responsible for the binding of target erythrocyte cells (Lin et al., 2016). There are 
however numerous other surface proteins present (reviewed in Cowman et al., 2012) and 
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the requirement for MSP1 in erythrocyte invasion is found not to be absolute (Das et al., 
2015). There is also some suggestion that MSP1 may function in the evasion of the host 
immune responses as opposed to erythrocyte invasion (Cowman et al., 2016). Once initial 
contact with the erythrocyte surface is made, the merozoite is re-orientated through an 
array of specific ligand-receptor interactions to bring its apical end into direct contact with 
the erythrocyte membrane and enters the cell, thereby forming a new parasitophorous 
vacuole (Weiss et al., 2015). Once inside the erythrocyte, the parasite development enters 
the ring stage, the name based on its appearance in Giemsa-stained blood smears. Here, 
the parasite’s nutrient uptake is at first achieved by feeding on small amounts of nutrients 
from the cell plasma through a nutrient channel located within the parasitophorous vacuole 
membrane (Desai & Rosenberg, 1997). Continued growth leads to the trophozoite stage 
where the most pronounced nutrient uptake, growth, and modification to the erythrocyte 
cell occurs. Faced with the problem of nutrient assimilation, the parasite begins to 
metabolise the cellular haemoglobin as a source of amino acids, and also begins to alter 
the permeability of the host cell membrane through the modification of surface anion 
channels, which subsequently facilitates the transport of purines, sugars and other 
essential nutrients (Desai et al., 2000; Decherf et al., 2004). In addition, the parasite forms 
a tubulovesicular network that extends from its vacuole to the cell surface. This network 
has also been implicated in the uptake of nutrients such as nucleosides and amino acids 
(Lauer et al., 1997). The haemoglobin breakdown product, ferriprotoporphyrin IX, 
crystallises to form the darkly pigmented haemozoin crystals within the food vacuole. 
Secretory compartments known as Maurer’s clefts are formed which aid in the transport of 
parasite-derived proteins to the erythrocyte cell surface (Tilley et al., 2008). The 
presentation of P. falciparum proteins - such as those from the P. falciparum erythrocyte 
membrane protein 1 (PfEMP1) family - causes knob-like projections from the erythrocyte 
surface and facilitates cytoadherence to the endothelial cells of the host blood vessels. 
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This cytoadherence aids in immune evasion by preventing clearance of infected cells by 
the spleen (reviewed in Hviid & Jansen, 2015). Lastly, some of the surface antigens are 
responsible for the binding of healthy erythrocytes by infected cells. This process is known 
as rosetting and is thought of as a possible strategy to mask infected cells from the host 
immune system (Plattner & Soldati-Favre, 2008). The parasite next enters the schizont 
stage. Here it undergoes a series of nuclear divisions and begins to synthesise the 
molecules needed for erythrocyte invasion. The new parasite nuclei start to move toward 
the cell periphery as they bud off from the main parasite compartment to form new 
merozoites. Finally, a signalling cascade involving serine protease (PfSUB1) together with 
calcium-dependent (PfCDPK5) and cGMP-dependent (PfPKG) protein kinases trigger the 
release of infective merozoites through the rupturing of the parasitophorous vacuole and 
erythrocyte membrane (Salmon et al., 2001; Dvorin et al., 2010; Collins et al., 2013). 
During the transition to the schizont phase, a small proportion of parasites undergo a 
metabolic switch and are committed to the formation of male and female gametocytes. 
Gametocyte maturation is a process lasting approximately 6-8 days. The gametocytes are 
able to avoid clearance by the spleen during maturation by being sequestered in the bone 
marrow (Joice et al., 2014). Mature gametocytes are subsequently released back into the 
bloodstream, being made available for further transmission through the blood uptake of a 
feeding mosquito. The exact molecular mechanisms controlling commitment to the sexual 
cycle are unknown. However, increased gametogenesis has been linked to high levels of 
parasitemia as well as the presence of antimalarials such as chloroquine, suggesting that 
it is likely brought about through environmental cues (Cowman et al., 2016). Fertilization 
occurs in the midgut of the mosquito vector. Here, the resultant zygote matures within 
several hours to form an ookinete, which is able to migrate through the midgut epithelium 
and then to transition to a mature oocyst on the basal lamina of the epithelial cells. New 
sporozoites are formed through asexual sporogenic replication and released through the 
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subsequent rupturing of the oocyst. Migration to the salivary glands is then achieved via 
the mosquitos haemolymph system (reviewed in Beier, 1998; Cowman et al., 2016).                 
1.1.2 Epidemiology and natural acquired immunity of host 
Malaria is endemic across most of Africa, Central and South America, and Southeast Asia. 
The distribution and the intensity of transmission are determined by a combination of 
ecological factors involving the mosquito vector, the parasite, and the human host (WHO, 
2016). Key environmental factors are moderate temperature and moderate to high 
humidity, both of which are required for the proliferation of the mosquito vector. The 
proclivity of the African Anopheles species to feed on humans together with its relatively 
long lifespan is largely responsible for the disproportionately high number of malaria cases 
in Africa. In areas of extremely high transmission, severe disease and death is largely 
restricted to young children (WHO, 2016). This is due to a naturally acquired immunity 
developed in the older population through continuous parasitaemia. The adult acquired 
immunity is not absolute as the risk of infection continues throughout life. There is however 
a marked reduction in the disease state symptoms reflecting an acquired ability to tolerate 
levels of asymptomatic parasitaemia as opposed to immune responses that totally 
eradicate the parasite from the host system (Cowman et al., 2016). The ability of gamma 
globulins isolated from immune adults to markedly suppress parasitemia in children 
suggests that the acquired immunity involves antibody-mediated targeting of the blood 
stage parasite (Cohen et al., 1961). However, the extremely slow development of natural 
immunity together with evidence that a strong immune response can be developed against 
pre- (Riley & Stewart, 2013) and post- (Wu et al., 2015) erythrocytic parasite stages 
indicate that it is likely the result of a complex immune response developed against a 
number of targets over many generations of parasite invasion and proliferation.  
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1.1.3  Pathogenesis of P. falciparum malaria 
The clinical symptoms of malaria are mainly febrile, involving headaches, nausea, and 
general muscle fatigue. Early treatment of P. falciparum-induced malaria with antimalarial 
drugs will usually result in the alleviation of symptoms within 5-10 days and the eventual 
eradication of the parasite from the host system. In the case of an uncontrolled infection or 
a drug-resistant parasite, the disease can very quickly progress to the state of severe 
malaria (WHO, 2016). Symptoms of severe malaria differ depending on the age of the 
infected individual. Young children experience a combination of severe anaemia, 
respiratory distress, and/or cerebral malaria that can lead to malaria-induced coma and 
death. In addition, non-immune adults experience hepatic and renal dysfunction together 
with hypoglycaemia and respiratory distress due to pulmonary edema. The pathogenic 
effects of P. falciparum infection stem almost entirely from erythrocyte dysfunction brought 
about by parasite-mediated changes during the blood stage of the life cycle (Smith et al., 
2013). These changes lead to microvascular obstruction through cytoadherence to the 
epithelial cells of the vasculature together with localised endothelial activation (Wassmer et 
al., 2015). Microvascular obstruction causes direct organ damage through blood flow 
restriction as well as broader systemic problems such as metabolic acidosis and acute 
pro-inflammatory responses (Kwiatkowski et al., 1998; Dondorp et al., 2008). There is also 
a strong correlation between severe malaria and incidences of bacterial pathogenesis in 
young children with a marked increase in dual infection mortality (Church & Maitland, 
2014; Gómez-Pérez et al., 2014). In addition, pregnant woman are very susceptible to the 
development of severe malaria due to placental tissue providing new surface area for 
parasite sequestration through the adhesion of infected erythrocytes to placental 
chondroitin sulphate A (Khunrae et al., 2010). This can lead to low-birthweight or still birth 
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depending on the degree of natural immunity in the expectant mother (McLean et al., 
2015).  
1.1.4 Transmission control and current treatments  
Reductions in the rates of transmission within endemic areas are achieved mainly by way 
of vector control strategies such as long-lasting insecticidal nets (LLINs) and indoor 
residual spraying (IRS) within homes (WHO, 2016). The LLINs function as a physical 
barrier placed over the bed to prevent vector contact at night while insecticide residue on 
the walls and ceilings of homes help to reduce the vector population within a given area if 
large scale coverage (> 80%) is achieved. In addition, travellers to high risk areas may 
take preemptive antimalarial medications such as sulfadoxine-pyrimethamine to reduce 
the risk of infection. Control strategies have proved effective. However, resistance to the 
insecticides has started to emerge in vector populations, prompting the WHO to release 
the “Global plan for insecticide resistance management in malaria vectors” in May 2012, 
which is aimed at facilitating collaboration between the relevant stakeholders in the 
development of new tools and strategies for vector control (Mnzava et al., 2015). In the 
case of active malaria infections, the most effective treatments currently available are 
artemisinin-based combination therapies. Parasite resistance to many of the first 
generation malaria drugs such as chloroquine has necessitated the use of these multi-drug 
strategies whereby artemisinin or a semi-synthetic derivative is administered in conjunction 
with a second relatively long-lasting antimalarial to counteract the short half-life of 
artemisinin (Vugt et al., 1999). The mechanism of action is thought to involve a haem-
mediated activation of an endo-peroxide ring within the artemisinin structure resulting in 
increased oxidative stress and parasite death (Winzeler & Manary, 2014). Unfortunately, 
signs of artemisinin resistance have already begun to emerge in Southeast Asia (Dondorp 
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et al., 2008). Whole-genome studies of resistant parasites have identified at least 20 
polymorphisms in the K13-propellar gene as a set of useful genetic markers for resistance 
(Ariey et al., 2014; Miotto et al., 2015) with a concurrent study demonstrating that insertion 
of some of these mutations was indeed able to confer a measure of resistance to non-
resistant reference strains (Straimer et al., 2015). In addition, transcriptional analysis has 
indicated that resistant parasites display an up-regulation of their unfolded-protein 
response pathways together with a decrease in early ring-stage parasite growth rate, 
suggesting an increased tolerance of blood-stage parasites to the negative effects of the 
artemisinin induced oxidative stress (Mok et al., 2015). 
1.1.5 Development of novel antimalarial compounds 
Widespread resistance to current treatments have been met with a concerted effort by 
both public and private entities to find and develop novel antimalarial compounds (Gamo 
et al., 2010; Guiguemde et al., 2010; Meister et al., 2011; Spangenberg et al., 2013). To 
this end, both high-content screening (HCS) together with synthetic approaches are 
currently being used. HCS, also known as whole-cell screening, is a high-throughput 
method of drug screening that combines multi-colour fluorescence microscopy together 
with cellular imaging and data analysis software to examine phenotype responses to a 
large number of candidate compounds in order to identify possible lead molecules for 
further development (Zanella et al., 2010). Synthetic approaches form part of the rational 
drug design method which make use of computer modelling together with known structural 
aspects of either the drug target or available drugs to produce a blueprint for the chemical 
synthesis of novel compounds (Mandal et al., 2009). There is increasing overlap in the 
employment of these approaches as HCS technologies are often used to further test for 
efficacy and toxicity of newly synthesised compounds (Zanella et al., 2010). A number of 
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new drugs which have been found to disrupt the parasites Na+ homeostasis by binding to a 
Na+-ATPase (PfATP4) are currently in various stages of clinical trials (Spillman et al., 2013; 
Vaidya et al., 2014; Jiménez-Díaz et al., 2014). Further development is also underway for 
a more recent compound that has been identified as a potent inhibitor of protein synthesis 
through its inhibition of translation elongation factor 2 (eEF2) (Baragaña et al., 2015). In 
addition, a new class of compounds named imidazopyrazines have been identified, and 
act by inhibiting the parasite lipid kinase PI4K (McNamara et al., 2013). Significantly, the 
imidazopyrazines also show activity against the dormant liver stage of the simian parasite 
P. cynomolgi. Although not present in the P. falciparum life cycle, these dormant parasite 
forms known as hypnozoites are features of both P. vivax and P. ovale. Hypnozoites can 
lead to a series of relapse infections spanning a number of weeks or even months and 
therefore pose a serious challenge to the eradication of malaria. There is currently only 
one commercially available treatment active against these dormant cells. However, newly 
identified compounds are currently being tested (Ashley et al., 2014; Llanos-Cuentas et al., 
2014; Zeeman et al., 2014). Rational design approaches have also led to the development 
of a class of antimalarial molecules known as ozonides. These molecules are based on 
the conservation of the endoperoxide bridge found in artemisinin and thus likely cause 
oxidative damage to the cellular components of the blood stage parasite upon activation 
by the ferrous iron of the metabolised haemoglobin (O’neill, 2004; Vennerstrom et al., 
2004; Charman et al., 2011). Finally, the P. falciparum dihydrooratate dehydrogenase 
enzyme from the parasites pyrimidine biosynthesis pathway has been used as a target for 
the identification of potent triazolopyrimidine-based inhibitors, one of which has recently 
been advanced to human trials (Coteron et al., 2011; Phillips et al., 2015).  
1.1.6 Vaccine development  
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There is currently only one commercially available anti-malaria vaccine. RTS,S/AS01 
(Mosquirix) is a sporozoite-based vaccine that utilises a chimeric protein formed from the 
C-terminal half of the P. falciparum circumsporozoite protein (CSP) fused to the hepatitis B 
surface antigen (Cohen et al., 2010). Unfortunately, despite very promising phase II clinical 
trails, the phase III trials demonstrated only a very modest efficacy with a three dose 
regimen resulting in only a 28% reduction in malaria cases for immunised children aged 
5-17 months and with a further drop in the efficacy for infants (Greenwood & Doumbo, 
2016). Overall, the vaccine has however been judged by several disease modelling 
studies to be a cost effective tool when compared to the costs incurred by alternative 
control measures, thus making it an important milestone by which all future vaccine 
candidates will be judged (Penny et al., 2016). 
The difficulty in producing an effective anti-malaria vaccine is largely due to the complexity 
of the parasite life cycle and the high degree of antigenic variation brought about by the 
transient expression of multiple PfEMP1 gene variants during erythrocyte infection 
(reviewed in Scherf et al., 2008; Hviid & Jensen 2015; further discussed in Section 1.1.8). 
The current vaccine development strategies are mainly focused on the pre-erythrocytic 
and sexual stages of parasite life cycle as both of these stages represent a bottleneck in 
parasite numbers and a comparative lack in immune evasion capabilities relative to the 
blood stage merozoite form. There are currently a number of live-cell sporozoite vaccines 
under development using radiation attenuated (Seder et al., 2013) and genetically 
modified (Spring et al., 2013) sporozoites. These however all suffer the major drawback of 
only producing strain-specific immune protection. In addition, the most notable problem 
with strategies of this nature is that the immunogenic reactions elicited from different 
stages of the parasite life cycle are very specific to that stage (Felgner et al., 2013). This 
means that if a single parasite is able to evade the immune response long enough to reach 
 19
the red blood cells then the resistant parasite would be propagated and could result in a 
potential resurgence of infections. This eventuality seems even more likely when 
considering the declining efficacy of current antimalarial drugs. A possible strategy to 
prevent this would be to produce a vaccine using multiple antigenic targets from various 
stages in the parasite life cycle. One such candidate makes use of the blood stage antigen 
- glutamate-rich protein (GLURP), fused to a fragment of the sexual stage antigen 
Pfs48/45 to form a chimera that produced a strong antibody response in rodents (Theisen 
et al., 2014). This strategy will likely be central to vaccine development in the coming years 
as candidates for a broad stage anti-malaria vaccine have already been identified in both 
the sporozoite and erythrocytic parasite forms (Cohen et al., 2010; Douglas et al., 2015).  
1.1.7 Gene regulation in P. falciparum 
By its very nature, the complexity of the P. falciparum life cycle necessitates a highly 
controlled and equally complex gene expression program that sees the parasite 
transitioning between multiple morphological states in both intracellular and extracellular 
environments within two very different host organisms. This is indeed evidenced by the 
patterns of stage-specific gene expression seen throughout the parasites life cycle 
(Florens et al., 2002; Bozdech et al., 2003; Le Roch et al., 2003; Adjalley et al., 2016). 
Following on from the original publication of the P. falciparum genome sequence (Gardner 
et al., 2002), studies which investigated the changes in gene expression in response to 
external stimuli and physiological stresses such as temperature changes and glucose 
starvation found evidence of flexibility in the parasites expression profiles (Fang & 
McCutchan, 2002; Fang et al., 2004; Oakley et al., 2007). These observations, together 
with the periodic nature of mRNA levels during the sporozoite, intra-erythrocytic, and 
sexual stages, which correlated with the expression of discrete gene clusters, related by 
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function and/or cellular process to the immediate physiological demands of the parasite, 
led to the hypothesis that transcription immediately proceeded to the translation of mature 
protein and thus implicated transcription initiation as the primary point of gene regulation in 
P. falciparum (Bozdech et al., 2003; Le Roch et al., 2003). Subsequent studies questioned 
this idea. Quantitative microarray data together with a semi-quantitative protein analysis 
techniques employing multidimensional liquid chromatography coupled to mass 
spectrometry did not confirm a tight correlation between mRNA and protein abundance but 
instead found a distinct lag between mRNA production and translation. This finding led to 
the proposal that post-transcriptional mechanisms may play a predominant role in gene 
regulation (Le Roch et al., 2004). This hypothesis is supported by bioinformatics analysis 
of the P. falciparum genome sequence, showing a striking paucity of specific transcription 
factors (STF) and a comparative over-representation of CCCH zinc finger domain proteins 
involved in the stability, localisation, and translation of mRNA (Coulson et al., 2004; 
reviewed in Deitsch et al., 2007; Horrocks et al., 2009). In addition, studies into the 
mechanisms underlying the parasite antigenic variation through the differential expression 
of the var gene family (reviewed in Scherf et al., 2008), together with the determination of 
the P. falciparum genomic histone modification profile has placed much emphasis on the 
epigenetic aspects of gene regulation (Scherf et al., 1998; Horrocks & Lanzer., 1999; 
Deitsch et al., 2001; Miao et al., 2006; reviewed in Merrick & Duraisingh, 2010). The 
importance of gene regulation at the level of transcriptional initiation was, however, again 
highlighted by the discovery of a range of Apicomplexa STFs containing a novel Apetala 2 
(AP2) DNA-binding domain (Balaji et al., 2005; De Silva et al., 2008). This was followed 
shortly by the identification of a number of key RNA polymerase II (RNAP-II) general 
transcription factors that had up to that point been missed by traditional bioinformatics 
searches due to the extremely high (> 80%) A/T nucleotide base content of the parasite 
genome (Callebaut et al., 2005). Largely owing to the atypical nucleotide content of the 
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parasite genome, there has up until very recently been a distinct lack of data with respect 
to the regulation of basal RNAP-II transcription initiation beyond that of the in silico 
prediction of putative protein candidates for some conserved eukaryotic transcriptional 
machinery. So far, the P. falciparum TATA-binding (PfTBP) protein is the only general 
transcription factor that has been functionally characterised, albeit in a very preliminary 
manner. In these studies, results of electrophoretic mobility shift assays and DNase I 
footprinting assays are presented to suggest that PfTBP binds a consensus TATA-
sequence (TATAA) upstream of the kahrp gene and an atypical TATA-sequence (TGTAA) 
upstream of the gbp-130 gene (Ruvalcaba-Salazar et al., 2005). The notion that PfTBP 
binds to distinct sequences in parasites core promoters seem however not compatible with 
results of this work and with recently published work which produced a comprehensive 
map of transcription start site positions in the P. falciparum genome through RNA-seq 
data. These studies found little evidence of traditionally defined promoter elements but 
rather that transcription initiation events where correlated to the local A/T basepair content 
as opposed to a distinct sequence motif (Adjalley et al., 2016).  
1.1.8 P. falciparum antigenic variation  
A defining characteristic of the Plasmodium species is a highly evolved immune evasion 
strategy mediated by antigenic variation at the surface of infected erythrocyte cells. In the 
P. falciparum (3D7) genome there are 58 var genes (and 1 var pseudogene) encoding a 
clonally variant and immunodominant family of adhesion molecules known as Plasmodium 
falciparum erythrocyte membrane protein 1 (PfEMP1) (reviewed in Kraemer & Smith, 
2006; Scherf et al., 2008). These are presented at the cell surface of infected erythrocyte 
molecules, causing the infected erythrocytes to adhere to various cell types within the host 
vasculature as a way of avoiding clearance by the spleen. In addition, there is evidence 
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that these molecules are able to interact directly with the host immune system, a 
characteristic which likely leads to immune suppression (Gilbert et al., 1998; Urban et al., 
1999; Donati et al., 2004).  
All var genes consist of two exons separated by a conserved intron. Exon 1 codes for a 
polymorphic extracellular region that contains multiple Duffy-binding-like (DBL) adhesive 
domains as well as cysteine-rich inter-domain regions (CIDR), while the second exon 
codes for a semi-conserved cytoplasmic domain (Kramer & Smith, 2006). These genes 
are distributed across four of the fourteen parasite chromosomes (chromosome 4, 7, 8, 
and 12). Most var genes are positioned at the highly variable chromosomal ends, while 
approximately 40% are located near the chromosome centres (reviewed in Kirkman & 
Deitsch, 2012). The subtelomeric var genes are flanked by six distinct regions of non-
coding DNA known as telomere-associated repeat elements (TARE 1-6). Subtelomeric var 
genes are typically arranged in a head to head orientation with the transcription of adjacent 
genes proceeding in opposite directions while the centrally located var genes are found 
clustered in tandem-arrays. The var genes of the P. falciparum 3D7 strain are further 
characterised by five possible promoter sequences: upsA, -B,- C, -D, and -E, as well as a 
sixth combinatorial promoter sequence designated upsBC. There is a strong correlation 
between these various promoter sequences with both the chromosomal positioning and 
the orientation of transcription associated with the cognate gene (Lavstsen et al., 2003; 
Kirkman & Deitsch, 2012). Subtelomeric var genes that are transcribed toward the centre 
of the chromosome are typically flanked by upsB, those in the same region but transcribed 
away from the centre are typically flanked by upsA but can also be found associated with 
upsD and/or upsE sequences. The internal var genes however are typically associated 
with the upsC promoter. Finally, upsBC var genes can be found at both chromosomal ends 
as well as within the central regions. Interestingly, despite these differences in promoter 
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sequence and gene orientations, all of the var gene variants are subject to mutually 
exclusive expression. The molecular mechanisms underlying this system of expression 
has been a central research focus for many years in the malaria field (Scherf et al., 2008). 
Fluorescent in situ hybridization (FISH) data showing the localisation and clustering of both 
subtelomeric and centralised var genes to the nuclear periphery provide clues to the 
mechanisms behind the high rates of genetic recombination within the var gene family as 
well as the promoter-dependent regulation of transcription from these loci (Freitas-Junior 
et al., 2000; Ralph et al., 2005). Indeed, PCR analysis of the var genes from two P. 
falciparum genotypes (3D7 and HB3) have demonstrated phenotypic variations at rates 
exceeding that which could be explained by genetic drift. Subsequent analysis of var gene 
sequences in the progeny of recombinant laboratory strains provided further evidence of 
intergenic recombination occurring at the sites of var gene clustering (Taylor et al., 2000). 
Although epigenetic control of var gene expression is well established (reviewed in Ralph 
& Scherf, 2005; Cui & Miao, 2010; Gupta et al., 2013), the principle of context-dependent 
activation of transcription from promoters influenced by proximity to other core promoters 
(reviewed in Andersson et al., 2015) is strongly indicated in the repression of the var gene 
family. A series of experiments by several groups using reporter gene constructs under the 
control of var gene promoters demonstrated that promoter pairing is likely to play a 
significant role in transcriptional silencing. These studies began with the observation that 
the conserved var intron was able to repress transcription when placed at the 3’ end of a 
var gene, and that this intron in fact possessed transcriptional activity (Deitsch et al., 2001; 
Calderwood et al., 2003). It was then demonstrated that activated var promoters (upsB 
and upsC) in a stably transfected episome were localised to the nuclear periphery and 
were sufficient to elicit total endogenous var gene silencing in the absence of any virulence 
factor expression. This demonstrated that promoter activity, and not the gene product, is 
central to the mutually exclusive expression of the var gene variants (Voss et al., 2006; 
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Voss et al., 2007). These important findings were confirmed independently by a second 
laboratory using similarly modified parasite lines (Dzikowski et al., 2006). Leading on from 
these results, the same group demonstrated that the apparent intron-mediated silencing 
could be achieved by pairing a var promoter with a number of P. falciparum promoters at 
the 3’ of the reporter gene and that uncoupling the var gene from a downstream promoter 
would remove it from the mutually exclusive var gene expression patterns (Dzikowski et 
al., 2007). In summary, the data as a whole supports the notion that in addition to 
epigenetic regulation, transcriptional silencing of inactive var genes is mediated by a novel 
coupling mechanism that sees a second downstream promoter sequence functioning as a 
type of repressor in the context of antigenic switching of the PfEMP1 gene family in 
P. falciparum.                   
1.2 Overview of eukaryotic transcription 
The process of transcription is defined as the DNA-dependent synthesis of RNA molecules 
by cellular RNA polymerases. With respect to nuclear gene expression in humans, there 
are four distinct RNA polymerases that take part in this highly co-ordinated process, each 
of which is responsible for the synthesis of a distinct sub-class of RNA molecules (Roeder 
& Rutter, 1969; Roeder & Rutter, 1970; Weinmann & Roeder, 1974; Kravchenko et al., 
2005). RNA polymerase I (RNAP-I) is responsible for the transcription of 18S, 28S, and 
5.8S ribosomal RNA. RNA polymerase II (RNAP-II) transcribes the bulk of the cellular 
messenger RNA (mRNA) molecules as well as microRNAs and long non-coding RNAs 
from intergenic and enhancer regions. RNA polymerase III (RNAP-III) synthesises the 5S 
ribosomal RNA as well as the various transport RNAs (tRNAs). More recently, a single-
polypeptide nuclear RNA polymerase (spRNAP-IV) was discovered in human HeLa cells 
(Kravchenko et al., 2005). Structurally, this protein is an N-terminal truncation of the 
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mitochondrial RNA polymerase (mtRNAP) peptide that is coded for by the nuclear 
POLRMT gene. It has been found that spRNAP-IV is responsible for the transcription of a 
subset of nuclear protein-coding genes that are not recognised by the RNAP-II 
transcription machinery. In addition to the essential RNA polymerases found in all 
eukaryotes (RNAP-I,-II, and -III), plants contain two more RNAP variants, RNAP-IV and 
RNAP-V (or -IVb), both of which play a central role in transcriptional silencing through the 
production of short interfering RNAs (siRNAs) (Onodera et al., 2005; Pikaard et al., 2008; 
Ream et al., 2009). Despite sharing a common functionality in the production of RNA from 
a defined DNA template, the RNA polymerases all lack DNA-sequence recognition 
capabilities and as such require accessory proteins to facilitate the recognition of the 
promoter and transcription start site of a particular induced gene. These accessory 
proteins are collectively termed general transcription factors (GTFs), with each RNA 
polymerase requiring a distinct set of GTFs to initiate site-specific transcription of their 
target genes. Here, I focus on the RNAP-II pathway with particular emphasis on the 
RNAP-II general transcription factors: TATA-binding protein (TBP), Transcription Factor IIA 
(TFIIA), and the TBP-like protein TRF2 (TLP). These key RNAP-II factors play a vital role 
in promoter recognition and the subsequent transcription of protein coding genes within all 
eukaryotes subsequent to the evolution of the bilateria and are, with the exception of 
PfTBP (McAndrew et al., 1993; Ruvalcaba-Salazar et al., 2005), not studied in P. 
falciparum. 
1.2.1  The RNA polymerase II pre-initiation complex (PIC) 
Human RNAP-II is composed of 12 subunits designated RPB1 to RPB12. These are 
generally well conserved in other eukaryotes (Young, 1991; Armache et al., 2003) with 
RPB1 and RPB2 being responsible for the protein’s catalytic activity (Hampsey, 1998; Lee 
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and Young, 2000). A defining feature of RNAP-II is a C-terminal domain (CTD) located 
within the RPB1 subunit, containing a large number of heptapeptide repeats Tyr-Ser-Pro-
Ser-Pro-Ser (YSPTSPS). Structurally, the CTD is regarded as a disordered region and 
therefore vulnerable to proteolytic degradation. The CTD of human RNAP-II contains 52 
heat peptide repeats. However, this number does vary significantly between different 
species (Dahmus, 1995; Hampsey, 1998; Lee & Young, 2000). The CTD is the site of 
multiple post-translational modifications such as phosphorylation, glycosylation, and 
ubiquitination. Three separate forms of human RNAP-II (-IIO, -IIA, and -IIB) can be 
distinguished based on differential phosphorylation as well as the presence or absence of 
the CTD (Kershnar et al., 1998). The RNAP-IIA form is typically associated with pre-
initiation complex (PIC) assembly and is marked by low levels of CTD phosphorylation 
(hypophosphorylation). In contrast, the RNAP-IIO state contains a hyperperphosphorylated 
CTD and is associated with the elongation and termination of the newly synthesised 
mRNA chain. Lastly, the RNAP-IIB variant lacks the CTD due to proteolytic cleavage. This 
form has, however, been shown to maintain its transcriptional activity on a number of 
different promoter constructs despite this alteration (Kim and Dahmus, 1989; Buermeyer et 
al., 1995; Zehring and Greenleaf, 1990). Glycosylation may occur on the threonine 
residues located at position four of the heptapeptide repeats. Glycosylation is only found 
on the RNAP-IIA variant and is thought to either sterically hinder protein kinases from 
phosphorylating the CTD or to this end alter the CTD conformation to a form that limits the 
interaction with protein kinases. Overall, the exact function of this modification is unclear. 
However, it is thought that glycosylation may help to regulate early stages of RNAP-II 
transcription by promoting the RNAP-A form involved in PIC assembly (Kelly et al., 1993; 
Comer & Hart, 2001). Poly-ubiquitination is the third of the well characterised RNAP-II 
post-translational modifications. It has been found that ubiquitination of the CTD occurs as 
a response to DNA damage incurred by both UV exposure and oxidative stress, which 
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leads to the activation of the transcription-coupled repair process and often results in the 
degradation of transcriptionally stalled RNAP-II by the 26S proteasome (Bregman et al., 
1996; Inukai et al., 2004).  
Evidence of accessory factors required for promoter-specific transcription initiation by 
RNAP-II was first seen when purified RNAP-II was supplemented with crude nuclear 
extract fractions to facilitate in vitro transcription from the Adenovirus type 2 major late 
promoter (Ad2ML) (Weil et al., 1979; Thomas & Chiang, 2006). These nuclear extract 
fractions were then further purified to isolate and to identify the factors required for 
promoter-specific RNAP-II transcription initiation. Collectively these factors were 
designated the general transcription factors (GTFs) and consist of Transcription factor IIA 
(TFIIA), TFIIB, TFIID, TFIIE, TFIIF, and TFIIH (Fig. 2B). Subsequent work demonstrated 
that the positioning of RNAP-II at the start site of transcription requires the assembly of a 
pre-initiation complex (PIC), a large protein mega-complex at the core promoter of an 
activated gene (Fig. 2A). Core promoter regions are highly variable in structure and often 
gene-specific (further discussed in Section 1.2.2). The text book model of PIC assembly 
discussed here is based on studies with TATA box-containing model promoters, such as 
the adenovirus type 2 major late promoter (Ad2ML). Major advances have been made in 
the understanding of  PIC formation within the last five years with the publication of cryo-
EM data for both human and yeast PIC structures (He et al., 2013; Murakami et al., 2013). 
A simplified order of events leading to the initiation of transcription in human cells can be 
described as follows (reviewed in Kandiah et al., 2014). PIC formation commences with 
binding of TATA box-binding protein (TBP) to the TATA box element (Bleichenbacher et al., 
2003; Cianfrocco et al., 2013). TFIIA and TFIIB are then recruited and stabilise this 
interaction (Imbalzano et al., 1994b; Hieb et al., 2007; Cianfrocco et al., 2013). Next, 
RNAP-II is recruited by TFIIB in the presence of TFIIF and TFIIE. The subsequent 
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recruitment of TFIIH then leads to a stable TBP-TFIIA-TFIIB-RNAP-II/TFIIF-TFIIE-TFIIH 
transcriptionally closed PIC complex in the absence of ATP. TFIIH-mediated promoter 
melting, in an ATP-dependent manner, transitions the complex to a transcriptionally open 
state. Once in the open state, RNAP-II typically cycles through multiple rounds of abortive 
transcription in which many short (2-15 base) mRNAs are produced before proceeding 
from initiation to elongation were it transitions along the DNA template to synthesise the 
nascent full-length mRNA molecule (Luse & Jacob, 1987; Holstege et al., 1997). In most 
eukaryotes, transcription by RNAP-II is briefly paused after synthesising approximately 
20-60bp of mRNA to allow for the disconnection of the actively transcribing elongation 
complex from the remaining transcriptional apparatus at the core promoter, the so-called 
re-initiation scaffold, in an event known as promoter escape (Dvir et al., 1997; Saunders et 
al., 2006; Hahn, 2004; Min et al., 2011 Adelman et al., 2012; Kwak et al., 2013). The re-
initiation scaffold at the core promoter acts to increase the overall rate of transcription re-
initiation as only RNAP-II, TFIIF, and the ejected TFIIB need to be re-recruited for 
subsequent rounds of transcription (Yudkovsky et al., 2000). In addition to the general 
transcription factors, the regulatory networks that govern gene activation involve a host of 
gene-specific transcription factors such as activator/repressor proteins, as well as the 
general cofactors that mediate the interactions between these two groups. Generally 
speaking there are two main classes of regulatory cofactors that govern the interactions 
between specific transcription factors and the general transcription factors of the RNAP-II 
PIC (reviewed in Thomas & Chiang, 2006).These are the TBP-associated factors (TAFs) of 
the TFIID complex, and a group of cofactors isolated from crude fractions of HeLa cell 
nuclear-extract known as the upstream stimulatory activity (USA) cofactors which include 
the mediator complex. With the exception of the TAFs, briefly discussed in the context of 
TFIID (Section 1.2.3), these regulatory networks go beyond the scope of the research 
presented here and as such will not be further discussed. 
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1.2.2 The Core Promoter Elements (CPEs) 
The core promoter is typically defined as the region of DNA (50-100bp) spanning the 
transcription start site of a given gene. In mammals, core promoters have been 
categorised as either “high-GC” or “low-GC” promoters based on the relative GC-content 
and CpG dinucleotide frequency within these regions (reviewed in Lenhard et al, 2012). In 
addition, high-GC promoters, also called broad type promoters, are found to have multiple 
transcription start sites (TSSs), while low-GC promoters exhibit a more clearly defined 
TSS, usually initiating from a single nucleotide position. Genome-wide studies have since 
been used to further differentiate mammalian promoters into three main sub-types. Type I, 
are low-GC promoters that are found to be responsible for tissue-specific gene activation, 
while type II promoters, generally associated with housekeeping genes, typically consist of 
a single CpG island overlapping the TSS. Lastly, type III promoters are associated with 
developmentally regulated genes and are defined by the occurrence of multiple large CpG-
islands. In addition to these atypically high CpG-sites, core promoters also contain one or 
more short DNA-motifs that are conserved with respect to both their sequence and their 
corresponding position relative to the TSS (Fig. 3A). These motifs are recognised and 
bound by components of the RNAP-II pre-initiation complex (Fig. 3B), and are collectively 
known as the core promoter elements (CPEs) (reviewed in Roy and Singer, 2015; Danino 
et al., 2015). There are currently eight common CPEs that are found in varying 
combinations within the core promoter regions of eukaryotes. The TATA box and initiator 
(Inr) elements are the two most abundant CPEs, and are found together or in isolation 
within eukaryotic promoters (Suzuki et al., 2001; Gershenzon & Ioshikhes; 2005). Both the 
TATA box and the Inr element provide a platform for the initial recognition and binding of 
the core promoter by TFIID. The TATA box is usually present 24-31 bp upstream of the 
transcription start site of TATA-containing genes and serves as the binding site for the  
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TATA-binding protein (TBP) of the TFIID complex (Bleichenbacher et al., 2003). When 
present, the Inr element spans 7bp over and around the transcription start site and is 
capable of initiating transcription independently of the TATA box element (Smale, & 
Baltimore 1989; Roy and Singer, 2015). Based on random DNA-binding site selection 
assays, recognition of the Inr element sequence is thought to take place through 
interactions with the TBP-associated factors TAF1 and TAF2 of TFIID (Chalkley & Verrijzer, 
1999). The downstream promoter element (DPE) has been found to occur with the Inr 
element in mostly TATA-less promoters at position +28 to +34 of the transcription start site 
(Burke & Kadonaga, 1996, 1997). Unlike the TATA box, it is not able to function 
independently but rather functions cooperatively with the Inr element in the binding of 
TFIID through TAF6 and TAF9 (Kutach and Kadonaga, 2000; Shao et al., 2005). A second 
core promoter element found downstream of the transcription start site is the downstream 
core element (DCE) (Lewis et al., 2000; Lee et al., 2005). The DCE is unique in that it is 
made up of three subelements spanning the +6 to +34 region and which are all bound by 
TAF1 of TFIID (Fig. 3B) (Lee et al., 2005). In vitro transcription experiments have also 
shown that the third subelement usually located within the +30 to +34 downstream region 
is able to function independently of the other sub-elements and bioinformatics analysis of 
both the Eukaryotic Promoter Database (EPD) and Database of Transcriptional Start Sites 
(DTSS) (http://dbtss.hgc.jp/) indicate that its presence strongly excludes the DPE 
sequence motif (Lee et al., 2005). The motif ten element (MTE), usually found between 
+18 and +29, functions in conjunction with the Inr in RNAP-II mediated transcription (Ohler 
et al., 2002; Lim et al., 2004). The MTE can work synergistically with the TATA box and 
DPE in in vitro transcription using either Drosophila or HeLa cell nuclear extract. However, 
the transcription factors that bind the MTE are yet to be determined (Lim et al., 2004). 
More recently, a new CPE element called the downstream transcription initiation element 
(DTIE) was found in the context of human genes that are negative for both TATA box and 
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Inr regulatory sequences. Bioinformatics analysis placed the DTIE in positions spanning 
+21 to +33 relative to the TSS at a frequency which may exceed the prevalence of the 
TATA box and Inr elements within human promoters (Marbach-Bar et al., 2016). Finally, 
there are the TFIIB-recognition elements that have been designated according to their 
spatial orientation around the TATA box element as the upstream BREu and downstream 
BREd elements  (Lagrange et al., 1998; Deng & Roberts, 2005). Although originally 
discovered in TATA box-containing core promoters, bioinformatics searches of the 
eukaryotic promoter database (EPD) and database of transcription start sites (DBTSS) 
have shown that the occurrence of BREu is in fact greater in TATA-less promoters (28.1% 
and 26.9%) than in TATA-containing promoters (11.8% and 13.8%) (Gershenzon et al., 
2005), with similar results observed for the BREd (Deng & Roberts, 2005). These elements 
are contacted by TFIIB through the TFIIB helix-turn-helix DNA-binding motif (contacting 
BREu) and the recognition loop located between helices BH2 and BH3 (contacting BREd) 
in order to stabilise and orientate the PIC (Nikolov et al., 1995; Lagrange et al., 1998; 
Deng & Roberts, 2005; reviewed in Thomas & Chiang, 2006). While the current text book 
model of core promoter architecture is still evolving by way of the new observations and 
potential insights that stem from the evidence of widespread transcription initiation at what 
were previously thought of as enhancer elements (Anderson et al., 2014; Core et al., 
2014), as well as promoter-promoter interactions between distal genes displaying context 
dependent enhancer-type activities (Li et al., 2012; Leung et al., 2015), it is clear that 
CPEs such as the TATA box, BREs and Inr play a vital role in the recruitment and 
positioning of the PIC through direct interactions with TBP(TFIID) and TFIIB, with TFIIA as 
an important modulator of TBP and TFIID DNA-binding activity.    
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1.2.3  Transcription factor IID (TFIID) 
TFIID is a large multi-protein complex comprised of TBP and a set of 13 TBP-associated 
factors (TAFs) (Dynlacht et al 1991; Pugh & Tjian., 1991; Timmers & Sharp., 1991; 
reviewed in Papai et al., 2011; Gupta et al., 2016). Within TFIID, TAFs 4, 5, 6, 9 and 12 are 
present in two copies. Nine of the thirteen TAFs contain a common histone fold domain 
(HFD) that facilitates the formation of TAF heterodimers within the TFIID quaternary 
structure. Cryo-EM images of human TFIID displays a U-shaped three-dimensional 
structure comprised of three roughly equally-sized lobes that are able to undergo a drastic 
conformational re-arrangement in response to interactions with TFIIA at the core promoter 
(Cianfrocco et al., 2013). The TBP subunit is responsible for the recognition and binding of 
the TATA box while recognition of other core promoter elements such as the downstream 
core element (DCE), initiator (Inr), and downstream promoter element (DPE) are mediated 
by interactions with TAFs 1, 2, 6, and 9 respectively (Chalkley & Verrijzer., 1999; Burke & 
Kadonaga, 1997). These TAF-DNA interactions have proven to be extremely important 
with respect to promoter recognition as many human genes do not contain the TATA box 
element within their respective core promoters (Suzuki et al., 2001; Gershenzon & 
Ioshikhes, 2005). Following the identification of TBP as the primary TATA box-binding 
factor (Kao et al., 1990; Peterson et al., 1990., Hoffman et al., 1990), early experiments 
involving transcriptional assays showed that purified TBP was not the functional equivalent 
of TFIID and that the TAFs played an important role in activated transcription (Pugh & 
Tjian, 1990). It has since been determined that the primary function of the TAFs within the 
TFIID complex is to act as a facilitator of core-promoter recognition, responsible for the 
proper positioning of the RNA Pol II pre-initiation complex (PIC) at the TSS. In addition, 
TFIID TAFs can function as co-activators, that enhance PIC assembly though direct 
interactions with activator proteins bound at proximal and distal promoter elements. Finally, 
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some TAFs play an active role in the post-translational modification of chromatin (reviewed 
in Thomas & Chiang, 2006). 
1.2.4 TATA-binding protein (TBP) 
TBP binds DNA via a saddle shaped, highly conserved C-terminal core domain composed 
of two imperfect direct repeats of secondary structures that adopt quasi identical tertiary 
structures. Each of these repeats are made up of five anti-parallel β-strands and two α-
helices (Fig. 4A) (Kim et al., 1993; Nikolov et al., 1996). The central DNA-binding surface 
is composed of two adjacent β-sheet regions forming a concave DNA-binding site that is 
flanked by two α-helices. The remaining two α-helices are located on the convex upper 
surface of the molecule where they act to facilitate interactions with transcriptional co-
factors (Kim et al., 1993; Nikolov et al., 1996; Bleichenbacher et al., 2003). The DNA-
binding surface also contains two pairs of highly conserved phenylalanine residues, in the 
human TBP ortholog residues F288/F305 and F197/F214. In the human TBP/TATA 
complex, F288 and F197 intercalate between the first and last DNA-base steps of the 
TATA box promoter element, with each interaction supported and positioned by the second 
phenylalanine residue, F305 and F214 respectively. Together, these insertions result in an 
overall widening of the DNA-minor grove and two kinks at the 5’ and 3’ end of the TATA 
box, resulting in the ≈ 80˚ bend of the DNA-helix architecture typically associated with TBP 
binding (Kim et al., 1993; Nikolov et al., 1996). The amino acid composition of the 
preceding unstructured N-terminal region is found to be highly divergent among species 
and does not seem to play any direct role in TFIID complex formation and function (Zhou 
et al., 1993). It has however been shown to play a role as a negative regulator of TBP/
TFIID by preventing the binding of TBP to the TATA box of some RNAP-II (Zhao & Herr, 
2002) and RNAP-III (Mittal & Hernandez, 1997) transcribed genes. Drastic alterations to  
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this N-terminal sequence in mice have also been shown to result in >90% mortality during 
gestation, linking it indirectly to maternal immunotolerance of the fetus during pregnancy 
(Hobbs et al., 2002). In humans it has been found that a large extension of a large poly-
glutamine stretch located in the N-terminus of the TBP molecule has been linked to the 
occurrence of some neurological pathologies (Nakamura et al., 2001). 
1.2.5 Regulation of TBP 
The formation of TBP dimers has been observed in the crystal structures of multiple TBP 
orthologs (Nikolov et al., 1992; Chasman et al., 1993; Nikolov et al., 1996) as well as 
biochemically through size exclusion chromotography and glycerol gradient sedimentation 
of recombinant TBP (Kato et al., 1994). It is thought that masking the DNA-binding 
surfaces through TBP homodimerization reduces the propensity for non-specific TBP/
TFIID interaction at AT-rich DNA sequences outside of the core promoter regions, which 
may ultimately lead to the formation of non-productive transcription complexes. The largest 
TFIID subunit, known as TAF 1, is also able to negatively regulate TBP binding to the TATA 
box through direct interaction of the TAF1 N-terminus with the TBP DNA-binding surface 
(Liu et al., 1998) as well as through competition for the TFIIA interaction sites (Kokubo et 
al., 1998) and thereby limits the stabilising effect of TFIIA on TBP-DNA binding as well as 
any TFIIA-mediated activation by transcription activators from distal regulatory elements. 
BTAF1 is a TBP-associated factor that was found to co-purify with TBP when whole-cell 
HeLa extracts where fractionated using a succession of column chromatography steps 
(Timmers et al., 1992). This TFIID-like complex was named B-TFIID based on the 
phosphocellulose (P11) B fraction from which it was further purified. BTAF1 functions by 
removing TBP from the TATA box in an ATP-dependent manner (Chicca et al., 1998). This 
function is thought to facilitate the clearance of TBP from non-promoter AT-rich sequences, 
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thereby promoting the formation of legitimate TBP-TATA complexes. As with TAF1, 
competition for interaction sites at the convex surface of TBP may impede any TFIIA- 
mediated transcriptional control (Klejman et al., 2005). NC2 is another example of a TBP 
co-factor implicated in both repression (Goppelt et al., 1996) and stimulation (Castaño et 
al., 2000; Lemarie et al., 2000; Willy et al., 2000) of transcriptional initiation. Crystal 
structure data shows that NC2 binds TBP-TATA complexes as a type of molecular clamp, 
interacting with both the TBP-bound DNA as well as the convex surface of the TBP 
molecule, thereby excluding TFIIA and TFIIB interaction and thus preventing the formation 
of the PIC complex (Kamada et al., 2001; Innostroza et al., 1992; Kim et al., 1995; Goppelt 
et al., 1996). Chromatin immunoprecipitation studies have shown that NC2 is found 
complexed with promoter-bound TBP in both TATA-positive and TATA-negative genes 
(Gilfillan et al., 2005). Lastly, the NC2 complex has also been shown to stimulate 
transcription from TATA-negative promoters in Drosophila via the DPE promoter element 
(Burke & Kadonaga., 1997; Willy et al., 2000). 
1.2.6 TBP-like protein (TLP, TRF2) 
With regard to TBP, the repertoire of eukaryotic transcriptional machinery has been 
expanded through gene duplication events that have led to multiple TBP paralogs called 
TBP-like proteins (TLPs) or TBP-related factors (TRFs) (reviewed in Thomas & Chiang, 
2006; Akhtar & Veenstra, 2011). In humans there are two such TBP paralogs, TBP-related 
factor 2 (TRF2; also known as TLP), and TBP-related factor 3 (TRF3). Of these, only TRF2 
has an ortholog predicted amongst the hypothetical proteins annotated in the P. falciparum 
genome. Sequence alignments and 3D modelling have shown a high degree of similarity 
between the known human TBP and putative TLP secondary structures, with an overall 
sequence identity of 41% and homology of approximately 60% in the conserved C-terminal 
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core domain responsible for TBP-DNA interaction (Dantonel et al., 1999; Berk, 2000). A 
defining characteristic of the TLP (TRF2) is the substitution of three of the four key 
phenylalanine residues (F288/F305 & F197/F214) associated with the TATA box-binding 
activity of TBP (Section 1.2.4) (Kim et al., 1993; Nikolov et al., 1996). Phylogenetic 
analysis aimed at tracing the emergence of TLP(TRF2) through the examination of these 
phenylalanine substitutions in multiple protist, plant and animal genomes has shown that 
TLP(TRF2) most likely arose from a TBP-gene duplication event that occurred just prior to 
the evolution of the bilateria (Duttke et al., 2016). The authors of this study also noted that 
the increased rate of amino acid substitution of TLP(TRF2) relative to TBP, correlated with 
the loss of TLP(TRF2) DNA-binding activity, possibly due to an uncoupling from 
evolutionary constraints. They also noted that this increased rate of mutation slowed 
significantly during vertebrate evolution. The authors do not postulate a reason for this. 
However, it seems reasonable to assume that by this time TLP had taken on specific roles 
within the organism’s transcriptional programs and therefore had again been tethered by 
positive selection. Indeed, there are abundant data to suggest that TLP functions in distinct 
regulatory pathways (Rabenstein et al., 1999; Ohbayashi et al., 2003; Chong et al., 2005 
Wang et al., 2014; Kedmi et al., 2014). Interestingly, nearly all TFIIA and TFIIB interaction 
sites are conserved in TLP(TRF2), potentially allowing for TLP(TRF2) to participate in the 
formation of variations of the canonical RNAP-II PIC (Maldanado, 1999; Moore et al., 
1999; Rabenstein et al., 1999, Teichmann et al., 1999). Functional data suggests that TLP 
(TRF2) can operate as a type of repressor protein by sequestering TFIIA away from TBP 
(Moore et al., 1999; Rabenstein et al., 1999, Teichmann et al., 1999). More recent work in 
Drosophila demonstrated that TLP functions as a positive regulator at TATA-less promoters 
for ribosomal protein genes under the control of the TCT sequence motif (Wang et al., 
2014) as well as DPE- and Inr- dependent genes (Ohbayashi et al., 2003; Kedmi et al., 
2014). It should be noted that the exact function or role of TLP(TRF2) is likely species 
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specific. RNAi knockdown experiments demonstrated embryonic lethality in TLP(TRF2)-
negative C. elegans and X. laevis lines. In contrast, transgenic mice lacking TLP(TRF2) 
were viable but defective in male spermatogenesis (Dantonel et al., 2000; Kaltenbach et 
al., 2000; Veenstra at al., 2000; Martinov et al., 2001; Zhang et al., 2001). In summary, it 
seems clear that in metazoans, TLP(TRF2) serves important gene- and cell-type specific 
functions, in particular in cell differentiation and development. However, the precise 
mechanisms by which TLP(TRF2) exerts its influence on gene expression programs 
remain poorly understood.            
1.2.7 Transcription factor IIA (TFIIA) 
TFIIA was one of the first TFIID/TBP general transcription factors that were identified by 
researchers aiming to reconstitute promoter-specific RNAP-II transcription in vitro (Matsui 
et al., 1980). In higher eukaryotes, the TFIIA complex is composed of three subunits: α 
(35kDa), β (19kDa), and γ (12kDa) (Fig. 5) (Bleichenbacher et al., 2003). Initial cloning 
experiments revealed that these three subunits were coded for by only two genes, with the 
α and β subunits being expressed as a single αβ peptide chain. In mammalian TFIIA, the 
56kDa αβ peptide is post-translationally cleaved to yield 35kDa and 19kDa subunits 
(DeJong & Roeder., 1993; DeJong et al., 1995). Originally, this cleavage was thought to be 
a universal aspect of active TFIIA complexes in metazoan cells. This paradigm was, 
however, challenged by the discovery that TFIIA can exist in an uncleaved form complexed 
with TBP monomers and led to the proposition that TFIIA cleavage may have a regulatory 
role (Mitsiou et al., 2000). The subsequent identification of the cleavage site, termed the 
cleavage recognition sequence (CRS), provided further evidence for this notion as these 
cleavage sites are highly conserved among many higher eukaryotes (reviewed in Høiby et 
al., 2007). Comparison of the CRS to other known protease cleavage sites soon identified  
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Taspase1 as the active protease in the processing of TFIIA (Zhou et al., 2006). It was 
found that inhibition of TFIIA cleavage through mutations in the CRS lead to a marked 
increase in TFIIA half-life (Høby et al., 2004). This vulnerability of processed αβ to 
proteasomal degradation indicated that Taspase1 cleavage may be the first step in a TFIIA 
degradation pathway and possibly facilitates the fluctuations of cellular TFIIA levels 
(reviewed in Høiby et al., 2007). More recent studies have shown Taspase1 to play a role 
in Inr-specific core promoter activity (Malecová et al., 2015). TFIID mobility-shift assays 
demonstrated a possible change in TFIIA-TFIID-DNA complex topology that was 
dependent on whether the complexed TFIIA variant was subject to Taspase1 processing. It 
was also found that a nucleoprotein-complex containing cleaved TFIIA was less 
susceptible to negative regulation by NC2. This decreased vulnerability was however 
dependent on the presence of the Inr element and lead to the proposal that Taspase1 
cleavage promotes Inr-specific transcription initiation.  
It is well established that TFIIA is able to stimulate transcription via stabilisation of the TBP-
TATA complex through interactions with both TBP and specific DNA base pairs upstream of 
the TATA box element (Fig. 6) (Reinberg et al., 1987; Imbalzano et al., 1994b; 
Bleichenbacher., et al 2003; Hieb et al., 2007). Despite this effect, multiple studies have 
shown TFIIA to have a negligible effect on basal transcription from TATA-positive genes 
when using a system constituted from highly purified factors (Sawadago et al., 1985; Van-
Dyke et al., 1988; Wu et al., 1998). These contradicting data have caused some in the field 
to question the classification of TFIIA as a general transcription factor (Thomas & Chiang, 
2006). TFIIA has however, in many cases, been found to play a role in activator-mediated 
transcription, indicating that TFIIA function may be best classed as having a dual anti-
repressor/co-activator role (Ozer et al.,1994; Yokomori et al., 1994; Kobayashi et al., 
1995). The main argument for classing TFIIA as an anti-repressor is that the stimulatory  
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effects of TFIIA on in vitro transcription is most notable when TBP-DNA binding conditions 
are such that negative regulators of TFIID/TBP may be involved i.e. when using partially 
purified TFIID nuclear fractions (Matsui et al., 1980; Reinberg et al., 1987). TFIIA is further 
noted to extend the range of ionic conditions under which TBP-DNA complexes can form 
(Imbalzano et al., 1994b), and has also been shown to effect the transition from dimeric to 
monomeric TBP and thus promote the formation of TBP-TATA complexes (Coleman et al., 
1999). Furthermore, crystallographic and biochemical data indicate that TFIIA interaction 
at the convex surface of the TBP N-terminal stirrup competes for interaction surfaces with 
various negative regulators of TFIID/TBP-DNA binding. These factors (all of which are 
likely present in the aforementioned TFIID crude fractions) include: TAF1, BTAF1, and 
NC2 (Kokubo et al., 1998; Innostroza et al., 1992; Kim et al., 1995; Goppelt et al., 1996; 
Kamada et al., 2001; Bleichenbacher et al., 2003; Klejman et al., 2005). In addition, results 
of studies of TFIIA point mutations in yeast that focused on transcription experiments using 
nuclear extracts depleted of TFIIA, demonstrated that TFIIA affects transcription 
dependent on the promoter-type (Kang et al., 1995; Ozer et al., 1998; Chou et al., 1999). 
In particular, it was noted that there was a significant decrease in transcription from genes 
requiring activator-mediated initiation (Ozer et al., 1998). In a separate study, TFIIA 
interactions with Gal4 linked VP16 and Zta activation domains have also been shown to 
stimulate TFIIA-TFIID-DNA complex formation in vitro (Kobayashi et al., 1995). Lastly, 
protein-affinity chromatography and run-off transcription assays that used a combination of 
yeast and human transcription factors have demonstrated direct TFIIA interaction with 
TFIIE as well as the RAP74 (TFIIF) subunit. The stimulatory effect of TFIIA on transcription 
within this system was dependent on the presence of TFIIE and TFIIF indicating that it may 
play an auxiliary activator-role by stimulating the efficient formation of the PIC by these 
factors (Langelier et al., 2001). 
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1.2.8 P. falciparum core promoter architecture and general transcription factors  
As was briefly mentioned in Section 1.1.7, putative orthologs for many of the basal RNAP-
II transcriptional machinery components have been identified (Coulson et al., 2004; 
Callebaut et al., 2005; Bischoff et al., 2010). These include the subunits for RNA 
polymerase II, as well as TFIIA, TFIIB, TBP, TLP(TRF2), TFIIE, TFIIF, and TFIIH. In 
addition, TFIID subunit orthologs for TAFs 1,2,7, and 10 were also identified. It is 
interesting to note that all of the histone-fold domain TAFs appear to be missing from the 
P. falciparum 3D7 genome. This suggests a TFIID complex that is very different to the 
known structures of eukaryotic TFIID (Cianfrocco et al., 2013). A recent landmark study 
mapping RNAP-II transcription initiation sites within the P. falciparum genome has 
provided first insights into the parasite’s core promoter architecture and a basis with which 
to compare experimental findings (Adjalley et al., 2016). The authors found that 
transcription start sites (TSSs) were generally distributed over broad promoter regions. 
Systematic analysis of these TSSs within each gene locus showed an average of 6 
clusters of TSSs both upstream and within the gene-coding regions (GCRs). The peculiar 
occurrence of multiple such clusters or “TSS blocks” in individual P. falciparum genes is 
possibly indicative of multiple core-promoter regions per gene, each of which has a loosely 
defined TSS. Eighty-one percent (81%) of these TSS blocks were located within 1000bp of 
the GCRs, with more than 65% of these falling within 500bp. The majority of TSS block 
distribution was found only 50bp upstream of the GCRs. The close proximity of TSS blocks 
to the translation start codon is significant as this suggests very short 5’ untranslated 
regions (UTRs) in the P. falciparum mRNA transcripts. Surprisingly, 49% of all TSS blocks 
were found downstream of the start codons. The vast majority (≈ 90%) of these 
downstream TSS were also found to be closely followed by an in-frame ATG codon, 
indicating that many P. falciparum transcription products code for truncated gene products. 
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Finally, 10% of the TSS blocks could not be matched to the current gene annotation, and 
were instead found within non-coding or very long intergenic regions. The authors 
speculate that a significant number of these transcripts may feature as part of the 
parasite’s transcriptional regulatory network. Thirty-one percent (31%) of the analysed 
genes also showed evidence of antisense transcription initiation with 47% of those 
initiation events occurring in non-coding genome regions and roughly 10% overlapping 
with the 3’ end of the sense-strand genes. It was noted that these overlaps could possibly 
lead to direct interference with processing and translation of sense strand mRNA. 
Bidirectional promoter regions were found to be relatively common in P. falciparum, as 
more than half of the annotated transcription units were present in a divergent 
arrangement, with the bidirectional TSS blocks usually falling within 400bp of each other. 
With respect to epigenetic markers, the researchers found that trimethylation of histone H3 
at lysine 4 (H3K4me3) and acetylation of histone H3 at lysine 9 (H3K9ac) at nucleosomes 
positioned upstream of the TSSs (+1 nucleosome) were good indicators of TSS blocks. 
However, these markers, together with nucleosomes containing the histone variants H2A.Z 
and H2B.Z, were in no way good indicators of transcriptional activity. This finding is in 
contrast to what has typically been noted in other eukaryotes. When analysing local base 
content around the most active TSSs, it was found that there was a strong A/T nucleotide 
bias within these regions. This was found to be true for TSS blocks both upstream as well 
as downstream of the GCRs, confirming that internal TSS sites are likely to be true TSSs, 
as opposed to an experimental artefact. The dinucleotide signature T-A at the -1/+1 
positions of the TSSs were found to be associated with the most dominant initiation sites. 
This trend was found not to correlate with relative promoter activity and, rather surprisingly, 
these TSS blocks also coincided with two downstream GC-islands located approximately 
150bp and 210bp from the TSS. Furthermore, it was found that these GC-islands 
correlated with a decline in local nucleosome occupancy and were equally visible 
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downstream of internal TSS blocks. An increase in GC content was also found around the 
borders of TSS blocks, particularly at TSS blocks controlling less active genes. These 
deviations in nucleotide content correlated with a shift in the +1 nucleosome position and a 
general decrease in nucleosome-free regions, indicating a link between nucleotide base 
content, nucleosome positioning, and transcriptional activity. Lastly, the authors provided a 
detailed analysis of TSS block usage during the blood stage development of the parasite. 
They first looked for correlations between the relative gene positioning within the genome 
and TSS block selection. It was found that bi-directional initiation occurred coordinately for 
the vast majority of the genes found in a divergent configuration, with adjacent 5’ regions 
located on opposite strands, suggesting that this  configuration may be a marker for co-
expression. Only a small minority (< 10%) of these divergent genes exhibited independent 
cycling behaviour, reflected in differential temporal patterns of their TSS block usage. 
Interestingly, the authors noted the occurrence of divergent gene pairs that exhibited 
distinct transcription profiles whilst maintaining uniformity in the temporal usage of their 
TSS blocks. This may point to the existence of additional, unidentified core promoter 
elements present in only one of the two gene promoters. Taken together, the results of this 
study suggest that bi-directional promoter regions may contain multiple regulatory 
elements enabling both co-ordinated and dissociated TSS usage. 
While this study provides a first advance in the understanding of P. falciparum promoter 
architecture, the precise biochemical mechanisms governing PIC formation and 
transcription initiation in P. falciparum remain to be elucidated. The extreme A/T bias of the 
P. falciparum genome poses an extreme challenge for identification of P. falciparum core 
promoter elements and the identification and functional characterisation of general 
transcription factors. This factor, together with the conservation of chromatin modifying 
enzymes (Coulson et al., 2004) led the field of malaria research to focus largely on the 
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epigenetic mechanisms of P. falciparum gene regulation in the past (see Section 1.1.7). 
The general focus of the project presented here was on gene activation at the point of 
transcription initiation, with a specific focus on PfTBP, PfTLP  and two putative PfTFIIA 
candidates (Callebaut et al., 2005) with the hope to highlight any differences to the human 





Materials and Methods 
2.1 Bioinformatic analysis of PfTBP, PfTLP, and putative PfTFIIA complexes 
All amino acid sequences for known and/or predicted P. falciparum general transcription 
factor orthologs were retrieved from the parasite genome database (PlasmoDB Release 
29) (Aurrecoechea et al, 2008). Sequences for human and yeast TBP and TFIIA orthologs 
were retrieved from the National Centre for Biotechnology Information (NCBI) GenBank 
online protein database (Benson et al., 2013). Protein sequences and associated identifier 
codes are listed in Table 1.  
   
2.1.1 Multiple sequence alignments  
Sequence alignments for TBP and TFIIA orthologs were conducted using the European 
Bioinformatics Institute (EBI-EMBL) Clustal Omega multiple sequence alignment tool with 
alignment order set to “input” (Larkin et al., 2007; Goujon et al., 2010). The sequence 
stretches chosen for alignment and the subsequent annotations were informed by either 
the known crystallographic structures (Tan et al.,1996; Nikolov et al., 1996; Bleichenbacher 
et al., 2003), and/or secondary structure predictions based on hydrophobic cluster analysis 
(HCA) of the putative PfTFIIA subunits (Callebaut et al., 2005). The TFIIA-γ subunit Clustal 
Omega alignments were adjusted manually based on the available HCA data. Gaps were 
removed in the alignment of residues 1-50 of ScTFIIA-γ1 and PfTFIIA-γ1s, and the 
PfTFIIA-γ2s sequence (K78 to S169) was shifted four residues to the right so that residue 
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K78 of PfTFIIA-γ2s was aligned with residues M1 of ScTFIIA-γ1 and PfTFIIA-γ1s. A three 
residue gap was inserted between T56 and Q57 of ScTFIIA-γ1 and a one residue gap 
inserted between N57 and Q58 of PfTFIIA-γ1s. The positions of the HsTFIIA-γ residues 
were added by superimposing the yeast TOA1 and HsTFIIA-γ alignment data from the 
human and yeast TBP-TFIIA-DNA crystal structures (Bleichenbacher et al., 2003). The 
ScTFIIA-γ1 region Q103 to E122, and the PfTFIIA-γ2s region A174 to I184, were each 
shifted left by nine and six residues respectively, so that Q103 of ScTFIIA-γ1 was aligned 
with D158 of PfTFIIA-γ1s, and A174 of PfTFIIA-γ2s. The HsTFIIA-γ1 region T85 to G104 
was superimposed as before. Overall, each TFIIA alignment is made up of two separate 
alignments, one N-terminal alignment, and one C-terminal alignment. The PfTLP alignment 
is adapted from a larger COBALT sequence alignment by Bing, 2015 of HsTBP and 
selected TRF orthologs (default settings). COBALT is a constraint based alignment 
program which uses conserved domain and protein motif databases together with local 
sequence similarity (RPS-BLAST, BLASTP, and PHI-BLAST respectively) to aid alignment 
of distantly related proteins (Papadopoulos & Agarwala 2007). For ease of comparison to 
the Clustal Omega alignments, residue similarities in the PfTLP alignment were annotated 
manually according to the Gonnet PAM 250 matrix parameters describe in the online EBI 
Clustal Omega FAQ section (http://www.ebi.ac.uk/Tools/msa/clustalo/help/faq.html). (*) 
indicates identical residues. (:) indicates conservation between groups of strongly similar 
properties scoring > 0.5 in Gonnet PAM 250 matrix. (.) indicates conservation between 
groups of weakly similar residues <+0.5 Gonnet PAM 250 matrix. For all alignments, 
residues were manually highlighted according to hydrophobicity and/or degrees of 
conservation. Schematics of the TFIIA secondary structure arrangements were based on 
the crystallographic data of the human TBP-TFIIA complex (Bleichenbacher et al., 2003) 
as well as HCA data of the putative P. falciparum TFIIA orthologs (Callebaut et al., 2005).    
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Table 1: Primary amino acid sequences for TBP and TFIIA orthologs: The sequence regions used for the 
alignments presented in Ch3. are shown in red. In the instances where more than one alignment was used for a single 
figure, the regions for the second alignment are shown in blue.  
2.2  Cloning of 6H-PfTFIIA-αβ-γ1 and 6H-PfTFIIA-αβ-γ2 expression vectors 
  
2.2.1  pET 11d expression system (Agilent technologies) 
The pET 11d expression vector contains the promoter and leader sequences from the T7 
bacteriophage gene 10. The T7 promoter sequence is rarely found outside of the T7 phage 
genome and is therefore not transcribed by the host cell polymerase. Target cDNA is 
cloned downstream of the T7 promoter which can be activated by the IPTG induced 
expression of  T7 polymerase from the LacUV5 promoter of  E. coli Bl21 (DE3) cells.   
2.2.3  Restriction digestion and gel isolation. 
Unless otherwise stated, all restriction enzymes, gel extraction kits, and PCR purification 
kits were obtained from Thermo Fisher Scientific (https://www.thermofisher.com). All 
protocols were followed as per manufacturers instructions. 
2.2.4  Agarose gel electrophoresis 
Agarose gels were cast with 0.8-2%(w/v) agarose dissolved in 0.5x TBE (40mM Tris-Cl; 
pH 8.3, 45mM Boric acid, 1mM Ethylenediaminetetraacetic acid [EDTA]). Electrophoresis 
was conducted at 80V in 0.5x TBE running buffer until sufficient separation was achieved.    
2.2.4 Polymerase chain reactions (PCRs) 
PCR reactions were performed according to standard protocol (Sambrook & Russel, 2001) 
using Kapa Taq PCR kits from Kapa Biosystems (07958447001) in Kapa Buffer A with a 
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final concentration of 1.5mM Mg2+. PCR amplification of P. falciparum sequences were 
carried out with an elongation temperature of 60˚C for optimal synthesis of A/T-rich 
sequences (Su et al., 1996).   
2.2.5 Primers and pET 11d vector constructs used in the cloning and sequencing of   
 the PfTFIIA-γ1 and PfTFIIA-γ2 co-expression vectors 
Primers were designed using SerialCloner (Version 2.6, SerialBasics, http://
serialbasics.free.fr/Serial_Cloner.html). Melting temperature and self-complementarity 
analysis was carried out using the Oligonucleotide Properties Calculator available at http://
biotools.nubic.northwestern.edu/OligoCalc.html. All primer sequences are listed in Table 2. 
The vector maps together with open reading frame (ORF) sequences and relevant plasmid 
features are presented in the appendix sections A1 and A2. 
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Procedure Primer name Primer sequence
Amplification of TFIIA-γ1 
expression unit
pET11d-T7XCISE-AatII-FWD TTCTTAGACGTCTAATACGACTCACTATAGG
GGAATTG  Tm (50mM NaCl): 63.1 °C | 




CTCAG  Tm (50mM NaCl): 63.5 °C | hairpin: 
no | self-complementarity: yes 
Amplification of TFIIAγ2 
expression unit
pET11d-T7XCISE-HindIII-FWD GCATTAAAGCTTTAATACGACTCACTATAGG
GGAATTG  Tm (50mM NaCl): 63.1 °C | hairpin: 
no | self-complementarity: yes 
Colony PCR TFIIA-γ1 PfIIA-SML1-NcoI-FWD GATATACCATGGAACATGGGAACTTTGATG 
Tm (50mM NaCl): 58.4 °C | hairpin: yes | self-
complementarity: yes 
Colony PCR TFIIA-γ1/γ2 pET11d-AMP-REV CTCATGAGCGGATACATATTTG Tm (50mM NaCl): 58.4 °C | hairpin: no | self-
complementarity: no 
Colony PCR TFIIA-γ2 PfIIA-SML2-PagI-FWD GATATATCATGAGCGATAATTTTTTTATACCCA  
Tm (50mM NaCl): 57.6 °C | hairpin: yes | self-
complementarity: yes
Table 2: Primer sequences for PfTFIIA expression vector construction: Restriction sites shown in blue.
2.2.6 Cloning strategy 
Bacterial expression vectors for the 6His-tagged variants of the individual PfTFIIA subunits 
6H-PfTFIIA-αβ, 6H-PfTFIIA-γ1s, and 6H-PfTFIIA-γ2s were previously cloned in 
collaboration with Dr Thomas Oelgeschläger (unpublished data; Milton, 2012). The 
expression vectors consist of a pET 11d (Promega) vector frame containing a 6His-tag 
inserted between NcoI and NdeI sites downstream of the T7 promoter. In an attempt to 
increase the solubility of the various PfTFIIA subunits (Ch3. Results, Section 3.4.1), co-
expression vectors were constructed to explore the possibility of complex formation at the 
point of translation. Preparative restriction enzyme digests followed by 5’ de-
phosphorylation reactions were set up to prepare two vector frames (Frame-γ1 and 
Frame-γ2) from the expression plasmid pET11d-6His-PfTFIIAαβ. Frame-γ1, which was 
used for the PfTFIIA-γ1 co-expression vector, was prepared by digestion with AatII at base 
position 73 (5882bp downstream of the T7 terminator sequence). Frame-γ2, which was 
used for the PfTFIIA-γ2 co-expression vector, was prepared by double digestion with 
HindIII at position 6195 (6122bp downstream of the T7 terminator sequence) and AatII 
(5882bp downstream of the T7 terminator sequence). A double digest for Frame-γ1 was 
not possible due to the PfTFIIA-γ1s cDNA containing an internal EcoRI site at position 408 
and an internal HindIII cleavage site at position 5797 of the ORF. The T7 expression units 
for the untagged PfTFIIA-γ1s and PfTFIIA-γ2s subunits were PCR amplified from plasmids 
already available in the laboratory: pET11d-6His-PfTFIIAγ1 and pET11d-6His-PfTFIIAγ2. 
The forward (pET11d-T7XCISE-AatII-FWD; pET11d-T7XCISE-HinDIII-FWD) and reverse 
(pET11d-T7XCISE-AatII-REV) primers contained the appropriate AatII and HindIII 
restriction site overhangs. PCR products purified using a ThermoScientific GeneJet PCR 
purification kit (K0701), were digested with AatII (PfTFIIA-γ1s insert) or AatII/HindIII 
(PfTFIIA-γ2s insert) and purified by gel extraction. Ligation reactions with a 1:3 vector to 
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insert ratio were conducted and followed by transformation into E.coli One Shot Stbl13 
Top10 cells (Invitrogen). Colonies were screened by colony PCR to identify colonies 
containing the plasmids with the correct inserts. Plasmid mini-preps were prepared from 
positive clones before being sent for sequencing analysis. The final vectors contained a T7 
expression unit for the 6His-tagged PfTFIIA-αβ subunit followed downstream by a second 
T7 expression unit for the untagged PfTFIIA-γ1s (396bp downstream) or PfTFIIA-γ2s 
(290bp downstream) subunits. 
2.2.7  DNA sequencing 
All DNA sequencing for this project was carried out by the Central Analytical Facilities DNA 
Sequencing Unit at the University of Stellenbosch, South Africa (http://www.sun.ac.za/
english/faculty/science/CAF).  
2.3 Expression of P. falciparum general transcription factors. 
 Note: Buffer recipes listed in the Appendix 
2.3.1  Bacterial expression system 
Codon optimised E. coli BL21 CodonPlus (DE3)-RIL (Agilent technologies) was used in all 
instances. The frequency of usage for the codons AGA (arginine), CUA (leucine), AUA 
(isoleucine) in E. Coli are relatively low in comparison to P. falciparum and thus may lead 
to tRNA depletion through the over-expression of heterologous proteins. The BL21 
CodonPlus (DE3)-RIL cells have been optimised for the expression of amino acid 
sequences from AT-rich eukaryotic genomes by including additional copies of the genes 
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argU, ileY, and leuW, all of which code for the less common tRNAs often used by P. 
falciparum. 
2.3.2 Transformation of protein expression vectors into E.coli BL21 CodonPlus (DE3)-RIL 
Cells were transformed according to manufacturers recommendations. We found that 
expression of P. falciparum general transcription factors was toxic to E. coli cells. For this 
reason, transformants were spread plated on Super Optimal Broth with Catabolite 
Repression medium (SOC; 2% w/v tryptone powder, 0.5% w/v yeast extract, 10mM NaCl, 
2.5mM KCl, 10mM MgCl2 , 20mM glucose, 1.5% w/v agar) containing 34µg/ml 
chloramphenicol and 100µg/ml ampicillin. The presence of glucose in the medium 
prevents leaky expression of toxic proteins and thus selection for cells in which expression 
is compromised by mutation or deletion in the expression plasmid. 
2.3.3 SDS-PAGE analysis and Immunoblot analysis 
SDS-PAGE assays were conducted using the Mini-PROTEAN Electrophoresis System 
(Bio-Rad). Gels were prepared according to standard protocol (Sambrook & Russel, 
2001). 5% stacking and 15% separating gels were used for PfTFIIA complexes. Samples 
were mixed with 4 x Laemmli Sample Buffer (Bio-Rad) and heated to 80˚C for 2min. Gels 
were run at a constant amperage of 45mA until completion. Gels were stained with Bio-
Safe G-250 Coomassie premixed stain (Bio-Rad) according to manufacturers protocol. 
Precision Plus Protein All Blue Prestained Protein Standards (Bio-Rad) or Colour 
Prestained Protein Standard Broad Range (NEB) were used in all instances as protein 
molecular weight markers. 
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Immunoblots were carried out using a Mini Trans-Blot Electrophoretic Transfer Cell (Bio-
Rad) apparatus. Proteins were transferred to polyvinylidene difluoride (PVDF) membrane 
(Immobilon-P Membrane; EMD millipore) as per the manufacturers protocol. Following 
transfer, the membranes were stained for 1hr with Colloidal Gold Total Protein Stain (Bio-
Rad) and rinsed with 100ml H2O and 100ml TBST buffer. The membrane was then blocked 
by incubation with 5% (w/v) fat free milk powder dissolved in TBST buffer for 30min. 
Incubation with previously determined primary antibody dilutions (unpublished data; Fig. 
13D; Bing, 2015; Talvik, 2016) was carried out in TBST buffer containing 5% (w/v) fat free 
milk powder overnight at 4˚C. Unbound primary antibody was removed by washing the 
membrane 4 x 5min in TBST buffer before incubating with a 1:3000 dilution of horseradish 
peroxidase conjugated anti-rabbit IgG (Sigma-Aldrich) in TBST buffer for 30min at room 
temperature. Immunoreactant proteins were visualised by chemiluminescence on X-ray 
film using Pierce ECL Western Blotting Substrate (Thermo Fischer Scientific). 
All primary antibodies were produced by Biogenes (www.biogenes.de) Germany. Rabbit 
polyclonal antibodies were raised against peptides from the respective proteins. Peptide 
sequences are listed in Table 3.    
  
 58






Table 3: Peptide sequences used to raise rabbit polyclonal antibodies
2.3.4 Thrombin cleavage removal of hexahistidine tag (6H-tag) 
Thrombin cleavage of the 6H-tag from the recombinant PfTFIIA complexes were carried 
out using immobilised thrombin (Thrombin CleanCleave Kit; Sigma). Two separate 200µl 
cleavage reactions were set up using 320ng of either 6H-PfTFIIA-γ1 or 6H-PfTFIIA-γ2 by 
combining 100µl protein sample (40mM Tris-HCl pH 7.2, 100mM KCl, 0.5% NP-40, 10mM 
β-EtSH, 100ng/µl BSA) with 100µl 2x reaction buffer (2x Cleancleave buffer,100mM KCl; 
0.3% NP-40; 10mM β-EtSH, 100ng/µl BSA). Reactions were incubated at 21˚C with 40µl 
immobilised thrombin agarose in a tabletop shaker set at 150rpm. Cleaved fractions were 
centrifuged briefly by microcentrifuge to settle the resin before being pipetted off. Cleaved 
and uncleaved fractions were analysed by SDS-PAGE and visualised by silver staining 
(ProteoSilver Silver Staining Kit; Sigma). 
2.3.5  Expression of PfTFIIA-γ1 and PfTFIIA-γ2 complexes 
The bacterial expression vectors for the 6H-PfTFIIA-γ1 or 6H-PfTFIIA-γ2 complexes were 
transformed into E. Coli BL21 CodonPlus (DE3)-RIL cells and plated on selective SOC-
agar plates containing 100µg/ml ampicillin (Amp) and 34µg/ml chloramphenicol (Cam). A 
freshly selected colony was then used to inoculate a 50ml LB starter culture containing 
100µg/ml Amp, 50µg/ml Cam, and 50mM glucose. The starter culture was incubated at 
37˚C overnight in an orbital shaker set at 250rpm. The following day the starter culture was 
harvested by centrifugation at room temperature at 3000rpm in a Beckman JA-14 rotor for 
5min. The cell pellet was resuspended in 25ml LB (Amp 100µg/ml, Cam 50µg/µl) pre 
warmed to 37˚C in order to remove β-lactamase and expose the cells to fresh antibiotics. 
Expression cultures (9 x 500ml LB, Amp 100µg/ml, Cam 50µg/µl) were then inoculated 
with 2.5ml resuspended starter culture and incubated at 37˚C in an orbital shaker at 250 
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rpm until an OD550 reading of 0.4-0.6 was reached. Cultures were then cooled on ice to 
25˚C before being incubated for a further 20 hours at 25˚C with shaking (250rpm). No 
IPTG was used for induction due to the toxicity of induced over expression. Instead, 
protein production relied solely on the leaky expression of the LacUV5 promoter, leading to 
bursts of mRNAs coding for the T7 polymerases required for the activation of the pET 11d 
expression system. Saturated cultures were harvested the next day by centrifugation at 
3000rpm for 10min at 4˚C in a Beckman JA-14 rotor. Cell pellets were combined and re-
centrifuged for 10min to remove the remaining LB medium. A combined wet cell mass of 
20g was obtained from 4.5L expression culture. The cell pellets were flash frozen in liquid 
N2 and stored at -80˚C before further processing. 
2.3.6 Purification of PfTFIIA-γ1 and PfTFIIA-γ2 complexes 
Cell pellets were resuspended in 5ml sonication buffer (50mM Tris-HCl pH 7.2, 500mM 
KCl; 0.5% Nonidet P-40; 10mM β-mercaptoethanol) per gram cell mass containing 50µl/g 
protease inhibitor (p8340, Sigma-Aldrich), 1mg/ml lysozyme, 1µl Benzonase per 5g cell 
mass (Sigma-Aldrich) to reduce viscosity of the resultant cleared lysate, and incubated on 
ice for 30min. Suspensions were sonicated 6 x 10sec with 20sec cooling periods between 
bursts. Lysates were cleared by centrifugation at 10 000 rpm at  4˚C in a Beckman JA-14 
rotor for 30min, transferred to a clean centrifuge tube, and centrifuged a second time. 
Cleared lysate (approximately 100ml total) was then passed over 300µl Nickel-
Nitrilotriacetic acid (Ni-NTA) affinity resin (Sigma) in a Poly-Prep chromatography column 
(Bio-Rad) by gravity flow. The protein-bound resin was washed with 10ml sonication buffer 
followed by 10ml wash buffer (20mM Tris-HCl pH 7.2, 500mM KCl, 0.5% NP-40, 10mM β-
EtOH, 20mM imidazole) and eluted with 3ml elution buffer (20mM Tris-HCl pH 7.2, 20% v/
v glycerol, 500mM KCl, 0.5% NP-40, 10mM β-EtSH, 250mM imidazole). Elutions were 
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collected in 500µl fractions and analysed by SDS-PAGE. The protein-containing fractions 
were then salt adjusted to 100mM KCl using a PD Miditrap buffer exchange column (GE 
Healthcare). Salt-adjusted Ni-NTA eluates were further purified, either on Q sepharose 
(PfTFIIA-γ1) or SP sepharose (PfTFIIA-γ2) ion exchange resins (Sigma). Eluates were 
passed three times over 250µl resin in Poly-Prep disposable columns (Bio-Rad) by gravity 
flow. The columns were rinsed with 6ml BC-100 buffer (BC-0 buffer containing 100mM 
KCl). The bound proteins were eluted stepwise in 300µl fractions with BC-0 buffer 
containing increasing KCl concentrations (BC-200,-300,-400,-500,-600,-700). BSA was 
added to eluted fractions to a final concentration of 100ng/µl before flash freezing in liquid 
N2 and storing at -80˚C. The purification scheme developed for PfTFIIA-γ1 and PfTFIIA-γ2 
can be found in figure 12A. 
2.3.7 Expression and purification of PfTBP and PfTLP 
Expression and purification of 6His-tagged PfTBP core domain (PfTBP) that was used for 
DNA-binding assays was done in collaboration with Ms. Gertrud Talvik (Talvik, 2015). 6His-
tagged PfTLP (PfTLP) used in DNA-binding assays was provided by Mr Steven Bing 
(Bing, 2015). A summary of the purification schemes developed are presented in figure 7.  
2.4 Promoter sequences and DNA probe preparation for EMSA and ITA analysis 
The promoter sequences chosen for this study are found upstream of genes critical to 
parasite pathogenicity. gbp-130 encodes a 130kD glycophorin-binding protein found on the 
merozoite cell surface. This protein has been shown to be an essential mediator of 
erythrocyte binding and subsequent parasite invasion (Perkins, 1984). The kahrp gene 






interactions between this protein and host RBC membrane proteins to the cytoadherence 
displayed by infected red blood cells (RBCs) (Pei et al., 2005; Weng et al., 2014). 
Transcription start sites (TSS) for both the gbp-130 and kahrp genes have been mapped 
(Lanzer et al., 1992a; Lanzer et al., 1992b). The GC-rich TATA-less mouse terminal 
deoxynucleotidyl transferase (TdT) promoter was used for comparative purposes. The 
wild-type TdT sequence lacks any TATA-motif while a mutated variant (TdT [TATA+]) 
contains a prototypical TATA-box element TATAAAA known to promote stable binding of 
eukaryotic TBPs (Tan., et al 1993; Nikolov et al., 1996; Malecová et al., 2015).   
Plasmid vectors containing the putative P. falciparum promoter sequences for the gbp-130 
(pTHG5gbp130) and kahrp (pTHG5Kharp) genes are derivatives of pGEM-7Zf (Promega) 
and contain promoter regions from -181 to +51 of the gbp-130 gene and -172 to +63 of the 
kahrp gene. For EMSA probe generation, the GBP-130 and KAHRP probes were PCR 
amplified from these vectors using biotinylated primers Bio-pTOTdTPCR-FWD and Bio-
pTOTdTPCR-REV listed in Table 4. The mouse TdT and TdT (TATA+) promoter sequences 
spanning the regions -41 to +33 and were amplified from plasmids pTOG5TdT(-41to+33) 
and pTOG5TdT(-41/TATA/to+33) respectively (Malcova et al., 2007). ITA probes were 
generated using a biotinylated forward primer (Bio-pTOPCR-US-FWD) and an unlabelled 
reverse primer (pTO(G5)TdTPCR-REV). Following PCR, probes were purified by 
polyacrylamide gel purification using the Qiagen QiAquick purification protocol for 
polyacrylamide gel extraction. The DNA probe sequences are listed in Table 5. 
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Procedure Primer name Primer sequence 
EMSA probe generation Bio-pTOTdTPCR-FWD GAATTCTAGAGTCTCCGCTCG 
Tm (50mM NaCl):61.2˚C| hairpin:no |Self-
complimentarity: yes 
EMSA probe generation Bio-pTO(G5)TdTPCR-REV AACGCGTTGGGAGCTCTCC
Tm (50mM NaCl):61.6˚C|hairpin:no |Self-
complimentarity: no 
ITA probe generation Bio-pTOPCR-US-FWD AATTGGGCCCGACGTCGCA 
Tm (50mM NaCl):61.6˚C|hairpin:no |Self-
complimentarity:no 
ITA probe generation pTO(G5)TdTPCR-REV AACGCGTTGGGAGCTCTCC
Tm (50mM NaCl):61.6˚C|hairpin: no | Self-
complimentarity: no 
 Table 4: Primer sequences for DNA-probe generation
Table 5: Sequences of DNA-probes used in EMSA and ITAs: Primer binding-sites shown in blue. Transcription start 
sites (TSSs) shown in red. TATA box motif shown in orange.


































2.4.1 Immobilisation of ITA probes to Streptavidin magnetic beads 
Probes were immobilised on Dynabeads M-280 Streptavidin (Invitrogen) as per 
manufacturers instructions. Beads were re-suspended and stored in 1x template 
immobilisation wash buffer (10mM Tris-HCl pH 7.5; 0.5mM EDTA; 1M NaCl) containing 
100ng/µl BSA. Binding efficacy was checked by an agarose gel comparison of known 
amounts of unbound probe to that of bound probe liberated from the beads through 
phenol-chloroform extraction and recovered by ethanol precipitation. 
2.5 Electrophoretic mobility shift assays (EMSAs) 
  
4µl template mix (50mM HEPES pH 8.0, 12.5mM MgCl2, 12.5mM DTT, 250ng/µl BSA), 
containing 5ƒmol promoter DNA-probe and the relevant amount of poly(dG-dC) competitor 
DNA, were combined with a 6µl protein mix’s, containing tested protein fractions diluted in 
BC-100 buffer (BC-0 buffer, 100mM KCl), to give a final reaction volume of 10µl (20mM 
HEPES pH 8.0, 5mM MgCl2, 5mM DTT, 62.5mM KCl, 12.5% glycerol v/v, 25mM Tris-HCl, 
100ng/µl BSA). Reactions were incubated either on ice (0˚C) or 30˚C for 45min. Protein-
DNA complexes were then separated from free probe by Mg2+ agarose gel electrophoresis 
at 4˚C (1.4-1.5% w/v agarose, 0.5x TBE, 5mM MgCl2). The probes were then transferred 
to a positively charged nylon membrane (Immobilon-Ny+, EMD Millipore), UV cross-linked 
three times for 1min (1200J/cm2), and visualised on X-ray film by chemiluminescence 
using a Pierce Chemiluminescent Nucleic Acid Detection kit (Thermo-Scientific). 
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2.6 Immobilised template assays (ITAs) 
20µl template mix’s (50mM HEPES pH 8.0, 12.5mM MgCl2, 12.5mM DTT, 250ng/µl BSA) 
containing 1000ƒmol immobilised probe and 400ng poly(dG-dC) competitor DNA were 
combined with 30µl protein mix’s, containing tested protein fractions diluted in BC-100 
buffer (BC-0 buffer, 100mM KCl) to give a final reaction volume of 50µl (20mM HEPES pH 
8.0; 5mM MgCl2 ; 5mM DTT, 100ng/µl BSA). Reactions were incubated at 30˚C for 45min. 
The probes were then magnetically separated from the binding reaction mix and washed 
with 100µl reaction buffer (20mM HEPES pH 8.0; 5mM MgCl2 ; 5mM DTT, 100ng/µl BSA). 
Finally, bound proteins were eluted with 1x SDS-loading buffer and heated at 80˚C for 
2min. These fractions were then loaded onto a 15% SDS-PAGE gel together with known 
quantities of protein input for immunoblot analysis. 
2.7 Systematic evolution of ligands by exponential enrichment (SELEX) 
SELEX is a well-established molecular biology approach that can be used to elucidate the 
DNA-binding specificity of proteins by making use of successive rounds of DNA-binding 
and amplification of selectively bound DNA by PCR to enrich a pool of random 
oligonucleotides for sequences that are favoured by the target protein(s). A detailed 
protocol is described in Ogawa & Biggin, 2012. Primers and DNA-probes that were used in 
the SELEX procedure are listed in Table 6. Unless otherwise stated, all restriction and/or 
DNA-modifying enzymes used here were obtained from New England BioLabs 
(www.neb.com). All PCR purification and gel extraction kits were obtained from Qiagen 
(www.qiagen.com). Procedures were carried out as per manufacturers instructions unless 
noted otherwise. A Qiagen QiAgility pipetting robot was used for all pipetting involved in 
the setting up of qPCR reactions. 
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2.7.1 Generation of SELEX input DNA library (n16 library) 
Single stranded 72bp DNA molecules (ssSELEX72-n16) containing a central randomised 
16bp sequence flanked by 28bp primer binding sites were synthesised and purified by the 
MCB oligonucleotide synthesis laboratory. A double stranded DNA library (dsSELEX72-
n16) was generated by a single-cycle polymerase reaction using the ssSELEX72-n16 
template and the reverse primer (SELEX80-BamHI-REV). 15 x 50µl single cycle reactions 
were carried out with the following parameters: 95˚C 5min, 95˚C 30sec, 64˚C 1min, 72˚C 
9min using a two step reaction profile. The first step consisted of a 95˚C 5min denaturing 
step followed by a cycle of 95˚C denaturation for 30sec, annealing at 64˚C for 1min, and 
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Procedure Primer name Primer sequence 

















Tm (50mM NaCl): 58.4˚C
Colony PCR M13-FWD GTTTTCCCAGTCACGAC 
Tm (50mM NaCl):52.4˚C











CT // Tm (50mM NaCl):73.8˚C
Table 6: Primer and template sequences used in the SELEX procedure: Restriction enzyme sites shown in blue. 
The SELEX concatemerization II formed part of a strategy used to identify truncated SELEX products formed in the 
original SELEX enrichment rounds (Ch3. Results, Section 3.6.3) 
elongation at 72˚C for 1min. The reactions were then pooled and gel purified using 15% 
PAGE and the user developed protocol for polyacrylamide gel extraction published in the 
Qiagen QIAEX II handbook. The concentration of the final preparation was determined by 
nano-drop and adjusted to 10ng/µl. The quality of the preparation was assessed by 
polyacrylamide gel electrophoresis analysis. In order to confirm that there is no inherent 
sequence bias within the commercially synthesised pool of random oligonucleotides, the 
SELEX procedure was carried out in the absence of the protein DNA-binding steps by 
using a dilution of the random sequence library (n16 library) as an “eluted” fraction with 
which to follow through with the subsequent amplification, cloning, and sequencing 
procedures (Fig. 8) (Ogawa & Biggin, 2012). A large amount of biotinylated n16 library 
sequences were produced by PCR amplification with biotinylated primers (Bio-Selex80-
BamHI-FWD, Bio-Selex80-BamHI-REV; Table 6) using a two step PCR reaction profile. 
The first step consisted of a 5min 95˚C denaturation step followed by 20 cycles of 95˚C 
denaturation for 30sec, annealing at 64˚C for 1min, and elongation at 72˚C 1min. After the 
initial 20 cycles a 20µl supplement mix containing fresh Kapa Taq polymerase and primers 
was added to each reaction (now 40µl in total) followed by a final single reaction step to 
ensure maximum yield of double stranded product with the following parameters: 
denaturation at 95˚C for 30sec, annealing at 64˚C for 5min, and elongation at 72˚C for 
10min. The resultant product was gel purified and analysed by native polyacrylamide gel 
electrophoresis. 10µg of the biotinylated sequences were digested with 1000U BamHI for 
3hrs in NEB Buffer 3.1 to remove the flanking sequences. This was followed by incubation 
with 40µl packed Streptavidin sepharose (GE healthcare) for 3hrs in 500µl 0.3M NaOAc 
pH 5.20 to remove flanking sequences from the cleaved 16bp random sequences (n16). A 
20µl ligation reaction containing the BamHI digested fragments in 1x T4 ligase buffer was 
incubated overnight at 4˚C with 10U T4 ligase. The resultant concatemers (250bp-1000bp) 
were isolated by agarose gel extraction. The 3’ and 5’ overhangs were filled in by 
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incubation in 1x NEB buffer 2 with 9U T4 DNA Polymerase and 15U Klenow fragment (Lrg) 
in a 50µl reaction incubated at 21˚C for 1hr. The resultant mixture of concatemers were 
separated by 1.5% agarose gel electrophoresis resulting in a  smear of DNA within the gel 
lane. Concatemers of the desired sizes were isolated using the molecular weight markers 
as a guide to identify the correct regions of the gel to be excised. Once isolated, the 
concatemers were gel purified using a GeneJet gel purification kit (ThermoScientific), 
followed by phenol–chloroform extraction and ethanol precipitation to remove any 
remaining salts from the extraction procedure. Purified concatemers were blunt-end cloned 
in a 10µl ligation reaction containing 24ng SmaI digested pUC19 sequencing vector and 
5U T4 ligase (Fermentas) in 1x T4 ligase buffer (Fermentas) incubated overnight at 16˚C. 
The resultant ligation reaction was then purified by phenol–chloroform extraction and 
ethanol precipitation, with the DNA being resuspeded in 2µl H2O. 1µl pUC19-ligated 
concatemers were then transformation by electroporation (2.0Kv 200Ω 25µF) into 
ElectroMAX DH5α-E competent cells (Invitrogen). Transformants were plated on LB agar 
plates containing 50mg/ml X-gal, 100mM IPTG, and 150µg/ml ampicillin. Recombinant 
transformants were identified by blue/white selection (Sambrook & Russel, 2001) and the 
resultant clones were further screened for inserts by colony PCR. Plasmids containing 
inserts > 300bp were then amplified and isolated by plasmid mini-prep before being sent 
for sequencing. The 16bp sequences were screened for any apparent sequence bias 
using the online Multiple Em for Motif Elicitation (MEME) application of the MEME-suite 
(http://meme-suite.org/; Bailey et al., 2009). 
2.7.2  Immobilisation of 6H-PfTBP on Ni-NTA magnetic beads 
100ng 6H-PfTBP was immobilised to 10µl nickel magnetic beads (Merck Millipore;) in a 
50µl binding reaction containing 20mM HEPES pH 8.0, 5mM MgCl2, 1mM DTT,  20% v/v  
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glycerol, and 100ng/µl BSA. Reactions were incubated at 21˚C for 1hr with shaking in 
Eppendorf LoBind microcentrifuge tubes. Beads were washed with 2 x 100µl reaction 
buffer and resuspended in 120µl BC-100 complete (BC-O, 100mM KCl, 100ng/µl BSA,
0.5% NP-40).   
2.7.3 Selective enrichment of PfTBP DNA-binding motifs by SELEX using 72bp    
 dsSELEX-n16 input library. 
Quantitative PCR (qPCR) using a Rotor-Gene 6000 (Qiagen) and the KAPA SYBR FAST 
qPCR Kit (Kapa biosystems) was used to determine the amount of immobilised 6H-PfTBP 
needed in a 20µl binding reaction (20mM Hepes pH 8.4, 5mM MgCl2 1mM DTT ,60mM KCl 
100ng/µl BSA; incubated at 21˚C) to bind 0.1% of 10ng input DNA in the presence of 
400ng poly(dG-dC) competitor DNA. 100ng 6H-PfTBP was immobilised and resuspended 
in BC-100 complete (Section 2.7.2). Dilutions were then made to set up for binding 
reactions containing 0ng, 5ng, 10ng, and 15ng 6H-PfTBP. Bound oligonucleotides were 
separated from the reaction mixture by magnetic pulldown of 6H-PfTBP, washed twice with 
1000µl aliquots of SELEX wash buffer (1xBC-0, 10mM HEPES pH 8.0, 60mM KCl, 5mM 
MgCl2, 5mM DTT, 100ng/µl BSA) and eluted with 200µl SELEX elution buffer (500mM 
NaCl,1x BC-0, 10mM HEPES pH 8.0, 60mM KCl, 5mM MgCl2, 5mM DTT, 100ng/µl BSA). 
Oligonucleotides were purified by phenol-chloroform extraction and ethanol precipitation 




3.1 Bioinformatics analysis of the Plasmodium falciparum TATA box   
 binding Protein (PfTBP). 
A bioinformatics analysis of the PfTBP amino acid sequence from the parasite genome 
database (Gene entry PF3D7_0506200; PlasmoDB Release 29) (Aurrecoechea et al., 
2008) was conducted in order to consolidate current data with the original gene 
characterisation and prediction of the P. falciparum TBP ortholog (McAndrew et al., 1993), 
and with structural data from the human and yeast crystallographic models of TBP-DNA 
and TBP-TFIIA-DNA interactions (Tan et al., 1996; Bleichenbacher et al., 2003). This was 
done to examine the degree of conservation of secondary structure elements as well as of 
residues shown to be important for TBP interaction with DNA and TFIIA. The amino acid 
sequences of the highly conserved C-terminal core domains responsible for DNA-binding 
(reviewed in Thomas and Chiang, 2006) from the human and yeast (S. cerevisiae) 
orthologs were aligned with the PfTBP core domain using the  EBI Clustal Omega multiple 
sequence alignment tool and default alignment parameters (Fig. 9). The PfTBP ortholog 
was originally predicted to be a 228 amino acid (26kDa) protein which, as with orthologs 
from other species, is comprised of a highly conserved C-terminal domain preceded by a 
variable unstructured N-terminal sequence of 45 amino acids (McAndrew et al., 1993). 
Current gene annotations based on the whole genome sequencing data (Gardner et al., 
2002; Aurrecoechea et al., 2008) have extended this N-terminal region, predicting a wild-
type ortholog with a much longer N-terminal domain, comprised of 327 amino  
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acids (38.1 kDa). The exact function of the non-conserved N-terminal region is not fully 
understood. Analyses of TBP mutants lacking the N-terminal domain have shown that this 
region is dispensable for TATA box binding and nucleation of PIC assembly.  
Despite a very low overall level of primary sequence identity between the PfTBP core 
domain and the human TBP core domain ortholog (39%) relative to the levels of sequence 
conservation seen among other eukaryotes, for example between human TBP and TBP of 
S. cerevisiae (79%), there are still stretches of identical residues interspersed with 
residues determined to have strongly similar properties (scoring > 0.5 in the Gonnet PAM 
250 matrix) which generally fall within the regions associated with secondary structure 
(Fig. 9). 27 of 29 (93%) residues shown to make contact with the minor groove of DNA in 
the yeast TFIIA-TBP-DNA crystal structure (Tan et al., 1996) through a combination of 
hydrogen bonding and hydrophobic interactions are either conserved or substituted with a 
highly similar amino acid residue. The two substitutions are serine S216 (HsTBP) to 
asparagine N202 (PfTBP), both of which have polar uncharged side chains and thus 
scored as weakly similar, and proline P289 (HsTBP) to alanine A276 (PfTBP), scored 
divergent. The most notable substitution is that of phenylalanine F197 in HsTBP 
corresponding to ScTBP F99, which is replaced by isoleucine I183 in PfTBP and scored as 
highly similar. Although both residues are hydrophobic and scored as highly similar,  the 
aromatic nature of the F197 R-group is considered to be critical for TBP-DNA interaction 
as it is one of the phenylalanine residues intercalating between base pairs to stabilise the 
bent DNA helix structure associated with TBP binding to the TATA box element (Nikolov et 
al., 1996). Indeed, mutation of conserved phenylalanine residues has been shown to 
severely compromise TBP-DNA binding activity in vitro and in vivo (Klejman et al., 2005). 
Based on these data it seems reasonable to predict that substitution of phenylalanine 
F197 (HsTBP) with isoleucine I183 (PfTBP) would minimally specifically affect DNA 
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bending by PfTBP and hence the trajectory of DNA in the PfTBP-DNA complex and would 
highly diminish overall PfTBP DNA-binding activity (Nikolov et al., 1996). Another 
potentially significant point regarding PfTBP-DNA interaction is that the spatial positioning 
of some residues known to interact with DNA has been altered by an insertion of 3 amino 
acids (TSN, positions 285-297 PfTBP). In yeast the motifs RXXXXXXTALIF and 
RXXXXXXVLLIF spanning the S3 to S4 and S3’ to S4’ regions have been shown by 
deletion studies to be essential for TBP-DNA interaction (Reddy & Hahn, 1991). In 
Plasmodium falciparum the second motif is altered by the addition of the three amino acids 
between R281 (PfTBP) and V291 (PfTBP), possibly leading to an alteration in the DNA 
sequence specificity of the PfTBP ortholog (McAndrew et al., 1993). Eight out of ten (80%) 
of the residues shown to interact with TFIIA when bound to promoter DNA in the human 
TFIIA-TBP-DNA crystal structure (Bleichenbacher et al, 2003) have been conserved in the 
PfTBP ortholog. The two exceptions being substitutions of alanine A186 (HsTBP) to 
isoleucine I173 (PfTBP) (scored divergent) and arginine R204 (HsTBP) to asparagine 
N191 (PfTBP) (scored weakly similar). Lastly, a conserved proline, P163 in HsTBP and 
P65 in ScTBP, which has been shown to be essential for RNA Pol II transcription in yeast 
(Schultz et al., 1992; MacAndrew et al., 1993) has been substituted to leucine L149 
(PfTBP) (scored divergent). The exact function of this residue is yet to be determined.  
In light of these observations it is likely that although PfTBP may have conserved function 
based on its secondary structure homology and TFIIA interaction sites, its interaction with 
DNA may well be altered with regard to overall DNA-binding activity, sequence specificity, 
and the structure/trajectory of DNA in the PfTBP-DNA nucleoprotein complex. 
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3.2 Bioinformatic analysis of putative Plasmodium falciparum transcription  
 factor IIA orthologs. 
Hydrophobic cluster analysis (HCA) and profile-based homology search methods such as 
PSI-Blast were used to identify P. falciparum general transcription factors known to be 
associated with RNAP-II transcription in metazoans (Callebaut et al., 2005). Among the 
hypothetical GTFs found in the P. falciparum genome, were candidates for the TFIIA αβ 
(Gene entry PF3D7_0716400; PlasmoDB Release 29) and TFIIA γ subunits, which 
associate to form the quaternary structure of transcription factor IIA (TFIIA). Interestingly, 
two potential candidates for the γ subunit were identified, termed here PfTFIIA-γ1s (Gene 
entry PF3D7_1250700; PlasmoDB Release 29) and PfTFIIA-γ2s (Gene entry 
PF3D7_0933700; PlasmoDB Release 29) (Aurrecoechea et al., 2008). This observation 
gives rise to the possibility that P. falciparum possesses two distinct TFIIA complexes 
containing different γ subunits and with possibly distinct function. This may be a feature 
unique to P. falciparum and may therefore provide opportunity for the elucidation of unique 
P. falciparum RNAP-II transcription initiation mechanistic insights.  
In order to consolidate data from the original homology predictions with structural data 
from the human and yeast  (S. cerevisiae) crystallographic models of TBP-TFIIA-DNA 
interactions (Tan et al., 1996; Bleichenbacher et al., 2003), the EBI Clustal Omega multiple 
sequence alignment tool (default alignment parameters) was used to perform multiple 
sequence alignments between the hypothetical Plasmodium proteins and their respective 
human and yeast orthologs for those regions predicted by HCA to contain conserved 
secondary structure elements (Callebaut et al., 2005) (Figs. 10B, 11A). 
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3.2.1 Alignment of PfTFIIA-αβ subunits 
The schematic presented in Fig. 10A shows the overall structure of the TFIIA-αβ subunit. 
TFIIA-αβ is composed of two structural domains, an N-terminal α-helical domain and a C-
terminal domain made up of β-strands. One significant difference between TFIIA-αβ 
orthologs is the length of unstructured species-variable sequences bridging these two 
regions (Fig. 10A) (Callebaut et al., 2005). It is important to note that the TFIIA-αβ subunit 
of P. falciparum does not contain a Taspase1 cleavage site, and is therefore likely to exist 
in an uncleaved form as is seen in yeast (S. cerevisiae). Multiple sequence alignments of 
the two structural domains show a significant lack of conservation of primary sequence 
identity between P. falciparum (Pf), human (Hs), and yeast (Sc) TFIIA-αβ (Fig. 10B). 
Indeed, the predicted PfTFIIA-αβ subunit is either matched with a high E value when using 
the human ortholog (E = 0.088), or not matched at all when using the full-length yeast 
TOA1 sequence as a BLASTp query sequence in the PlasmoDB database. The 
Plasmodium ortholog was originally identified by PSI-BLAST results showing significant C-
terminal similarities with the TOA1 sequence (residues 214 to 286) after the second 
iteration (E = 3 x 10-4 ). HCA analysis then revealed the presence of the N-terminal helical 
domain which could be aligned with the yeast and human orthologs (Callebaut et al., 
2005). Despite the lack of primary sequence conservation in both the N- and C-terminal 
regions, patterns of conservation are discernible when examining the hydrophobic residue 
positions (Fig. 10B). The DNA interaction site (residues 343-346 HRSK) located in the 
HsTFIIA-αβ β-strand 2 (S2) region (Fig. 10B, blue box marker), which has been shown to 
interact with the DNA backbone both within and upstream of the TATA box major groove in 
the human TFIIA-TBP-DNA structure has been substantially altered in the PfTFIIA-αβ 
ortholog. The S2 histidine H343 (HsTFIIA-αβ) is deleted and the S2 arginine R344 
(HsTFIIA-αβ) is substituted for isoleucine I134 (PfTFIIA-αβ) (scored divergent).  
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Furthermore, the TBP interaction sites in HsTFIIA-αβ have also not been conserved in 
PfTFIIA-αβ (Fig. 10B, green box markers). The loop between S2 and S3 that docks 
alongside tryptophan W376 in HsTFIIA-αβ near the N-terminal stirrup region of HsTBP 
forming a hydrophobic pocket is extended by an insertion of 8 amino acids directly after 
the conserved lysine K136 in PfTFIIA-αβ. Tryptophan W376 in HsTFIIA-αβ, which is 
inserted within this hydrophobic region, has also been substituted to phenylalanine F174 in 
PfTFIIA-αβ (scored strongly similar). In light of the human TFIIA-TBP-DNA structural data 
these changes to the DNA interaction sites suggest that the ability of PfTFIIA to stabilise 
binding of TBP to the TATA box is likely altered. Deletion of H343 in HsTFIIA-αβ results in 
the loss of a hydrogen bond to the phosphate backbone of the DNA sense-strand 
upstream of the TATA box element. In addition, substitution of R344 in HsTFIIA-αβ for 
isoleucine I134 in PfTFIIA-αβ results in the loss of another two hydrogen bonds located 
within the TATA box element on the anti-sense strand diagonally across from the H343 in 
HsTFIIA-αβ (Bleichenbacher et al., 2003). TFIIA stabilises the TBP-DNA interaction by 
altering the conformation of the nucleoprotein complex, demonstrated by a TFIIA-mediated 
reduction in the bending angle of TBP-bound DNA (Hieb et al., 2007). It is easy to imagine 
that the loss of direct TFIIA-DNA contacts at several positions spanning the width of the 
TBP-DNA interaction surface may prevent this conformational re-arrangement. With 
respect to TBP-TFIIA interaction, some of the aforementioned changes seem unlikely to 
abolish potential co-operation between the two transcription factors. Extension of the loop 
between β-strands S2 and S3 does not necessarily preclude this region from functioning in 
its original capacity as a shield for the hydrophobic pocket located near the TBP N-terminal 
stirrup. Similarly, the effect of tryptophan W376 in HsTFIIA-αβ being substituted for 
phenylalanine F174 in PfTFIIA-αβ is possibly small as both residues are hydrophobic in 
nature and have aromatic side chains. This substitution does however result in a loss of 
hydrogen bonding between tryptophan W376 in HsTFIIA-αβ and asparagine N189 in 
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HsTBP, which may be significant as N189 forms part of a highly conserved TBP region in 
both the human and P. falciparum orthologs (section 3.1). In summary, the TFIIA-αβ 
subunit of metazoan TFIIA is the primary site of interaction between TFIIA and DNA in the 
TFIIA-TBP-DNA nucleoprotein complex. Although secondary structure elements between 
human, yeast, and P. falciparum PfTFIIA-αβ orthologs appear to be conserved there are 
substantial alterations to the region involved in DNA interactions. These alterations likely 
lead to a loss in the ability of PfTFIIA to stabilise interactions between TBP and the TATA 
box promoter element. In addition, there are clear changes in the TBP-TFIIA interaction 
sites. 
3.2.2 Alignment of PfTFIIA-γ subunits 
The schematic presented in Fig. 11B shows the overall structure of the human TFIIA-γ 
subunit (HsTFIIA-γ), which is made up of a α-helical domain followed directly by a β-sheet 
domain (Fig. 11B). The yeast TFIIA-γ (ScTFIIA-γ) and P. falciparum (PfTFIIA-γ1s) 
orthologs differ from this in that they both contain insertions of an unstructured amino acid 
region that is located within their respective β-sheet domains (Fig. 11B) (Callebaut et al., 
2005; Bleichenbacher et al., 2003). An unstructured region is also present in the second 
P. falciparum ortholog (PfTFIIA-γ2s). However, this region precedes the N-terminal α-
helical domain (Fig. 11B). Multiple sequence alignments of the human and yeast orthologs 
with the structural domain regions of the PfTFIIA-γ1s and PfTFIIA-γ2s subunits predicted 
by HCA (Callebaut et al., 2005) show a substantial divergence in the primary amino acid 
sequences of these orthologs relative to the human and yeast variants as well as in 
respect to one another (Fig. 11A). It should be noted that minor adjustments to the Clustal 
Omega alignment had to be made at the extreme C-terminus corresponding to amino acid  
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positions 85-104 of HsTFIIA-γ in order to better align the subunits according to the HCA 
plots previously described (Callebaut et al., 2005). As with the PfTFIIAαβ subunit there is 
some conservation of hydrophobic positions but overall, the sequences lack large regions 
of conserved homology (Fig. 11A).  
The DNA interaction site R55 located in HsTFIIA-γ (Fig. 11A, blue box marker), which 
provides electrostatic interaction with the DNA in the crystallographic data (Bleichenbacher 
et al., 2003), is somewhat conserved both in the ScTFIIA-γ and PfTFIIA-γ2s orthologs, 
where this residue has been substituted for another positively charged polar amino acid, 
lysine K139 in PfTFIIA-γ2s,  lysine K59 in ScTFIIA-γ. PfTFIIA-γ1s however shows a more 
radical substitution with arginine R55 in HsTFIIA-γ1 being replaced with the negatively 
charged aspartic acid D61. The main TBP-TFIIA interaction sites in the human TFIIA-TBP-
DNA complex (Bleichenbacher et al, 2003) are parallel β-strand interactions made up of a 
H-bond network between Y65 and F67 in HsTFIIA-γ, and in the N189, A190, and Y192 
residues within the HsTBP S2 β-sheet domain, extended further by an indirect interaction 
between HsTBP N189 and HsTFIIA-γ N63 via a water molecule. A second H-bond network 
is formed between HsTFIIA-γ R66 and the A184, L185, and A187 residues in the the C-
terminus of the HsTBP H1 α-helical domain. Finally the R205 side chain in HsTBP forms 
direct contacts with HsTFIIA-γ L62 and HsTFIIA-γ N63 via hydrogen bonding to the main-
chain carbonyl groups (Bleichenbacher et al., 2003). With the exception of the lysine 
residue L62 in HsTFIIA-γ, there is no conservation of TBP interaction sites found in 
PfTFIIA-γ1s or PfTFIIA-γ2s. N63 of HsTFIIA-γ is substituted with K69 in PfTFIIA-γ1s, and 
I147 in PfTFIIA-γ2s. Y65 of HsTFIIA-γ is conserved in PfTFIIA-γ1s, but has been 
substituted for cysteine C149 in PfTFIIA-γ2s (scored divergent). Arginine R66 of HsTFIIA-γ 
is also not conserved, being substituted for Y72 in PfTFIIA-γ1s and K150 in PfTFIIA-γ2s. 
Lastly, phenylalanine F67 in HsTFIIA-γ is substituted for cysteine C73 in PfTFIIA-γ1s and 
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lysine K151 in the PfTFIIA-γ2s ortholog. It is important to note that two of these TBP 
interaction sites, N63 and R66 in HsTFIIA-γ, are also not conserved in the yeast ScTFIIA-
γ, and therefore, the differences seen at these positions in the PfTFIIA orthologs may not 
be of much significance to TBP-TFIIA interaction in P. falciparum. 
In summary, the bioinformatics analysis of the two putative PfTFIIA-γ subunits provides 
good evidence, based on secondary structure prediction, that PfTFIIA-γ1s and PfTFIIA-γ2s 
are indeed legitimate PfTFIIA orthologs. However, there is an extreme divergence in 
primary sequence identity with respect to one another as well as to the human ortholog 
(Fig. 11A). In addition, there are alterations to the spatial arrangement of the proposed 
secondary structure features in the PfTFIIA-γ1s and -γ2s orthologs relative to the known 
arrangement seen in the crystal structure of HsTFIIA (Fig. 11B) (Bleichenbacher et al., 
2003). As there is also almost no conservation of the main TBP interaction sites present in 
the human ortholog, located primarily on the TFIIA-γ subunit, one would expect the two 
different PfTFIIA complexes to posses biochemical characteristics that are very different 
from the human TFIIA and from each other (Bleichenbacher et al., 2003). 
3.3 Bioinformatic analysis of the Plasmodium falciparum TBP-like protein (PfTLP) 
The P. falciparum TBP-Like protein (PfTLP) (Gene entry PF3D7_1428800.2 ; PlasmoDB 
Release 29) (Aurrecoechea et al., 2008) is a putative TBP paralog predicted to be part of 
the set of general transcription factors associated with the parasite’s RNAP-II mediated 
transcription (Coulson et al., 2004; Bischoff et al., 2010). Vertebrates have evolved a range 
of TBP paralogs through gene duplication events leading to an expansion of the available 
TATA-binding factors able to promote basal transcription initiation (reviewed in Thomas & 
Chiang, 2006;  Akhtar & Veenstra, 2011). This is thought to have given rise to novel control 
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mechanisms through the preferential interaction of these paralogs with distinct core 
promoter sub-types as evidenced by TBP-related factor (TRF2) mediated control of TCT-
and DPE- dependent TATA-less promoters (Wang et al., 2014; Kedmi et al., 2014; Duttke 
et al., 2016). Three distinct TBP family proteins have thus far been identified: TBP-related 
factor (TRF1), discovered in Drosophila and later found to be specific to insect cells, TBP-
like factor (TRF2 or TLP), found in all metazoans, and finally the most recent vertebrate-
specific paralog, TBP2 (or TRF3) (Crowley et al., 1993; Dantonel et al., 1999; Bártfai et al., 
2004; reviewed in Akhtar & Veenstra, 2011). Multiple sequence alignment and 
phylogenetic analysis showed that of the three TBP paralogs, PfTLP is evolutionarily most 
closely related to TRF2 (TLP) (Bing, 2015). Secondary-structure modelling revealed that 
PfTLP is likely to have a structure very similar to the that of the conserved C-terminal core 
domain typically associated with TBP family proteins (Bing, 2015). Figure 12 shows an 
adaption of a COBALT sequence alignment by Bing, 2015 of HsTBP and selected TRF 
orthologs. It has been included as a point of reference for later discussions regarding data 
obtained from functional assays. For purposes of comparison to the Clustal Omega 
alignments of PfTBP and PfTFIIA, residue similarities in the PfTLP alignment are indicated 
according to the Gonnet PAM 250 matrix parameters (Ch2. Materials & Methods, Section 
2.1.1). As with preceding alignments, Fig. 12 has been annotated according to structural 
data for the human and yeast TBP-DNA (Nikolov et al., 1996; Tan et al., 1996) and TBP-
TFIIA-DNA (Bleichenbacher et al., 2003) complexes. PfTLP shows a substantial 
divergence in primary sequence identity relative to HsTBP with the most notable difference 
being the insertion of large unstructured regions in the S4 and S4’ β-strand regions (131 
and 31 amino acid residues respectively), as well as a very short N-terminal region (Fig. 
12). Examination of the DNA-interaction sites show that only 16 of 29 (55%) residues is 
HsTBP known to interact with the DNA minor groove (Tan et al., 1996; Bleichenbacher et 
al., 2003) have been either conserved or substituted with highly similar (scoring > 0.5 in  
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the Gonnet PAM 250 matrix) amino acid residues (Fig. 12). In addition, it should also be 
noted that the two unstructured loop regions (131 and 31 amino acid residues) are 
inserted into the RXXXXXXTALIF and RXXXXXXVLLIF motifs, which have been shown in 
yeast TBP to contain residues vital for DNA-binding activity (Reddy & Hahn, 1991; 
discussed in Section 3.1). Surprisingly, all four of the highly conserved phenylalanine 
residues F197, F214, F288, and F305 in HsTBP, essential for stable TBP-DNA interaction 
at the TATA box (Nikolov et al., 1996; Klejman et al., 2005), are conserved in PfTLP. This is 
a characteristic that is unique among TRF2-type TBP paralogs, which in other eukaryotes 
lack one or more of these residues. The lack of conserved phenylalanine residues in 
TRF2-type TBP paralogs is thought to be the reason for their lack of TATA-binding activity 
(reviewed in Thomas & Chiang, 2005; Duttke et al., 2016). Similarly, only 2 of 10 (20%) 
residues associated with TFIIA interaction in HsTBP (Bleichenbacher et al., 2003) have 
been conserved in PfTLP, with all other residues showing substitution to either divergent or 
weakly similar (scoring < 0.5 in the Gonnet PAM 250 matrix) residues. In addition, the 
analysis of associated DNA-interaction sites (Bleichenbacher et al., 2003) seem to indicate 
that, despite the relatively low conservation (55%) of important DNA-interaction sites 
compared to PfTBP (97%), key residues typically associated with TATA-binding activity are 
conserved (Fig. 12) (Nikolov et al., 1996). It is also evident, based on the low level of TFIIA 
interaction site conservation, that any traditional relationship to TFIIA would likely 
necessitate an interaction partner that has a biochemical surface distinct from that found 
on human TFIIA. In summary, P. falciparum TLP (PfTLP) is unique compared to currently 
described metazoan TLP (TRF2) orthologs in that it possesses all four of the highly 
conserved phenylalanine residues associated with the TATA-binding activity of TBP. This is 
a very surprising feature in that it seems to indicate DNA-binding activity, and possibly 
TATA-binding activity for PfTLP, a characteristic not seen with other TLP orthologs. 
However, aside from this key similarity with TBP, the overall conservation of DNA 
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interaction sites outside of these four phenylalanine residues is relatively low. In addition, 
the insertions of large unstructured loop regions within the C-terminal domain of PfTLP 
adds precedence to the notion that PfTLP may have an altered DNA-sequence specificity 
With respect to TFIIA interaction, the levels of TFIIA interaction site conservation is very 
low, indicating the altered surface chemistry of PfTLP suggests at the very least a very 
different mode of interaction with TFIIA or perhaps an inability to interact with TFIIA all 
together.    
  3.4 Co-expression and purification of two putative PfTFIIA complexes 
Transcription factor IIA (TFIIA) was one of the earliest general RNAP-II transcription 
factors (GTFs) shown by in vitro transcription assays to be necessary for site-specific 
transcription initiation by RNAP-II (Weil et al. 1979; Matsui et al., 1980; Samuels et al., 
1982). Human TFIIA is a multi-subunit complex made up of three polypeptide chains: α 
(35kDa), β (19 kDa), and γ (12 kDa) which are initially transcribed from two genes, with the 
αβ chain being translated as a single unit and subject to post-translational cleavage by 
Taspase 1 (reviewed in Høiby 2007; Malecová et al., 2015). The TBP-TFIIA-DNA crystal 
structure shows a tightly bound and intertwined α-β-γ ternary complex forming contacts 
with both DNA and promoter-bound TBP (Bleichenbacher et al., 2003). Bioinformatics 
studies identified an ortholog for the αβ subunit and two putative orthologs for the γ 
subunit, raising the possibility that P. falciparum contains two distinct PfTFIIA complexes 
with different gamma subunits.  
  
 87
3.4.1 Cloning and expression of isolated 6His-tagged PfTFIIA-αβ, PfTFIIA-γ1s, and   
 PfTFIIA-γ2s subunits 
Initial efforts focused on the expression and purification of the individual subunits in 
isolation with the view of generating PfTFIIA complexes through previously established 
techniques of controlled denaturation/renaturation, which achieved human TFIIA complex 
formation with individual subunits during the re-folding process (Sun et al.,1994; Dejong et 
al., 1995; Ozer et al., 1994; Malecova et al., 2007). Bacterial expression vectors for 6His-
tagged variants of the putative PfTFIIA subunits PfTFIIA-αβ, PfTFIIA-γ1s, and PfTFIIA-γ2s 
were previously cloned in collaboration with Dr Thomas Oelgeschläger (Milton, 2012; 
unpublished data). Vectors were transformed into the codon optimised E.coli strain BL21-
DE3-RIL and expression induced by the addition of IPTG. SDS-PAGE analysis of whole-
cell lysates before and after induction followed by Ni-NTA affinity purification of cleared 
lysate prepared under native conditions (QIAexpressionist, 2002) failed to show 
enrichment of these proteins (data not shown). To investigate whether these proteins were 
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expressed but insoluble, bacterial pellets were resuspended in 8M urea sonication-buffer. 
After sonication and centrifugation, the cleared solubilised pellet was passed over a Ni-
NTA column and elution fractions were analysed by SDS-PAGE (Fig. 13). The 6H-PfTFIIA-
αβ subunit has a calculated molecular mass of 22kDa but migrated as a single enriched 
band with an apparent molecular mass of about 30kDa in the SDS-PAGE gel. This 
unusually low mobility of the PfTFIIA-αβ subunit in SDS-PAGE can be explained by its very 
low pI (4.84). The resultant negative charge is known to hamper the association of SDS 
molecules, thereby reducing the net negative charge per unit length of the denatured 
protein subunit and thus its mobility in the electric field (Fig 13A). The two γ subunit 
candidates PfTFIIA-γ1s (23.4 kDa) and γ2s (24.3 kDa) can be seen migrating around the 
25kDa markers of Figures 13B and 13C respectively, consistent with the calculated 
molecular mass of the 6H-tagged variants. Low molecular mass peptides visible around 
the 20kDa marker in lanes 4 + 5 of figure 13B are evidence of possible proteolytic 
degradation, which may account for the comparatively low expression levels of the 
PfTFIIA-γ1s and γ2s subunits relative to the PfTFIIA-αβ subunit. Multiple variations of 
these initial expression conditions were employed in an attempt to alleviate the protein 
solubility problem. Changes included variations in expression temperature, IPTG 
concentration, cell density at point of induction, as well as the use of commercially 
available auto-induction media. Ultimately these attempts were unsuccessful and did not 
result in the production of appreciable levels of soluble protein (data not shown). 
3.4.2 Co-expression of the PfTFIIA-γ1s and PfTFIIA-γ2s containing PfTFIIA complexes 
The heterologous co-expression of protein complex subunits is a well-established method 
to circumvent protein aggregation of individual subunits and the subsequent solubility 
problems that are often associated with high levels of expression in E.coli cells (Tolia et al., 
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2006). It is thought that the exposure of hydrophobic surfaces, which would otherwise be 
shielded by the relevant interaction partner, may lead to the formation of insoluble protein 
aggregates known as inclusion bodies (Kane & Hartley, 1988; Carrio & Villaverde, 2002). 
Simultaneous expression of subunits from one or several expression vectors within the 
same cell has in many cases been shown to alleviate this problem through complex 
formation at the point of translation. The crystal structure of the ternary TBP-IIA-DNA 
nucleoprotein complex (Bleichenbacher et al., 2003) shows that interaction between the 
TFIIA αβ and γ subunits leads to a very intertwined and tightly associated structure that 
likely explains the difficulties experienced when expressing the isolated subunits. In 
addition to possibly alleviating solubility problems, co-expression also provides a means to 
test if the γ-subunits can stably interact with PfTFIIA-αβ. This would be evidenced by co-
purification of untagged putative γ subunits with an epitope-tagged PfTFIIA-αβ subunit (i.e 
6H-PfTFIIA-αβ), and would consequently also provide evidence to suggest that these are 
indeed bona fide PfTFIIA complexes. Co-expression vectors were constructed through the 
insertion of untagged PfTFIIA-γ1s and PfTFIIA-γ2s cDNA expression units (T7 promoter + 
ORF + T7 terminator) downstream of the expression unit for 6His-tagged PfTFIIA-αβ (Ch2, 
Materials & Methods 2.2). Complexes were expressed after cold shock at 25˚C without the 
use of IPTG, relying solely on leaky expression from the LacUV5 promoter of the host 
strain plasmid. Figure 14 shows the SDS-PAGE analysis of the Ni-NTA column and 
subsequent ion-exchange chromatography steps used to purify the PfTFIIA-γ1 (Figs 14A, 
B) and PfTFIIA-γ2 (Figs 14C, D) complexes following co-expression. 6His-tagged 
complexes were purified on Ni-NTA columns under high salt (500mM KCl) and eluted with 
250mM imidazole buffer. Early elution fractions (Figs 14A, C; lanes 3-5) were analysed by 
SDS-PAGE and clearly show the presence of the 6H-PfTFIIA-αβ subunit in roughly 
equivalent amounts. Analysis of the PfTFIIA-γ1s and γ2s subunits clearly shows the co-
purification of the PfTFIIA-γ1s subunit (Fig 14A; lane 3), enriched relative to the input 
 90
 91
fraction and present in a roughly 1:1 ratio relative to the PfTFIIA-αβ subunit. In contrast, 
the PfTFIIA-γ2s subunit could initially not be detected (Fig 14C). The presence of 
contaminating proteins in the Ni-NTA purifications (Figs 14A, C) can be attributed to the 
low expression levels of PfTFIIA complexes. Following Ni-NTA purification PfTFIIA-
containing fractions were adjusted to 100mM KCl (Ch2, Materials and Methods 2.3.6) and 
subjected to ion-exchange chromatography (Figs 14B, D). The combined subunits of the 
PfTFIIA-γ1 complex have a pI of 5.38, and was therefore further purified on a Q-sepharose 
anion exchange resin (Fig. 14B). Fractions were eluted by increasing the KCl 
concentration of the elution buffer from 200mM to 700mM in a stepwise manner. The 
PfTFIIA-γ1 complex was eluted in the 400-500mM KCl range (Fig 14B; lanes 8-10) with 
some low molecular weight (<15 kDa) contaminants being excluded in the earlier elutions 
(Fig 14B; lanes 5-10). The PfTFIIA-γ2 complex has a combined pI of 7.69 and was 
therefore purified on a SP-sepharose cation exchange resin (Fig. 14D). Interestingly, the 
PfTFIIA-γ2s subunit was now found to be visible after SDS-PAGE and coomassie staining. 
This suggests that higher concentrations of the complex were present on the gel and that 
the subunit stains poorly below a certain threshold amount on the gel (Fig. 14D). Overall, 
the elution profile of the PfTFIIA-γ2 complex was similar to that of PfTFIIA-γ1, with the 
complex eluting gradually over the 400mM to 700mM KCl range (Fig 14D; lanes 5-8). 
Figure 15 shows a summary of the purification protocols developed for the two putative 
PfTFIIA complexes. The fact that both untagged PfTFIIA-γ1s and PfTFIIA-γ2s subunits co-
purified with 6H-tagged PfTFIIA-αβ subunit over two separate purification steps, provides 
strong evidence for stable association with PfTFIIA-αβ and the formation of two distinct 
bona fide PfTFIIA complexes. Two independent preparations of both PfTFIIA complexes 
were expressed and purified (Fig 16A). Western blot analysis was then carried out using 
PfTFIIA preparation 1 to confirm the identity of PfTFIIA-αβ, PfTFIIA-γ1s, and PfTFIIA-γ2s 




assays which were later used in the initial functional characterisation of the two PfTFIIA 
orthologs (Fig. 16B) (Section 3.7). Thrombin cleavage experiments were also carried out 
to remove the 6H-tag from the PfTFIIA complexes (preparation 2) in anticipation of 
possibly using these proteins in conjunction with PfTBP to examine PfTBP DNA-binding 
specificity using a modified SELEX assay (further discussed in section 3.6). Partially 
successful cleavage of these tags from the complexes were indicated by changes in the 
mobility of the αβ subunits in both PfTFIIA-γ1 (Fig. 16C, compare lanes 1 and 2) and 
PfTFIIA-γ2 (Fig. 16C, compare lanes 3 and 4) complexes. No new bands became visible 
in the SDS-PAGE analysis of the cleaved fractions, indicating that the integrity of the two 
PfTFIIA complexes remain unaffected by thrombin cleavage. Interestingly, it is noted that 
the mobility of the low molecular weight contaminants are also altered by the thrombin 
digestion (Fig. 16C, lanes 2 and 4), indicating that these contaminants are truncated 6H-
tagged PfTFIIA-αβ subunits. The incomplete cleavage seen in these preparations is likely 
due to aggregation brought about by the relatively low salt concentration of the cleavage 
reactions (100mM KCl) compared to the conditions under which the complexes were 
initially purified (500mM KCl). It was thought that these uncleaved aggregates would not 
necessarily pose a problem in later assays as they will likely not be able to form 
complexes with PfTBP and thus not effect the site selection of PfTBP in the SELEX 
experiment. At this stage, the effects of PfTFIIA on PfTBP DNA-binding specificity has not 
been addressed due to time constraints on the project however this data does provide a 
starting point from which this question can further be explored.  
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3.5 Initial characterisation of PfTBP and PfTLP 
TBP and at least some of its TLP paralogs are the only sequence-specific DNA-binding 
proteins in the eukaryotic RNAP-II general transcription machinery (reviewed in Thomas & 
Chiang, 2006). Their structure is primarily made up of a conserved C-terminal domain 
responsible for the recognition and stable binding of the core promoter in order to direct 
the assembly of the RNAP-II PIC (Tan et al., 1993; Kim et al., 1993; Nikolov et al., 1996; 
Duttke et al., 2016; reviewed in Thomas & Chiang, 2006 ). P. falciparum orthologs for both 
TBP and TLP were identified through bioinformatics analysis several years ago but their 
DNA-binding properties have so far not been sufficiently characterised (McAndrew et al., 
1993; Ruvalcaba-salazar et al., 2005; Bischoff et al., 2010). Initial work in our lab on the 
characterisation of these proteins was done in collaboration with two MSc students, 
Steven Bing and Gertrud Talvik. This work provided first evidence for stable binding of both 
PfTBP and PfTLP to previously characterised putative P. falciparum promoter regions of 
the genes gbp-130 and kahrp (Ruvalcaba-Salazar et al., 2005; Bing, 2015; Talvik, 2016).  
EMSAs are a powerful and effective way of analysing protein-DNA interactions in vitro 
(Garner & Revzin., 1981; Hellman & Fried., 2007). In these assays proteins are incubated 
with nucleic acid probes and stable protein-DNA complexes are separated from unbound 
DNA by non-denaturing gel electrophoresis. Protein-DNA interaction is detected by 
reduced mobility of the DNA probe when bound to protein (a mobility shift or gel shift). 
Traditionally, EMSA assays are performed using native polyacrylamide gels. However, 
results from our early attempts to perform EMSAs showed that protein-DNA complexes 
formed with PfTBP or PfTLP were quantitatively retained in the loading wells (Bing, 2015; 
Talvik, 2016). This suggested aggregation of PfTBP/PfTLP nucleoprotein complexes or the 
occurrence of multiple PfTBP/PfTLP binding events to a single DNA-probe leading to the 
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formation of large multi-protein complexes that were unable to migrate into the gel. This 
problem was solved by switching to a Mg2+ agarose-gel system as the increased pore size 
of the agarose-gel matrix is able to accommodate larger protein-DNA assemblies (Zerby & 
Lieberman, 1997; Malecová et al., 2005). In these EMSAs it was found that binding of 
putative P. falciparum promoters with increasing amounts of PfTBP or PfTLP resulted in a 
gradual decrease of probe mobility that corresponded to a decrease in free-probe signal 
until quantitative binding was reached (Talvik, 2016). These data were consistent with the 
polyacrylamide EMSA results and confirmed binding of multiple PfTBP or PfTLP molecules 
to the DNA probes under the conditions used. To determine whether PfTBP binding is site-
selective, further experiments were carried out using poly(dG-dC) as competitor DNA. 
Because of the extremely high A/T-base content of the P.  falciparum genome (Gardner et 
al., 2002), a G/C-rich competitor such as poly(dG-dC) was deemed to be best suited to 
discriminate specific and non-specific protein-DNA interactions. The results of 
representative experiments are shown in Fig. 17. 
3.5.1 PfTBP forms stable DNA complexes at A/T-rich sequences distinct from a    
 consensus TATA box 
In EMSA competition experiments, GBP-130 probes (5ƒmol) were first incubated with 
saturating amounts of PfTBP in the absence of competitor DNA. This resulted in a 
quantitative shift of the free-probe (Fig. 17, compare lanes 1 and 2). The mobility of the 
PfTBP-DNA complex is relatively high when compared to Mg2+ agarose EMSA shifts seen 
with HsTBP under similar reaction conditions (Malecová et al., 2015). In EMSAs, the 
movement of a protein-DNA complex relative to that of free-probe is largely influenced by 
three factors: the molecular weight of the bound protein, the tertiary structure of the bound 
protein, and the structure of the DNA-protein complex. Stable binding of HsTBP to the  
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minor groove of TATA box containing DNA induces a severe bend in the DNA-helix (> 80˚) 
through the insertion of two phenylalanine side chains into the first and last base steps of 
the the TATA box element (F288 & F197) (Nikolov et al., 1996; Hieb et al., 2007). This 
bend causes an unusually slow migration of TBP-DNA complexes in EMSAs (Lieberman et 
al., 1991; Zhao & Herr, 2002). Considering the similarities in both size and structure of the 
PfTBP and HsTBP C-terminal regions, together with the absence of one of the conserved 
phenylalanines in PfTBP (see Section 3.1), it seems likely that the relatively high mobility 
of the PfTBP-DNA complex seen in our experiments indicates the absence of, or a much 
lesser degree of, DNA bending in the PfTBP-DNA complex. Competition with 100ng 
poly(dG-dC) resulted in a partial disruption of PfTBP complexes leading to roughly 50% 
recovery of the free-probe signal (Fig. 17, compare lanes 2 and 4). Interestingly, further 
increasing the amount of competitor DNA to 400ng poly(dG-dC) did not further decrease 
the amount of PfTBP-DNA complexes (Fig. 17, compare lanes 4 and 6). The resistance of 
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the remaining PfTBP-DNA complexes to poly(dG-dC) challenge can be interpreted as 
follows: Binding of PfTBP to the DNA-probe occurs at multiple sites. A sub-population of 
these sites is sensitive to poly(dG-dC) challenge, suggesting that the relative affinity of 
PfTBP for these sites is low and likely due to non-specific protein-DNA interaction. A 
distinct population of sites is bound with comparatively higher affinity and is resistant to 
poly(dG-dC) challenge, suggesting that these sites mediate sequence-specific 
interactions, and thus contain sequence motifs recognised by PfTBP. The data therefore 
suggest that the formation of stable PfTBP-DNA complexes is sequence-specific.  
To test whether a consensus TATA box can mediate the formation of stable PfTBP-DNA 
complexes, protein-DNA binding experiments were repeated using two variants of the GC-
rich TATA-less mouse terminal deoxynucleotidyl transferase (TdT) promoter (Malecová et 
al., 2007), the wild-type TdT sequence lacking the TATA-motif and a mutated variant 
containing the prototypical TATA box element TATAAAA known to promote stable binding 
of eukaryotic TBPs (Tan., et al 1993; Nikolov et al., 1996; Malecová et al., 2015). As with 
GBP-130, addition of saturating amounts of PfTBP resulted in quantitative binding of both 
TdT-probe variants (Fig. 17, compare lanes 1 and 2 with lanes 7 and 8, and 13 and 14). 
However, in contrast to the putative GBP-130 promoter region addition of just 40ng 
poly(dG-dC) was sufficient to completely abolish the PfTBP binding to the TdT promoter 
sequence (Fig. 17, compare lanes 3 and 15). Furthermore, and most significantly, the 
presence of a TATA box element did not increase the resistance of PfTBP-TdT complexes 
to poly(dG-dC) challenge (Fig. 17, compare lanes 9 and 15). In summary, these data 
suggest that PfTBP binds in a sequence-specific manner to A/T-rich DNA probes such as 
the P. falciparum gbp-130 and Kahrp promoter sequences. However, PfTBP differs from 
other eukaryotic TBPs in that it does not appear to form stable complexes with a 
consensus TATA-sequence. 
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3.5.2 Temperature dependence of PfTBP DNA binding 
We initially used reaction conditions established for human and yeast TBP in our DNA-
binding assays. Eukaryotic TBPs have been shown to bind DNA in a two stage process in 
which the DNA is at first bound loosely, followed by a transition to a more stable complex 
through the bending of the DNA-helix (Hoopes et al., 1992; Zhao & Herr, 2002; Masters et 
al., 2003; Delgadillo et al., 2009). Incubation at 30˚C thermodynamically favours the 
transition to a bent TBP-DNA complex and is therefore generally used as the standard 
condition for TBP DNA-binding experiments (Petri et al., 1995; Lieberman et al., 1991; Lee 
et al., 1992). In our initial experiments, reactions were placed on ice after incubation at 
30˚C, before being loaded for electrophoresis. However, we noticed a high degree of 
variability in the efficiency and stability of protein-DNA complex formation by PfTBP in Mg2+ 
agarose EMSAs that appeared to correlate with the amount of time reaction samples were 
left on ice before electrophoresis (Talvik, 2015). This prompted investigations into the 
effects of incubation temperature on PfTBP-DNA complex formation. The results of these 
experiments are summarised in Fig. 18. In this experiment, GBP-130 DNA-probe was 
incubated with increasing amounts of PfTBP either on ice (0˚C) or at 30˚C. In order to limit 
PfTBP interactions to specific sites, non-specific interactions were suppressed by the 
addition of 400ng poly(dG-dC) to the binding reaction (Fig. 18). The results in Fig. 18 
clearly demonstrate increased PfTBP DNA binding activity at 0˚C compared to 30˚C. Thus, 
in contrast to human and yeast TBP, PfTBP does not require higher incubation 
temperatures to facilitate stable complex formation. Rather, higher incubation 
temperatures appear to diminish stable PfTBP-DNA complex formation. This observation 
is consistent with the notion that stable PfTBP DNA binding does not involve severe DNA 
bending, indicated by the relatively high mobility of PfTBP-DNA complexes in Mg2+ 
agarose EMSA experiments.      
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3.5.3 DNA binding properties of PfTLP are distinct from those seen in PfTBP 
Preliminary Mg2+ agarose EMSA analysis of PfTLP demonstrated that it had the ability to 
form stable complexes with the putative P. falciparum promoters KAHRP and GBP-130 
(Bing, 2015; unpublished data). Additionally, it was shown to form complexes with the 
TATA-containing Adenovirus type 2 major late (Ad2ML) promoter sequence in the absence 
of competitor DNA (Bing, 2015). Differences in PfTLP binding affinity for these probes was 
not immediately apparent as in all three cases DNA binding reactions presented very 
similar EMSA results. The PfTLP mediated mobility-shifts were characterised by the 
appearance of a predominant fast-migrating shift that was followed by several slower and 
comparatively faint shifts. The formation of multiple PfTLP-dependent shifts were attributed  
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to two possible causes: the first being that several PfTLP molecules would bind to the 
same DNA-probe leading to PfTLP-DNA complexes of varying sizes, and the second being 
that single binding events at different positions along the probes lead to PfTLP-DNA 
complexes with dissimilar conformations. This second explanation stemmed largely from 
the observation that all four of the conserved phenylalanine residues responsible for DNA-
bending in eukaryotic TBPs are conserved in PfTLP (Ch1. Introduction, Section 1.2.4 & 
1.2.6) (Bing, 2015). The DNA-binding activity of recombinant PfTLP is illustrated by a 
representative experiment shown in Fig. 19. In this experiment 60ng PfTLP was incubated 
with 5ƒmol GBP-130 probe at 0˚C for 45min. This resulted in a PfTLP-mediated shift and a 
corresponding reduction in the free probe signal (Fig 19, compare lanes 1 and 2). The  
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resolution of PfTLP-DNA shifts were at first very poor. The diffuse appearance of shifts was 
suggests dissociation of complexes during electrophoresis (Fig. 19, lanes 2, 3 and 4)  
(Bing, 2015). Through assay optimisation experiments it was found that increasing the 
agarose-gel percentage by just 0.1% drastically improved the visualisation of these PfTLP-
DNA complexes (see Fig. 20 and Fig. 28). Competition experiments revealed that PfTLP 
binding to A/T-rich putative P. falciparum promoter regions was abolished by the presence 
more than 20ng poly(dGdC) in the binding reaction (Fig. 19; compare lanes 2, 4 and 5). 
These findings indicate a very high sensitivity of PfTLP-DNA interaction to poly(dG-dC) 
relative to what was seen with PfTBP under similar conditions when using the same DNA-
probe (Fig. 17; lane 3). As with PfTBP, addressing the possibility of site-specific PfTLP 
binding was done through additional DNA-binding experiments using the putative 
 103
GBP-130 promoter and mouse TdT and TdT(TATA+) promoter sequences. A summary of 
these results is shown in Figure 20. In these experiments, increasing amounts of PfTLP 
were first added to protein-DNA binding reactions containing 5 ƒmol of the GBP-130 DNA-
probe and 100ng poly(dG-dC). The addition of increasing amounts of PfTLP to the 
GBP-130 binding reactions resulted in the gradual emergence of a mobility-shift seen 
above the free-probe signal (Fig. 20, compare lanes 1,2,3,4 and 5). Interestingly, based on 
the relative mobility of the complex, PfTLP appears to form an unbent complex with the 
GBP-130 promoter despite the conservation of the phenylalanine residues responsible for 
the intercalation into the DNA minor groove (Nickolov et al., 1996). To further test the 
observed PfTLP-Ad2ML shifts (Bing, 2015) and to provide a means of direct comparison to 
the DNA-binding activity of PfTBP seen in Fig. 16, the experiment was repeated using the 
mouse TdT and TdT(TATA+) probes.  Even after the addition of 40ng PfTLP, stable PfTLP-
DNA complexes with the TdT promoter could not be detected in the presence of 100ng 
poly(dG-dC) (Fig. 20, compare lanes 11 and 15). Furthermore, no TATA box mediated 
binding of PfTLP was found under similar conditions when using the TdT(TATA+) DNA-
probe (Fig. 20, compare lanes 6 and 10). Taken together, these data indicate that as seen 
with PfTBP, there appears to be a sequence-specific recognition of binding sites on the 
GBP-130 probe by PfTLP. In addition, these sites appear to be absent in the mouse TdT 
promoter sequence. Thirdly, as with the human TLP ortholog (TRF2), PfTLP does not 
appear to recognise or form stable-complexes with the TATA box element (Duttke et al., 
2016). There is also evidence of both quantitative and qualitative differences between the 
respective complexes formed by PfTBP and PfTLP with the GBP-130 DNA-probe. PfTLP 
binding appears to be less efficient considering the relative amounts of protein needed to 
produce a shift signal, approximately 200 ƒmol/µl PfTLP versus approximately 40 ƒmol/µl 
PfTBP. Furthermore, the PfTLP-DNA complexes appear to be less stable as evidenced by 
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their increased sensitivity to poly(dG-dC) challenge and the dissociation of the protein-
DNA complexes seen as a smear below the PfTLP-DNA complexes. 
3.6  Characterisation of PfTBP sequence specificity by Systematic Evolution of   
 Ligands by Exponential Enrichment (SELEX) 
The positioning of the RNAP-II PIC is achieved primarily by the recognition of short DNA-
sequence motifs known as core promoter elements (CPEs). This process is mediated by 
several RNAP-II general transcription factors, often acting in conjunction with gene-specific 
transcriptional activators bound to distal promoter elements (reviewed Smale & Kadonaga, 
2003; Gross & Oelgeschläger, 2006; Thomas & Chiang, 2006). Studies of eukaryotic 
promoter architecture have identified several such sequences found in varying 
combinations within approximately 50bp of most transcription start sites. Typically, CPEs 
are identified using in vitro transcription in conjunction with DNA-binding assays such as 
DNase I footprinting (Burke & Kadonaga, 1996; Marbach-Bar et al., 2015). The data 
generated from these assays are then used in bioinformatics searches to locate the given 
sequence elements in the promoter regions of other genes. The extremely high A/T-base 
content of P. falciparum intergenic regions (often > 90% A/T) has however made the in 
silico prediction of CPEs very difficult (Gardner et al., 2002). This extreme base content 
bias and the dearth in functional data regarding the parasites general transcription 
machinery are the main reasons why the structure of core promoters in P. falciparum could 
not be determined thus far. Motivated by the observation that DNA binding by PfTBP is 
sequence-specific, and that this specificity is not mediated by the TATA box element 
(Section 3.7), a systematic evolution of ligands by exponential enrichment (SELEX) 
approach (Ch2. Materials & Methods, Section 2.7) was adapted to try elucidate sequence 
motifs recognised by PfTBP. The SELEX assay is a PCR-based method for the enrichment 
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of DNA sequences from a random DNA sequence  pool based on their potential to be 
bound by a protein of interest (Ogawa & Biggin, 2012).  
For the experiments described here, a DNA library containing 16 nucleotide random 
sequences (n16 library) was prepared (Ch2. Materials & Methods, Section 2.7.1). Briefly, 
6H-PfTBP was immobilised on Ni2+-magnetic beads and incubated with a pool of random 
16bp target sequences flanked by primer-binding sites. Bound oligonucleotides were 
isolated by magnetic pull-down of 6H-PfTBP and eluted with high salt. The eluted 
sequences were then PCR amplified, purified, and used for another round of SELEX 
selection. After seven cycles of enrichment, the primer sites were removed by enzyme 
restriction digestion. The enriched DNA pool was ligated to form concatemers containing 
10-15 copies of 16bp target sequences. These concatemers were then cloned into a 
pUC19 sequencing vector and analysed. The resultant datasets were scanned for 
reoccurring sequence motifs using the online Multiple Em for Motif Elicitation (MEME) 
application of the MEME-suite (Bailey et al., 2009; http://meme-suite.org/). 
3.6.1  Construction and verification of a 16 nucleotide random-sequence DNA library   
 (n16 Library) 
The success of the SELEX assay is largely predicated on the input DNA being truly 
random. Any nucleotide and/or sequence bias brought about either by way of the initial 
chemical synthesis procedure and/or the various amplification and cloning steps would 
obviously lead to a skewed result. The results of this procedure are summarised in Fig. 21. 
In order to test for any possible intrinsic sequence biases, the SELEX procedure was 
carried out in the absence of PfTBP selection and subjected to the respective PCR 
amplification and cloning steps. The n16 library was constructed using single stranded 
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oligonucleotides (ssSELEX72-n16), 72 nucleotides in length, comprised of a 16bp random 
DNA-sequence flanked by 22bp PCR-primer binding sites and containing BamHI 
recognition sequences (Fig. 21A). Single-cycle polymerase reactions were carried out  
using the ssSELEX72-n16 templates and the reverse SELEX80-BamHI primer 
(Ch2. Materials & Methods, Table 5) to produce the double stranded n16 library. Reactions 
were pooled and gel-purified before being analysed on a native poly-acrylamide gel (Fig. 
21B). A single sharp 72bp band reactive to ethidium bromide staining was seen, confirming 
the completion of the dsDNA synthesis (Fig. 21B). The next step in the SELEX procedure 
requires PCR amplification of the enriched n16 library using biotinylated primers (Fig. 21C, 
lane 1). This is done to facilitate the removal of the flanking sequences. BamHI digestion 
resulted in a mixture of fully digested n16 target sequences, together with biotin-linked 
flanking sequences and any remaining undigested or partially digested oligonucleotides 
(Fig. 21C, lane 2), which were removed by incubation with streptavidin-coated beads (Fig. 
21C, lane 3). Following gel purification, the n16 sequences were ligated to form 
concatemers, which in agarose gel electrophoresis, appeared as a long smear due to the 
variation in concatemer lengths (Fig. 21D). Concatemers ranging from approximately 
250bp to 1000bp in length were cut out from the agarose gel, purified, cloned into pUC19 
vector, and transformed by electroporation into E.coli DH5-α cells. Positive clones were 
selected by blue/white screening on X-gal-containing agar plates (Sambrook & Russell, 
2001), and white colonies were then analysed by colony PCR to select clones with an 
insert > 350bp (Fig. 21E). The plasmid DNA from these clones was subsequently isolated 
and sent for sequencing analysis. The raw sequence data of the n16 sequences was 
manually curated to exclude any truncated sequences or cloning artefacts prior to MEME 
analysis. The results of the MEME analysis are shown in Fig. 21F. No significant evidence 
of sequence motifs could be detected in a total pool of 480 sequences (Appendix A3). 
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Furthermore, the A/T:G/C ratio was found to be roughly equal to a 1:1 ratio, indicating that 
there was no significant nucleotide bias in the n16 library. 
3.6.2 n16 library enrichment by PfTBP selection 
In order to elucidate potential PfTBP binding motifs from the verified library, seven 
consecutive rounds of SELEX selection were carried out. The results of this procedure are 
summarised in Fig. 22. Quantitative PCR (qPCR) was used to determine the amount of 
immobilised 6H-PfTBP that would be needed in a 20µl SELEX binding reaction to bind 
approximately 1% (0.1ng) of the 10ng input DNA in the presence of 400ng poly(dG-dC) 
competitor DNA. These conditions favour isolation of high affinity binding sites over sites 
bound in a non-specific manner (Ogawa & Biggin, 2012). The amount of competitor DNA 
was chosen based on previous EMSA results showing that 400ng poly(dG-dC) was 
adequate to suppress non-specific PfTBP-DNA interactions (Section 3.7.1). Four binding 
reactions containing 0ng, 5ng, 10ng, and 15ng immobilised 6H-PfTBP were incubated with 
10ng n16 DNA library at 21˚C for 45min in 20µl standard transcription buffer (Ch2. 
Materials & Methods, Section 2.5). The bound oligonucleotides were separated together 
with PfTBP from the sequence pool and extensively washed before elution. Quantification 
of the elutions by qPCR indicated that 10ng PfTBP was sufficient to bind 0.1ng of the input 
DNA under the given reaction conditions (Fig. 22A). The seven rounds of SELEX selection 
were then carried out with the bound DNA from each enrichment cycle being PCR 
amplified and analysed by native poly-acrylamide gel electrophoresis (Fig. 22B). It was 
found that, in addition to the specific 72bp PCR product, a second shorter product with 
higher mobility was formed between enrichment cycles 5 and 7 (Fig. 22B, compare R5, 
R6, and R7). Further processing of the enriched n16 library after seven rounds of selection 
(R7) by PCR biotinylation (Fig. 22C, lane 1) and BamHI cleavage, revealed that this lower 
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band was resistant to BamHI cleavage (Fig. 22C, lane 2). This resulted in its removal from 
the sequence pool in the streptavidin sepharose pulldown (Fig. 22C, lane 2). The n16 
library R7 sequence pool that was responsive to BamHI digestion was concatemerised, 
cloned, and analysed (Fig. 22C, lane 4). Motif-search analysis of 397 sequences of the 
n16 enriched DNA sequence pool (R7), did not reveal any significant motifs. However, 
notably, the overall A/T content of enriched sequences was 61% (Fig. 22D), compared to 
48.6% in the original library (Fig. 22E). Thus, although no definite consensus motif for 
PfTBP binding could be discerned, binding of PfTBP clearly enriched A/T-containing DNA 
sequences, consistent with the observed preference of PfTBP in the EMSA DNA-binding 
experiments (Section 3.7). 
3.6.3 Analysis of a truncated SELEX product enriched in selection rounds  5-7 
Two explanations were posited to explain the enrichment of a truncated SELEX product 
seen between the R5 and R7 enrichment cycles (Fig. 22D). The first theory was that this 
DNA product was a PCR artefact which preferentially amplified over other library 
sequences during consecutive selection cycles. To eliminate this problem the correct DNA 
band from cycle 5 (R5) was excised from polyacrylamide gels and purified prior to being 
used as input DNA for continued SELEX enrichment. This approach was however 
unsuccessful as the truncated SELEX product re-emerged within two cycles (data not 
shown). This result suggested that the truncated DNA sequences were indeed selected by 
PfTBP. In order to determine the precise reason why these DNA-sequences could not be 
digested with BamHI and displayed increased mobility in native polyacrylamide gels, a 
new set of extended biotinylated primers complimentary to the 5’ ends of the original 
SELEX primer sequences were synthesised, each of which contained a 3’ EcoRI 
restriction site. This strategy allowed for the inclusion of the truncated PCR product into 
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the sequence pool that would later be analysed for motif enrichment. The results of these 
experiments are summarised in Fig. 23. The SELEX enrichment procedure was continued 
for a further two cycles using the R7 library containing both PCR products as input DNA 
(Fig. 23A). The resultant R9 library sequences were then amplified and biotinylated using 
the primers containing the EcoRI sites (Fig. 23B, lane 1). Analysis of the EcoRI digestion 
of the biotinylated PCR products prior to concatemerization confirmed that both the correct 
and truncated SELEX products were now included in the analysis (Fig. 23B, lane 2). After 
removal of EcoRI cleaved 3’ and 5’ ends as before with streptavidin sepharose (Fig. 23B, 
lane 3), target sequences were concatemerised, isolated by agarose gel extraction (Fig.
23B, lane 4), and cloned into the pUC19 vector. Sequencing of positive clones revealed 
that the aberrant SELEX PCR products were composed primarily of truncated 16bp target 
sequences bordered by defective BamHI sites (Fig. 23C). It seems reasonable to assume 
that these sequences originated initially from aberrant PCR amplification of PfTBP-
enriched DNA during the SELEX procedure. The fact that these sequences were strongly 
enriched through PfTBP binding suggests that they may contain high affinity PfTBP 
binding sites. However, as with full length enriched SELEX-selected DNA sequences, 
MEME analysis revealed no specific DNA motifs enriched in the truncated enriched PCR 
products. 
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3.7 Functional characterization of  PfTFIIA-γ1 and PfTFIIA-γ2 complexes 
Transcription factor IIA has in itself no inherent DNA binding capabilities. It has however 
been shown to act as a positive regulator of TBP for both basal and activated transcription 
in vitro (Reinberg et al., 1987; Imbalzano et al., 1994b; Maldonado et al., 1990; Lieberman 
et al., 1997; reviewed in Thomas & Chiang, 2006). This stimulatory effect can broadly be 
attributed to three main functional roles of TFIIA. In the first instance, TFIIA mediates a 
conformational change to the TBP-DNA complex through the alteration of the DNA 
bending-angle within the TBP-TATA nucleoprotein complex, and thereby increases the 
stability of the TBP-DNA interaction (Hieb et al., 2007). TFIIA also acts as an antagonist to 
negative regulators of TBP such as NC2 by competing for overlapping regions of 
interaction on the convex surface of TBP (Kim et al., 1995; Malecová et al., 2015; reviewed 
in Thomas & Chiang, 2006). Lastly, TFIIA is thought to play a co-activator role by 
facilitating interactions between transcriptional activator proteins and the TFIID complex in 
order to promote the assembly of the RNAP-II PIC (Kobayashi et al., 1995; Kang et al., 
1995; Ozer et al., 1998; Chou et al., 1999; reviewed in Thomas & Chiang, 2006). In 
addition to these well established TBP-related functions, TFIIA has also been shown to 
form stable complexes with TBP-like protein (TLP or TRF2) and appears to facilitate the 
localisation of TLP to the cytoplasm (Teichman et al., 1999; Nakadai et al., 2004). A 
comprehensive understanding of TLPs involvement in transcriptional regulation is yet to be 
elucidated. However, there is strong evidence indicating that it functions in the recognition 
of promoter subtypes lacking the TATA-box element (Wang et al., 2014; Kedmi et al., 2014; 
Duttke et al., 2016). Having co-expressed and purified two distinct P. falciparum TFIIA 
complexes, the PfTFIIA complexes were tested in regard to their ability to (i) bind to DNA 
complexes formed with either PfTBP or PfTLP, and (ii) to affect the previously established 
DNA-binding activity of PfTBP or PfTLP. In order to answer the question as to whether the 
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PfTFIIA-γ1 and PfTFIIA-γ2 can indeed form ternary complexes with PfTBP or PfTLP, 
immobilised template assays were conducted. Immobilised-template assays serve as a 
direct measure of protein-DNA interaction. Biotinylated DNA-probes immobilised to 
streptavidin-coated magnetic beads are used as binding targets in protein-DNA binding 
reactions that contain the protein(s) of interest. The unbound fraction is washed from the 
beads and the bound proteins are eluted and analysed by SDS-PAGE and by 
immunoblotting. Experimental parameters such as template and protein concentration in 
the binding reaction for the analysis of PfTBP and PfTLP DNA-binding using immobilised 
template assays (ITAs) were established early on in the laboratory by myself and Steven 
Bing, an MSc. student (Bing, 2015). 
3.7.1 PfTBP dependent recruitment of PfTFIIA to putative GBP-130 promoter DNA 
To test whether PfTBP can recruit PfTFIIA-γ1 or PfTFIIA-γ2 complexes to DNA, proteins 
were incubated with 1pmol immobilised GBP-130 probe in the presence of 500ng poly(dG-
dC) competitor DNA to suppress unspecific PfTBP-DNA interaction (see Fig. 17, Section 
3.5.1). Bound-proteins were eluted, separated by SDS-PAGE, and analysed by 
immunoblot together with the PfTBP and PfTFIIA-γ1 input fractions using  anti-PfTBP and 
anti-PfTFIIA-γ1 antibodies developed in the laboratory. As shown in Fig. 24A, PfTBP 
bound  quantitatively to the GBP-130 DNA template under these conditions (Fig. 24A, 
compare lanes 1 and 3). In contrast, there was no visible binding of the isolated PfTFIIA-γ1 
complex to the immobilised DNA beads (Fig. 24A, compare lanes 2 and 4). In the 
presence of PfTFIIA-γ1, binding by PfTBP to the putative promoter was clearly diminished 
(Fig. 24, compare lanes 3 and 5). However, PfTFIIA-γ1 binding could not be detected (Fig.
24A, lane 5). In contrast, the presence of the PfTFIIA-γ2 complex did not affect PfTBP 
DNA binding (Fig. 24B, compare lanes 1 and 3). However, the addition of both PfTBP and 
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PfTFIIA-γ2 to the binding reaction resulted in the recruitment of the PfTFIIA-γ2 complex to 
the GBP-130 DNA-probe (Fig. 24B, compare lanes 4 and 5). Overall, the data presented in 
Fig. 24 demonstrate that PfTFIIA-γ2 is able to form a stable protein-DNA ternary complex 
on putative GBP-130 promoter DNA in the presence of PfTBP. This presented data provide 
strong evidence for the identification of PfTFIIA-γ2 as a functional P. falciparum TFIIA 
ortholog. PfTFIIA-γ1 appears to act as a negative regulator of PfTBP binding, however, 
binding of PfTFIIA-γ1 to PfTBP could not be detected under these conditions. 
3.7.2 PfTFIIA-γ2, but not PfTFIIA-γ1, stimulates PfTBP-DNA binding activity 
The ability of the putative PfTFIIA complexes to stimulate DNA-binding by PfTBP was 
tested in Mg2+ agarose gel EMSAs using previously established reaction conditions  as a 
guide (see Section 3.7; Bing, 2015; Talvik, 2016). The binding reactions were set up as 
follows. GBP-130 DNA-probes (5ƒmol) were first incubated with saturating amounts of 
PfTBP. This resulted in a quantitative shift of the free probe (Fig. 25, compare lanes 1 and 
2). PfTBP binding was suppressed by the addition of 100ng and 400ng poly(dG-dC), 
resulting in the recovery of approximately 80% of the free probe (Fig. 25, compare lanes 2, 
3 and 4). Increasing amounts of either PfTFIIA-γ2 or PfTFIIA-γ1 were then added to the 
PfTBP DNA binding reactions (Fig. 25, lanes 5 to 7 and 8 to 10 respectively). PfTFIIA-γ2 
restored PfTBP DNA binding in a dose-dependent manner (Fig. 25, compare lanes 4, 5, 6, 
and 7). No such effect was seen with the PfTFIIA-γ1 complex. Importantly, no mobility 
shifts were seen with either PfTFIIA ortholog in the absence of PfTBP (Fig. 25, lanes 11 
and 12). These results are consistent with the results of the immobilised template assays 
and confirm that recombinant PfTFIIA-γ2, but not PfTFIIA-γ1, is able to interact with PfTBP 
to form a ternary PfTBP/PfTFIIA-γ2/DNA complex (Fig. 24). Importantly, the results also 
demonstrate that PfTFIIA-γ2 interactions stimulate PfTBP DNA-binding activity.  
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3.7.3 PfTLP dependent recruitment of PfTFIIA to putative GBP-130 promoter DNA 
The possibility of P. falciparum having two distinct PfTFIIA complexes led to the interesting 
question as to whether the two different putative PfTFIIA orthologs may specifically interact 
with either PfTBP or PfTLP. The demonstrated ability of PfTLP to stably bind putative 
P. falciparum promoter DNA in both EMSAs and ITAs (Figs. 19 and 20, Section 3.5.3; Bing, 
2015) provided a means by which to test for, and characterise, PfTLP-PfTFIIA interaction. 
ITAs were carried out as described with PfTBP, however, these reactions contained only 
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100ng poly(dG-dC), which is sufficient to suppress non-specific PfTLP and PfTFIIA DNA 
binding (Fig. 19, Section 3.5.3). Under these conditions PfTLP was able to bind to the 
immobilised template but neither of the PfTFIIA complexes were able to bind the promoter 
template in isolation (Fig. 26, lanes 3 and 4). As seen with PfTBP, addition of PfTFIIA-γ1 
complex resulted in a diminished PfTLP DNA binding, but no PfTLP dependent recruitment 
of the PfTFIIA-γ1 complex was detected. However, as seen with PfTBP, the PfTLP 
dependent recruitment of PfTFIIA-γ2 was detected (Fig. 26B, lanes 5 and 5b). Overall, 
these results are very similar to what was seen in ITAs using the PfTBP ortholog (Fig. 24), 
with the overall decrease of PfTLP and PfTBP DNA-binding in the presence of PfTFIIA-γ1 
suggesting a possible role for PfTFIIA-γ1 as a negative regulator of PfTBP and PfTLP 
DNA-binding activity. 
3.7.4 PfTFIIA-γ2, but not PfTFIIA-γ1, stimulates PfTLP-DNA complex formation 
In order to further investigate the effect of PfTFIIA on PfTLP DNA-binding, Mg2+ agarose 
EMSAs were carried out. A representative result is shown in Fig. 27. Again, the stimulatory 
effect on PfTLP DNA-binding was investigated under conditions where PfTLP DNA-binding 
was suppressed by the addition of poly(dG-dC) competitor DNA to the binding reactions. 
Binding reactions containing PfTLP and 100ng poly(dG-dC) showed little evidence of a 
PfTLP-mediated mobility shift (Fig. 27, compare lanes 1 and 2). The addition of the 
PfTFIIA-γ2 to the binding reaction resulted in a quantitative shift of the KAHRP probe (Fig.
27, compare lanes 2 and 3), whereas the addition of PfTFIIA-γ1 to binding reactions had 
no noticeable effect on PfTLP-DNA complex formation (Fig. 27, lane 4). Interestingly, 
conducting these experiments in the absence of competitor DNA demonstrated a change 
in the mobility of the PfTFIIA-PfTLP-DNA complexes relative to the mobility shift seen with 
PfTLP alone. Binding reactions containing saturating amounts of PfTLP resulted in 
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quantitative binding of the free probe (Fig. 27, compare lanes 1 and 5). The addition of 
PfTFIIA-γ2 resulted in a further shift of the bound DNA-probe to a higher position which 
corresponds to the PfTFIIA-γ2 mediated shift seen in the presence of the competitor DNA 
(Fig. 27, compare lanes 5 and 6, with lane 3). This result further corroborates the 
conclusion that PfTFIIA-γ2 forms a stable ternary complex with PfTLP on DNA. Overall, 
these data clearly demonstrate that PfTFIIA-γ2 binds to PfTLP-DNA complexes and 
stimulates DNA-binding by PfTLP. 
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3.7.5  Effect of reaction temperature on stimulation of PfTLP binding of PfTFIIA-γ2 
In vitro PfTBP DNA-binding was found to strongly favour low (0 to 4˚C) reaction 
temperatures (see Fig. 19, Section 3.5.2; Talvik, 2016). In contrast, DNA binding by PfTLP 
was found to be enhanced at 30˚C compared to 0˚C (Fig. 28). Interestingly, the addition of 
PfTFIIA-γ2 resulted in an increase in PfTLP DNA-binding at 0˚C (Fig. 28, compare lanes 3 
and 6), but not at 30˚C, at which the formation of PfTLP DNA complexes is greatly 
stimulated (Fig. 28, compare lanes 3 and 7, and 7 and 10). Based on what is known about 
TFIIA function in the context of eukaryotic TBP-TATA-box binding energetics (Ch1. 
Sections 1.2.3 to 1.2.7) (Hoops et al., 1992; Starr et al., 1995; Nikolov et al., 1996; Tan et 
al., 1996; Masters et al, 2003; Hieb et al., 2007; Delgadillo et al., 2009), the increased 
stimulatory effects of PfTFIIA-γ2 on PfTLP DNA-binding at low temperature can most likely 
be attributed to thermodynamic considerations. PfTFIIA-γ2 may contribute to the binding 
energy required to form the IIA-TLP-DNA nucleoprotein complex, either by inducing a 
conformational change when complexed with PfTLP, which in turn leads to an increase in 
favourable PfTLP-DNA interactions, or else through direct interactions with the bound DNA 
in the context of the IIA-PfTLP-DNA complex. 
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      Chapter 4 
     Discussion 
4.1 Bioinformatic analysis of the Plasmodium falciparum TATA box binding   
 protein (PfTBP). 
The original identification and analysis of the gene coding for P. falciparum TBP 
(McAndrew et al., 1993) had followed on from the publication of similar studies in 
S. cerevisiae (Horikoshi et al., 1989), S. pombe (Fikes et al., 1990), A. thaliana (Gasch et 
al., 1990), D. melanogaster (Hoey et al., 1990), and H. sapiens (Hoffman et al., 1990). By 
making use of highly conserved motifs in the C-terminal core domain of the known TBP 
orthologs, together with the knowledge of P. falciparum codon usage (Hyde et al., 1989), 
McAndrew and colleagues were able to sequentially amplify sections of the PfTBP open 
reading frame (ORF) and thereby construct a consensus sequence for the full length gene. 
By using a combination of multiple sequence alignments and hydrophobicity plots, the 
group demonstrated that, relative to other eukaryotes, PfTBP had a highly divergent 
primary amino acid sequence but still likely maintained a conserved secondary and tertiary 
structure profile. McAndrew also pointed out that many of the residues that were at that 
time known to be important for TBP-DNA interaction (Reddy & Hahn, 1991) had also been 
conserved in PfTBP and that the spatial orientation of some of these residues had been 
altered by a small insertion of several amino acids in the P. falciparum ortholog. McAndrew 
postulated that these changes may reflect a loss of reliance on the TATA box element by 
P. falciparum and that this was possibly necessitated by the extremely high A/T base 
content of the parasites intergenic sequences. Finally, the author went on to state that any 
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abnormalities seen in the transcriptional mechanisms of P. falciparum may offer insight into 
novel stratagems for the development of anti-malarial chemotherapeutics. These data and 
predictions from the McAndrew group were used as a starting point in this thesis for a 
more in-depth bioinformatics analysis of PfTBP that utilised the now known 
crystallographic structures of the human and yeast TBP orthologs in complex with the 
TATA box (Nikolov et al., 1996; Tan et al., 1996; Bleichenbacher et al., 2003), as well as 
the available P. falciparum (3D7) genome sequence (Gardner et al., 2002). Initial 
examination of the annotated PfTBP gene in the PlasmoDB database (PF3D7_0506200) 
showed that the ORF actually extended upstream of the ATG start codon originally 
predicted by McAndrew et al., 1993. The current annotation for the full-length PfTBP-gene 
codes for a 38.1 kDa protein composed of 327 amino acids. At present there appears to be 
some confusion in the literature regarding which ATG is actually used as the start codon 
for PfTBP translation and the actual size of the full-length PfTBP protein. The reasons for 
this become quite clear when carefully analysing published western-blot data (Ruvalcaba-
Salazar et al., 2005, 2006; Gopalakrishnan et al., 2009). In a 2005 paper entitled 
“Recombinant and native Plasmodium falciparum TATA-binding protein binds to a specific 
TATA box element in promoter regions”, Ruvalcaba-Salazar and colleagues expressed a 
26kDa PfTBP core domain protein fused to a GST-tag (total MW of 52kDa) for which they 
produced a polyclonal anti-GST-PfTBP antibody that is specific to the PfTBP portion of the 
fusion protein (Ruvalcaba-Salazar et al., 2005). The authors then go on to present 
western-blot data using this anti-PfTBP antibody to probe P. falciparum nuclear extract 
(PfNE) (Ruvalcaba-Salazar et al., 2005; Fig.1) and to show the specific detection of a 
protein band in PfNE migrating close to the 26kDa protein molecular weight marker. This 
result is clearly contrary to the expected size of 38.1kDa of PfTBP predicted in the most 
recent iteration of PlasmoDB (38.1kDa) (Gene entry PF3D7_0506200; PlasmoDB Release 
29). A second set of western-blot data is then presented (Ruvalcaba-Salazar et al., 2005; 
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Fig. 8) showing that a polyclonal antibody raised against human TBP (anti-HsTBP) is also 
able to specifically detect PfTBP in parasite nuclear extract, in order to justify the use  of 
anti-HsTBP in chromatin-immunoprecipitation (ChIP) experiments. No explanation was 
given as to why the author chose not to use their anti-PfTBP antibody in these 
experiments. It seems likely that the anti-PfTBP antibody turned out not to be suitable for 
ChIP experiments. Shortly after the publication of this initial paper, the author released a 
second paper entitled “Preparation and Characterization of a Monoclonal Antibody Specific 
to Plasmodium falciparum TATA Binding Protein”, (Ruvalcaba-Salazar et al., 2006). Here 
the authors clearly re-use the image of the western-blot probed with the anti-HsTBP 
antibody in the 2005 paper (Ruvalcaba-Salazar et al., 2005; Fig. 8), and present this data 
as a western blot probed with their new monoclonal anti-PfTBP antibody (Ruvalcaba-
Salazar et al., 2006; Fig. 2). In addition, western-blot data published by Gopalakrishnan 
and co-workers in 2009 contradict the Ruvalcaba-Salazar western-blot data. Here, the 
authors probe P. falciparum nuclear extract with a custom-made polyclonal anti-PfTBP 
antibody (Washington Biotechnology). This experiment detected a specific interaction with 
a protein band that migrated between the 32kDa and 47kDa protein molecular weight 
markers, consistent with the calculated molecular weight of PfTBP (38.1kDa) in the current 
PlasmoDB release. It should be noted that Gopalakrishnan et al. claimed that the full-
length PfTBP band seen in their western-blot data migrated corresponding to a molecular 
mass of 42kDa, a value stated to be in accordance with the calculated mass of PfTBP in 
the genome annotation at the time of their publication. However, it appears to be difficult to 
distinguish between these two values (38.1kDa and 42kDa) in their data figure based on 
the migration of the molecular weight markers (Gopalakrishnan et al., 2009, Fig. 1A). 
Added to this point, Gopalakrishnan et al. stripped and re-probed the same immunoblot 
membrane with anti-HsTBP, and the resulting PfTBP band is then shown in Fig. 1B to 
migrate alongside HsTBP (calculated MW 37.6 kDa). The anti-HsTBP antibody used here 
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was a polyclonal antibody able to detect TBP orthologs from multiple species; likely due to 
the highly conserved nature of TBP C-terminus secondary structure (https://www.scbt.com/
scbt/product/tfiid-antibody-si-1). It may be possible that the PfTBP identified in the nuclear 
extracts of the Ruvalcaba-Salazar papers was a distinct PfTBP isoform produced from the 
ATG transcription start site originally proposed by McAndrew, 1993. However, in light of 
the apparent duplication of images in the two papers published by Ruvalcaba-Salazar, as 
well as the contradictory findings of Gopalakrishnan et al., 2009, there is some doubt as to 
the veracity of these western-blot data. The conclusion here is that the 38.1 kDa 
annotation, confirmed by Gopalakrishnan et al., 2009, is likely the correct molecular weight 
of full-length PfTBP.  
The alignment and subsequent annotation of the TBP-core sequences in Fig. 9 (Section 
3.1) confirmed the extremely low degree of primary sequence identity in the C-terminal 
domain of PfTBP (39%) relative to the human ortholog, a value much lower than that seen 
when comparing the HsTBP sequence to the S. cerevisiae ortholog (79%). However, 
Fig. 9 illustrates the overall conservation of hydrophobic positions between the three 
orthologs, a feature implying conserved secondary structure motifs (Gaboriaud et al., 
1987; MacAndrew et al., 1993). Furthermore, a detailed examination of the residues 
involved in TBP-DNA interaction in the yeast TFIIA-TBP-DNA crystal structure (Tan et al., 
1996), shows that 27 of 29 (93%) residues that are known to contact the DNA minor 
groove are either conserved or substituted with a highly similar amino acid. However, a 
key point to remember when considering the DNA-binding characteristics of PfTBP, is that 
the substitution of F197 in HsTBP (F99 in ScTBP) for isoleucine I183 in PfTBP is likely to 
result in a change in the the topology of the PfTBP-DNA complex through a loss of DNA 
kinking at the last base step in the TATA box motif. This is due to the elimination of the 
DNA-helix distortion brought about by the intercalation of this phenylalanine residue 
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(Fig. 4) (Kim et al., 1993; Nikolov et al., 1996). Additionally, the relative spatial positioning 
of residues involved in TBP-DNA interaction have been altered by a small insertion 
between β-strands S3’ and S4’ of PfTBP. In summary, the substitution of F197 together 
with the insertion of amino acids TSN at positions 285-297 of PfTBP predict a loss of 
TATA-specific PfTBP DNA binding activity as well as a PfTBP-DNA nucleoprotein 
architecture that is distinct from that which is seen in other eukaryotic systems. 
Examination of the known TFIIA interaction sites in the human and yeast TBP orthologs 
shows that 8 of 10 (80%) of these sites are conserved, suggesting a retention in the ability 
of PfTBP to interact with TFIIA. Lastly, the conserved proline P163 in HsTBP P163 (P65 in 
ScTBP), shown to be essential for RNAP-II transcription in yeast (Schultz et al., 1992), and 
also found to be conserved in TBP orthologs from A. thaliana, and D. malanogaster 
(Hoffman et al., 1992), has been substituted to leucine L149 in PfTBP (Fig. 9). These data, 
together with the absence of nearly all the histone-fold containing TAFs in the parasites 
genome sequence (Bischoff et al., 2010), make a strong case for a functionally divergent 
P. falciparum TFIID complex, which can thus be considered as a highly interesting target 
for the development of potent anti-malarial drugs aimed at lethality across all stages of the 
parasite life cycle. 
4.2 Bioinformatic analysis of the putative P. falciparum transcription factor IIA   
 (PfTFIIA) orthologs. 
Owing to the extremely high A/T base content of the parasite genome, together with the 
resultant divergence in amino acid profiles of P. falciparum proteins, the putative PfTFIIA 
subunits were among the last of the P. falciparum general transcription factor orthologs to 
be identified (Callebaut et al., 2005). Interestingly, these in silico studies predicted two 
possible variants of the TFIIA-γ subunit but only one TFIIA-αβ subunit. This led to the 
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possibility of two distinct PfTFIIA complexes, each containing one of two γ subunit variants 
(denoted: PfTFIIA-γ1s and PfTFIIA-γ2s) complexed with the common αβ ortholog 
(PfTFIIA-αβ). In this study, multiple-sequence alignments were used to analyse the 
predicted secondary structure motifs (Callebaut et al., 2005) as well as the levels of 
conservation of TBP and DNA interaction sites (Bleichenbacher et al., 2003) within each of 
the putative subunits (Figs. 10 and 11). Examination of the primary amino acid sequences 
and, in particular, the clustering of hydrophobic residues, indicated the likely conservation 
of secondary structure profiles with respect to the human and yeast orthologs (Figs. 10 
and 11) (Callebaut et al., 2005). It should however be noted that the spatial arrangement of 
the predicted β-strand secondary structures within the two γ subunit variants are altered 
with respect to one another, and as such, would likely form dissimilar three-dimensional 
structures when complexed with αβ. This is an important point when considering the 
relation of three-dimensional protein structure to the specificity of protein-DNA interactions 
(Fig. 11B; Murphy & Churchill, 2000; Garvie & Wolberger, 2001; Slattery et al., 2014). With 
regard to PfTFIIA-αβ, it was also found that there are substantial alterations to the main 
points of contact seen between HsTFIIA and DNA in the TFIIA-β chain of the human TFIIA 
crystal structure (Fig. 10) (Bleichenbacher et al., 2003). These changes to the common αβ 
subunit potentially point to a loss in the ability of the two PfTFIIA complexes to stabilise 
interactions between TBP and the TATA box element (Bleichenbacher et al., 2003; Hieb et 
al., 2007). Furthermore, there is almost no conservation of the residues involved in TBP 
interaction on either of the PfTFIIA-γ subunits, the γ subunit being the primary site of TBP 
interaction in the human and yeast orthologs (Bleichenbacher et al., 2003). This is a very 
peculiar feature of PfTFIIA as most (80%) of the TFIIA interaction sites on PfTBP are 
conserved (Fig. 9) (Fig. 11A). However, when considering the overlaps seen in the 
interaction sites of TFIIA with that of other transcription associated factors such as TAF1, 
NC2, and BTAF1 (Ch1. Introduction, Section 1.2.5), it is entirely possible that these 
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regions are conserved within PfTBP for reasons other than TFIIA interaction, and that the 
PfTFIIA interactions seen with PfTBP in the mobility shift and immobilised template data 
(Ch3. Results, Section 3.7; discussed in Section 4.7) is in fact brought about in a different 
way.  
Interestingly, RNA-seq analysis of erythrocytic stage steady state mRNA levels for 
PfTFIIA-γ1s (PF3D7_1250700) and PfTFIIA-γ2s (PF3D7_0933700) (Appendix A7), shows 
different expression profiles for the two PfTFIIA-γ subunits. The mRNA levels of PfTFIIA-
γ1s remain relatively constant in the early stages of erythrocyte infection, around 2-4 fold 
higher than mRNA levels of PfTFIIA-γ2s, and increase 1.5 to 2 fold 30-35 hours post-
invasion. In contrast, PfTFIIA-γ2s mRNA levels increase 6 to 10-fold by hours 32-40, 
raising transcript levels to a number roughly equal to PfTFIIA-γ1s. Furthermore, the 
expression profiles of the antisense transcripts in these regions are such that antisense-
PfTFIIA-γ1 transcripts are only produced in late blood stage while the antisense-PfTFIIA-
γ2 transcripts mimic the PfTFIIA-γ2 sense strand profile. It is now widely accepted that 
antisense transcripts can play a significant regulatory role in the transcription, translation, 
and mRNA degradation pathways of sense strand transcripts (reviewed in Pelechano & 
Steinmetz, 2013). As such, the differences in antisense mRNA expression patterns for the 
two subunits may be taken as further evidence for the independent regulation and 
presumably distinct functional roles of the two PfTFIIA complexes analysed in this study. In 
addition, available transctiptomics data for male and female gametocytes, show that 
PfTFIIA-γ2s transcription is down-regulated in female gametocytes. Assuming similar 
mechanisms of direct PfTFIIA-DNA interaction as seen in the human and yeast systems, 
and considering the overall differences in PfTFIIA-γ1 and PfTFIIA-γ2 complex topologies 
brought about by the distinct PfTFIIA-γ subunit architectures, as well as the fluctuations in 
mRNA levels for both the sense and antisense transcripts coding for the two PfTFIIA-γ 
 130
candidates, it seems reasonable to postulate distinct developmentally linked activities for 
the two putative TFIIA complexes, presumably at distinct P. falciparum promoter subtypes. 
Indeed, this hypothesis is in line with the different abilities of the PfTFIIA-γ1 and PfTFIIA-
γ2 complexes to stimulate PfTBP binding to GBP-130 promoter DNA in in vitro DNA 
binding experiments (discussed in Section 4.7). Lastly, in addition to differential stimulation 
of PfTBP or PfTLP DNA-binding activity, the two different PfTFIIA complexes could 
differentially affect activator or repressor function at different core promoters. 
4.3 Bioinformatic analysis of Plasmodium falciparum TBP-like protein (PfTLP) 
An adapted version of a larger COBALT sequence alignment originally carried out by 
Steven Bing (Bing, 2015) was used to illustrate the conservation of the known DNA and 
TFIIA interaction sites usually present in the conserved C-terminal domain of eukaryotic 
TBPs (Fig. 12; Tan et al., 1996; Bleichenbacher et al., 2003). This was included as a point 
of reference to aid discussion of the immobilised template and mobility shift data described 
in sections 3.5 and 3.7 of Chapter 3. PfTLP was among the first P. falciparum general 
transcription factors identified (Coulson et al., 2004) and is, to my knowledge, the only 
Apicomplexan TBP-like protein to have been analysed beyond the point of in silico 
prediction. As would be expected, the degree of divergence of PfTLP from typical 
eukaryotic TBP model orthologs is even greater than that seen in the already divergent 
PfTBP. In particular, the conservation of DNA-interaction sites drop from 93% in PfTBP to 
53% in PfTLP. In addition, there are large insertions of unstructured low-complexity regions 
located in the S4 (131 amino acids) and S4’ (31 amino acids) β-strand regions, as well as 
a shortened N-terminal region (Fig. 12). Furthermore, the degree of conservation of TFIIA 
interaction sites also drops significantly, from 80% in PfTBP to 20% in PfTLP. Despite 
these substantial alterations to the primary amino acid sequence of the PfTLP paralog, 
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there is one distinct TBP characteristic that is conserved in PfTLP but not in PfTBP. All four 
phenylalanine residues that are vital for the TATA box-binding activity of TBP are 
conserved in PfTLP. This feature stands in contrast to what is seen in the human and 
Drosophila TLP orthologs where three of these four residues have been substituted for 
either tryptophan, histidine, asparagine, or valine (Duttke et al., 2016). Taken together, 
these observations are somewhat paradoxical in that they both seemingly support and 
contradict the potential of PfTLP having TATA box-binding capabilities. The important point 
to note is that whatever the effect of the conservation and/or substitution of the various 
residues in PfTLP shown to interact with DNA in the canonical TBP core domain is, the 
data overall suggest that PfTBP and PfTLP have distinct DNA-binding specificity, and as 
such, support the notion that PfTLP potentially plays a role in specific developmentally 
regulated gene transcriptional programs as postulated for other eukaryotic TLPs (Duttke et 
al., 2016)  
4.4 Expression and purification of putative PfTFIIA-γ1 and PfTFIIA-γ2 complexes 
The heterologous expression of soluble Plasmodium proteins in E.coli is known to be an 
extremely challenging endeavour (reviewed in Birkholtz et al., 2008), with the extremely 
low success rate being a major hurdle to the commencement of structural and/or functional 
studies aimed at the development of much needed anti-malarial drugs (Aguiar et al., 2004; 
Mehlin et al., 2006). There are currently around 650 P. falciparum protein structures listed 
among the 130 000 macromolecular assemblies available in the Protein Data Bank (PDB) 
(http://www.rcsb.org/pdb/static.do?p=general_information/about_pdb/index.html). This is a 
surprisingly high number considering the total number of P. falciparum genes is 
approximately 5300, and reflects a sustained effort from both the public and private 
research sectors over the last decade despite the considerable difficulties experienced by 
 132
many earlier large-scale expression efforts (Aguiar et al., 2004; Mehlin et al., 2006; Vedadi 
et al., 2007). The challenges associated with P. falciparum protein expression in E.coli 
stem mainly from cloning artefacts and solubility problems brought about by a number of 
variables. The extremely A/T-rich genome sequence can severely compromise basic 
cloning procedures such as restriction digestion, ligation reactions, and bacterial 
transformations, resulting in the production of re-arranged recombinant clones 
(unpublished observations; Triglia & Kemp, 1991). If viable clones can be obtained, protein 
expression is often compromised by diminished cell growth and cell death due to protein 
toxicity (Cinquin et al., 2001; Bing, 2015). A large-scale study found correlations between 
expression problems and the relatively high molecular mass of P. falciparum orthologs 
which are typically 50% larger than their yeast ortholog (Aravind et al., 2003; Mehlin et al., 
2006), as well as with the abundance of low-complexity disordered regions in the 
P. falciparum proteome (Pizzi & Frontali, 2001). In addition, proteins which lack homology 
to E.coli proteins, and, in particular, those which exhibit a very basic pI, are strongly 
correlated with solubility problems, whereas a very low pI typically results in no observable 
expression at all (Mehlin et al., 2006). Lastly, size exclusion chromatography experiments 
demonstrated that a significant number (51%) of soluble expressed P. falciparum proteins 
tend to form aggregates through self-association. It is important to note that a number of 
eukaryotic expression systems are available that have been successfully used in the 
heterologous expression of some Plasmodial proteins (Birkholtz et al., 2008). These 
include yeast, baculovirus, and mammalian cell systems. Ultimately however, low levels 
protein glycosylation in P. falciparum (Gowda & Davidson, 1999), and the time and costing 
advantages afforded by the E.coli system, led to the decision to endure the inherent 
difficulties of this approach.  
 133
In this study, two putative untagged TFIIA-γ subunits, PfTFIIA-γ1s and PfTFIIA-γ2s, were 
each co-expressed with a 6His-tagged variant of the putative PfTFIIA-αβ subunit in order 
to overcome the solubility problems experienced when expressing the proteins in isolation. 
Furthermore, toxicity problems brought about by over-expression of these proteins were 
mitigated by eliminating IPTG induction, relying instead on the leaky expression of the 
LacUV5 promoter together with a lowered incubation temperature (25˚C as opposed to 
37˚C) to slow down cellular processes. The amount of soluble PfTFIIA proteins obtained 
under these conditions was very low, typically 5-10µg/L cell culture, but sufficient to 
conduct functional studies. In light of the toxicity problems experienced, using a cell-free 
expression system (Shimizu et al., 2006; Mudeppa et al., 2007; Tsuboi et al., 2008) may 
be a possible alternative strategy if one were to pursue structural studies of these 
orthologs, which require much higher amounts of recombinant protein.  
Purification of PfTFIIA complexes was achieved through a two step process starting with a 
Ni-NTA affinity chromatography step at high salt (500mM KCl cleared lysate) in order to 
minimise any masking of the 6His-tag by protein aggregation. A subsequent buffer 
exchange to 100mM KCl was followed by ion exchange chromatography using Q-
sepharose anion exchange resin for PfTFIIA-γ1 (pI 5.38) or SP-sepharose cation 
exchange resin for PfTFIIA-γ2 (pI 7.69), with the two complexes eluting between 
400mM-500mM KCl and 400mM-700mM KCl, respectively. The purity of the resultant 
preparation was deemed sufficient for subsequent assays. Notably, based on the tightly 
intertwined structure of human and yeast TFIIA structures (Fig. 5) (Bleichenbacher et al., 
2003), the stable association of the two untagged PfTFIIA-γ subunits with 6H-PfTFIIA-αβ, 
as evidenced by co-purification over two separate purification steps, provides strong 
evidence that both proteins are legitimate PfTFIIA γ-subunits, and as such, provide 
convincing evidence for the existence of two distinct TFIIA complexes in P. falciparum. 
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4.5 Initial characterisation of PfTBP & PfTLP 
Electrophoretic mobility shift assays (EMSAs) were carried out in order to characterise the 
DNA-binding activity of PfTBP and PfTLP and to test predictions made in the 
bioinformatics analysis of these key plasmodial transcription initiation factors (Ch3, 
Results, Section 3.5), and to establish systems in which to functionally characterise the 
two putative PfTFIIA complexes. In protein-DNA binding reactions, three modes of DNA-
protein interactions must be considered: specific, non-specific, and unspecific interactions. 
Specific binding occurs when a protein recognises and binds to a specific DNA sequence. 
Non-specific binding occurs when that same protein binds a DNA sequence that is 
different from its ideal binding sequence. Lastly, unspecific binding refers to protein-DNA 
interaction with no inherent sequence preference (reviewed in Murphy & Churchill, 2000; 
Garvie & Wolberger, 2001). Structural biology has long provided key insights into the 
molecular mechanisms by which proteins interact with specific DNA sequences through 
the analysis of hundreds of co-crystal structures of DNA-bound protein complexes. Two 
main mechanisms of DNA sequence recognition can be distinguished, termed base and 
shape readout (reviewed in Slattery et al., 2014). Base readout broadly refers to direct 
interactions between a proteins amino acid side chains and the chemical signatures of 
specific DNA base pairs in the major and, to a much lesser extent, minor grooves of the 
DNA molecule. These interactions are comprised of direct and indirect (water mediated) H-
bonds as well as van der Waals interactions. Shape readout refers to the recognition of 
sequence-specific structural features at a given target site. These include features such as 
the propensity for DNA-bending, the formation of kinks, and the unwinding of the double-
helix, which can be brought about by local nucleotide composition (Slattery et al., 2014; 
Hieb et al., 2007). Examples of both base and shape readout can be seen in the co-crystal 
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structures of TBP-core domains bound to the TATA box promoter element (Kim & Burley., 
1994; Tan et al., 1996; Nikolov et al., 1996; Bleichenbacher et al., 2003).  
TBP recognises and binds to the TATA box through the minor grove of the DNA double 
helix by an induced-fit mechanism (reviewed in Nikolov & Burley, 1997). Intercalation of 
phenylalanine residues into the first and last base steps of the 8bp recognition sequence 
causes two kinks at the 5’ and 3’ ends of the TATA box resulting in a partial unwinding of 
the DNA-helix between these two points. This unwinding causes a widening of the minor 
grove and facilitates multiple H-bond and hydrophobic interactions between TBP and the 
TATA box nucleotides (Nikolov et al., 1996). The alterations to the helix structure and 
trajectory at the point of binding ultimately cause a significant bend in the DNA-helix that 
can average in excess of 100˚ (Nikolov et al., 1996; Hieb et al., 2007). The TBP-DNA 
interactions can be further stabilised by accessory proteins, such as TFIIA and TFIIB. 
TFIIA interaction is mediated by a number of protein-protein contacts at the N-terminal 
stirrup of the TBP core domain as well as direct contacts with DNA base pairs upstream of 
the TATA box (Bleichenbacher et al., 2003). These interactions result in a conformational 
change in the TBP-TATA complex reducing the bend angle to 80˚, thereby significantly 
increasing the kinetic stability of the complex under physiological conditions 
(Hieb et al., 2017).  
The key findings regarding the DNA binding activity of PfTBP from the mobility shift assays 
presented in chapter 3 were that PfTBP binding of putative GBP-130 promoter DNA is 
possibly sequence-specific. However, as predicted in the sequence analysis data of 
Section 3.1,  which predicted a loss in TATA-specific DNA binding activity due the 
substitution of F197 (HsTBP) for isoleucine I183 (PfTBP), as well as the spatial alterations 
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observed among key amino acid residues involved in TBP-DNA interaction, PfTBP does 
not appear to recognise and bind to a consensus TATA box element.  
Consistent with the lack of conventional TATA box-binding activity, the production of a 
PfTBP-DNA complex with high mobility relative to other eukaryotic TBP-DNA complexes in 
Mg2+ agarose EMSAs, can be taken as evidence for a lack of (or a much reduced) bending 
angle in the PfTBP-DNA nucleoprotein complex. This notion is further supported by the 
observation that PfTBP-DNA complex formation and stability is greatly enhanced at low 
incubation temperatures. This temperature preference for DNA binding is incompatible with 
the 30˚C preference seen in other eukaryotic TBPs, which require a higher energy system 
to facilitate DNA-bending through the intercalation of phenylalanine residues into the TATA 
box promoter element (Kim et al., 1993; Nikolov et al., 1996). 
Similar to PfTBP, PfTLP was also shown to exhibit possible sequence-specific DNA 
binding activity. However, as with TBP, this sequence-specific binding does not appear to 
be mediated by a consensus TATA box element despite the conservation of all four of the 
phenylalanine residues typically associated with TATA-binding activity (Thomas & Chiang, 
2006; Duttke et al., 2016). It is also important to note that, although both PfTBP and PfTLP 
exhibited binding activity when using probes generated from the same putative 
P. falciparum promoter sequence (GBP-130), there are clear quantitative differences in 
these binding activities, with PfTBP-DNA complexes displaying a much higher stability 
when challenged with non-specific poly(dG-dC) competitor sequences.  
Overall, the demonstration of PfTBP and PfTLP DNA-binding activity, together with the 
observation that both of these transcription factors are able to form stable complexes with 
PfTFIIA-γ2, suggest that both PfTBP and PfTLP are involved in promoter recognition. More 
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work needs to be done to describe in detail the precise differences in PfTBP and PfTLP 
DNA sequence specificity and to determine which of these is the pre-dominant factor 
involved in nucleating the RNAP-II pre-initiation complex.   
4.6  Characterisation of PfTBP sequence specificity by Systematic Evolution of   
 Ligands by Exponential Enrichment (SELEX) 
Motivated by our observation that PfTBP DNA-binding is sequence specific, but that 
sequences distinct from the typical TATA box core promoter element (CPE) are required, a 
PCR-based method for the enrichment of short DNA sequences from a pool of randomly 
generated oligonucleotides (SELEX) was used to try elucidate any putative CPEs 
recognised by PfTBP. After seven rounds of selection, no significant motifs were detected. 
Rather, there was a marked increase in the A/T content of the nucleotide library. This may 
indicate that sequence specificity seen in our Mg2+ EMSA data purely relates to the high A/
T content of the GBP-130 probe (>80%) relative to that of the TdT probes (<50%) as 
opposed to any defined CPE. This notion is further supported by the lack of PfTBP DNA-
binding seen using DNA-probes containing a consensus TATA box element (Ch3. Results, 
Section 4.5). Significantly, these results are in agreement with a recent seminal study 
analysing P. falciparum transcription start sites by way of 5’ cap RNA sequencing (Adjalley 
et al., 2016). Here the authors assembled a comprehensive map of RNAP-II transcription 
initiation sites giving new and much needed insight into the parasites transcriptome and 
core promoter sequence context. Examination of the nucleotide content around the most 
active transcription start sites indicated that the preference for parasite transcription 
initiation sites is governed by a locally increased A/T nucleotide base composition. It may 
indeed however be possible that the the limitations of this assay, brought about by the 
experimental artefacts that begin to emerge after five rounds of SELEX, have prevented 
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the elucidation of a motif which may have only arisen in successive rounds. A possible 
solution to this would be to start the SELEX procedure with a random library that contains 
an A/T base content that is more representative of what is found in the parasites intergenic 
regions, i.e > 80% A/T. This would remove any “wasted rounds” filtering out G/C-rich 
sequences from the pool and thereby minimise the total number of rounds needed. 
Alternatively, it may be that TFIIA and TFIIB are required in the binding reactions in order 
to observe any real sequence specificity in the PfTBP binding events.  
4.7  Initial characterization of two putative PfTFIIA orthologs 
In order to test for the interaction with, and effects of, the two putative TFIIA complexes 
with respect to PfTBP and PfTLP DNA-binding, a series of immobilised template assays 
(ITAs) and electrophoretic mobility shift assays (EMSAs) were carried out. In both 
instances, it was found by ITA that the second of the two orthologs, PfTFIIA-γ2, was able 
to be stably recruited to putative GBP-130 promoter DNA in a PfTBP- and PfTLP-
dependent manner. It was also noted that overall DNA-binding of PfTBP and PfTLP was 
decreased in the presence of PfTFIIA-γ1. This may well indicate a function of PfTFIIA-γ1 in 
reducing non-specific PfTBP and PfTLP DNA interactions. Consistent with these results, it 
was demonstrated by EMSA that the presence of PfTFIIA-γ2 was able to help both PfTBP 
and PfTLP to overcome DNA binding suppression with non-specific poly(dG-dC) 
competitor, presumably by promoting specific interactions with promoter DNA over non-
specific interactions with the competitor DNA. Despite a lack of detectable PfTFIIA-γ1 
interaction with both PfTBP and PfTLP in these assays, it would be unwise to discount this 
complex as a valid part of the P. falciparum general transcription machinery. It may well be 
necessary that additional transcription factors, both general and specific, be present for 
PfTFIIA-γ1 incorporation into the pre-initiation complex. In particular, PfTFIIB has been 
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shown through bioinformatics analysis to contain conserved TFIIA interaction sites (Bing, 
2015) and could likely play a role in PfTFIIA-γ1 association with TBP/TFIID. It is also 
important to note that nuclear TBP is complexed with multiple TBP-associated factors 
(TAFs), some of which could play a key role in PfTFIIA-γ1 recruitment. Recent studies 
have demonstrated that in mouse testis, TFIIA forms part of a large 280kDa complex 
containing both TLP and TFIIA-like factor (ALF) together with a heat-shock protein 
chaperone. The studies suggest, that TLP (TRF2), together with the alternative TFIIA 
complex, TFIIA-like factor (ALF), and TFIIA, from a type of “TFIIA super complex” in 
haploid spermatid cells that is recruited to the RNAP-II PIC (Martianov et al., 2016). 
Whether PfTBP or PfTLP can interact with both PfTFIIA-γ1 and PfTFIIA-γ2 simultaneously 
is a interesting possibility that still needs to be tested.  
Finally, a paper published at the time of writing this thesis reported the identification of a 
novel core promoter element, the TFIIA recognition element (IIARE), located upstream of 
the TATA box, which is recognised by TFIIA (Wang et al., 2017). The authors show that 
IIARE is able to enhance the activity of TATA-containing core promoters by stimulating the 
recruitment of TFIIA, RNAP-II, TAF4 and the coactivator p300. Furthermore, it was found 
that the presence of IIARE was also able to activate or repress transcription at TATA-less 
promoters. These findings support the interesting possibility that the two different PfTFIIA 
complexes characterised in this work may have important roles in directing PfTBP and 
PfTLP to distinct core promoter sequences.  
4.8  Summary and Outlook 
The data presented here provide strong evidence for the existence of two P. falciparum 
TFIIA complexes. With respect to PfTBP, it was found that PfTBP DNA-binding very likely 
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leads to “unbent” PfTBP-DNA nucleoprotein complexes, dissimilar from those seen in 
other eukaryotic systems. Furthermore, mobility shift and SELEX data indicate that DNA-
binding activity, although sequence-specific, is not dependent on a TATA box element but 
rather on local nucleotide content. Similarly, PfTLP has also been shown here to have 
sequence specific DNA-binding activity that is distinct from that of PfTBP. Despite some 
structural indications of TATA box binding activity, PfTLP DNA-binding activity was also 
found not to be positively influenced by the presence of a TATA box element. Overall, this 
work provides a first important basis for more detailed studies on the in vitro DNA-binding 
activities of PfTBP and PfTLP together with two newly confirmed TFIIA complexes.  
The demonstrated interactions between PfTFIIA-γ2 and both PfTBP and PfTLP may well 
provide a novel stratagem for antimalarial small molecule development. It is widely 
accepted that a large majority of the approximately 3000 druggable proteins in the human 
system function as complexes within  various interaction networks and not as isolated 
effectors (Hopkins & Groom, 2002), a characteristic that is likely shared by P. falciparum 
(LaCount et al., 2005) and indeed all other metazoans. This prevailing paradigm has led to 
the research and development of a class of small organic molecules known as protein-
protein interaction disruptors (PPIDs) (Fontaine et al., 2015). Based on the high levels of 
divergence seen in the bioinformatics analysis of PfTBP and the PfTFIIA orthologs with 
respect to their human counterparts, the key role of these proteins in parasite transcription, 
and the demonstrated interactions of PfTFIIA-γ2 with both PfTBP and PfTLP, it seems 
reasonable to suggest that a PPID targeting PfTFIIA-γ2 interactions with PfTBP/PfTLP 
may well be the source of an effective antimalarial drug treatment. 
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Appendix 
A.1  PfTFIIA expression vectors and pET 11d vector maps 
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Vector name Coding Purification tag Size (bp)
pET 11d-6His N/A 6His- 5708
pET11d-6His-PfTFIIA-αβ PfTFIIA-αβ subunit 6His- 6228
pET11d-6His-PfTFIIA-γ1 PfTFIIA-γ1 subunit 6His- 6237
pET11d-6His-PfTFIIA-γ2 PfTFIIA-γ2 subunit 6His- 6258
pET11d-PfTFIIA-γ1 PfTFIIA-γ1 subunit non 6177
pET11d-PfTFIIA-γ2 PfTFIIA-γ1 subunit non 6198
pET11d-6His-PfTFIIA-αβ-γ1 PfTFIIA-αβ-γ1 complex 6His- 6935
pET11d-6His-PfTFIIA-αβ-γ2 PfTFIIA-αβ-γ2 complex 6His- 6850
Table A1 : PfTFIIA expression vectors
                            
                  




A.2  Expression vector ORFs and surrounding sequences  
 Blue- T7 promoter; purple- 6His tag; red- thrombin cleavage site; lower case   

















































































































A.3 SELEX n16 library verification: MEME results 
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A.4 SELEX Round 7 (R7) final analysis: MEME results 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A.5 Stock buffers: Oelgeschläger Lab Protocols (2012) 
Unless otherwise stated all reagents were obtained from Sigma-Aldrich 
Ampicillin 
• 100mg/ml in Ro H2O.  
• Store at -20˚C 
• Use 100µg/ml for selection on agar plates/liquid medium 
Chloramphenicol 
• 34 mg/ml in ethanol. 
• Store at -20°C. 
• Use 34 µg/ml for selection on agar plates and 50 µg/ml in liquid medium 
EDTA 0.5M, pH 8.0 
For 500ml: 
• Add 93.06g EDTA disodium (MW 372.24) to 400ml H2O. 
• Stir vigorously on a magnetic stirrer. 
• Adjust the pH to 8.0 with NaOH pellets (~ 10g). 
note: the disodium salt of EDTA will not go into solution until the pH approaches 
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~ pH 8.0 
• Sterilize by autoclaving.  
• Store at RT. 
Ethidium Bromide (EtBr) 10mg/ml 
• Add 1g ethidium bromide to 100ml H2O. 
Note: ethidium bromide is a known mutagen. Handle with caution. 
• Stir vigorously on a magnetic stirrer to ensure that the dye has dissolved. 
• Wrap the bottle in aluminium foil. 
• Store at RT. 
• Use 0.5µg/ml in agarose gel during electrophoresis. 
• Add to 1900ml RoH2O 
• Shake/stir until solutes are completely dissolved. 
• Adjust pH to 7.0 with 5N NaOH (~ 0.2 ml) 
• Adjust to a final volume of 2L 
• Sterilize by autoclaving 
• Store at RT. 
LB medium (Luria-Bertani medium)
Composition Stock Solutions for 2L
Tryptone (Merck) n/a 20g
Yeast extract (Merck) n/a 10g
171mM NaCl n/a 20g 
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• Add to 1900ml Ro H2O 
• Shake/stir until solutes are completely dissolved. 
• Adjust pH to 7.0 with 5N NaOH (~ 0.2 ml) 
• Add 10 ml of 250mM KCl 
• Adjust to a final volume of 2L 
• Sterilize by autoclaving 
• Store at RT. 
IMPORTANT: Just before use add 5ml of sterile 2M MgCl2 (10mM final) and 20 ml 
of 1M glucose. 
• Add to 1800ml Ro H2O 
• Shake/stir until solutes are completely dissolved. 
• Make up to 2L with Ro H2O 
• store at RT 
SOC medium (Super Optimal Broth with Catabolite repression)
Composition Stock Solutions for 2L
Tryptone (Merck) n/a 40g
Yeast extract (Merck) n/a 10g
8.6mM NaCl n/a 1g 
5x TBE Buffer
Composition (1x) Stock Solutions for 2L
40 mM Tris•HCl n/a 108.0g
45mM Boric acid n/a 55g
1mM EDTA pH 8.0 0.5M 40ml 
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5x Tris-glycine electrophoresis buffer 
• Dissolve 30.2 g Tris base and 188g of glycine in 1800ml RoH2O.  
• Add 100ml of 10% SDS stock solution and adjust volume to 2L. 
• Store at RT. 
A.6 Protein purification and western blot buffers: Oelgeschläger Lab Protocols   
Unless otherwise stated all reagents were obtained from Sigma-Aldrich.  
Note: All proteins were flash frozen and Stored at -80˚C. Aliquots were prepared to 
avoid repeated freeze/thaw cycles. 
Lysozyme 
• Prepare a stock solution at a concentration of 50 mg/ml in water. 
• Dispense into aliquots and store at -20°C. 
• Discard each aliquot after use. 
• adjust volume to 2L with RoH2O. 
• sterilize by autoclaving. 
Composition (1x) Stock Solutions for 2L
25 mM Tris•HCl n/a 30.2g
190mM Glycine n/a 188g
0.1% SDS 10% 100ml
2x BC-0
Composition Stock Solutions for 2L
40 mM Tris•HCl pH 7.37 at RT 1M 80ml
40% Glycerol 100% 800ml
0.4 mM EDTA pH 8.0 500mM 1.6ml 
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• store at 4°C 
• adjust volume to 100ml with RoH2O. 
• keep on ice or store at 4°C. 
• add immediately before use: 
70 µl β-EtSH (14.3 M), final concentration: 10mM 
• adjust volume to 20ml with Ro H2O. 
• keep on ice or store at 4°C. 
• add immediately before use: 
14µl β-EtSH (14.3M), final concentration: 10mM 
40µl protease inhibitor cocktail for purification of His:tagged proteins 
(Sigma; P8849) 
Sonication and wash buffer
Composition Stock Solutions for 100ml
50 mM Tris•HCl pH 7.37 at RT 1M 80ml
500mM KCl 2M 20ml
20mM Imidazole 2M (pH 7.4) 1ml
0.5% NP40 10% 5ml
Elution Buffer
Composition Stock Solutions for 20ml
BC-0 2x 10ml
500mM KCl 2M 5ml
250mM Imidazole 2M (pH 7.4) 2.5ml
0.5% NP40 10% 1ml
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• Dissolve 30.28g Tris-HCl and 144.13g Glycine in 1800ml RoH2O  
• Make up to 2L with RoH2O 
• For 2L 1x buffer, add 400ml 100% Methanol (20% final conc.) to 400ml 5x buffer. Make 
up to 2L with  RoH2O 
• Dissolve 30.28g Tris-HCl and 144.13g Glycine in 1400ml RoH2O 
• For 1x buffer, add Tween 20  to 0.1% v/v 
• Make up to 2L with RoH2O 
5x Transfer buffer
Composition (1x) Stock Solutions for 2L
25mM Tris-HCl n/a 30.28g
192mM Glycine n/a 144.13g
10x TBST
Composition (1x) Stock Solutions for 2L
50mM Tris-HCl n/a 121.14g
150mM NaCl n/a 175.32g
0.1% Tween 20 20% n/a
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A7.  Blood stage mRNA levels of PfTFIIA-γ1s and PfTFIIA-γ2s. 
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